

**B-CELL LYMPHOMA 2-ASSOCIATED ANTHANOGENE 3 (BAG3) GENE
THERAPY USING AAV VECTOR**

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of priority to U.S. Provisional Patent Application No. 63/333,798, filed April 22, 2022, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

STATEMENT REGARDING THE SEQUENCE LISTING

[0002] The Sequence Listing XML associated with this application is provided in XML file format and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing XML is ROPA_028_01WO_SeqList_ST26.xml. The XML file is 156,193 bytes, and created on April 19, 2023, and is being submitted electronically via USPTO Patent Center.

BACKGROUND

[0003] Both heart failure and cardiac myopathy are serious life-threatening diseases. Loss-of-function mutations in the gene B-cell Lymphoma 2-Associated Anthanogene 3 (*BAG3*) have been implicated as causing cardiomyopathy e.g., dilated cardiomyopathy (DCM), including BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial isolated dilated cardiomyopathy, and cardiomyopathy, dilated, 1hh (CMD1HH). Downregulation of BAG3 is also associated with cardiac dysfunction and heart failure.

[0004] BAG3 mediates chaperone-assisted autophagy by serving as a cochaperone with Hsp70, blocks apoptosis by coupling with Bcl-2, preserves integrity of the sarcomere by coupling the actin filaments with the Z disc, and enhances β -agonist-stimulated excitation-contraction by linking the β -adrenergic receptor and the L-type Ca^{2+} channel. BAG3 downregulation disrupts the chaperone-assisted selective autophagy (CASA) complex, which mediates the turnover of cardiac proteins, such as filamin-C.

[0005] Current treatment modalities including pharmacological therapies and cardiac ablation remain ineffective for BAG3-deficient cardiomyopathy patients. There remains, therefore, an unmet need in the art for treatments for BAG3-related diseases and disorders,

including cardiomyopathy and other heart conditions. The compositions and methods disclosed herein address this need.

SUMMARY

[0006] The present invention relates generally to gene therapy vectors and gene therapy for a disease or disorder, *e.g.*, a cardiac disease or disorder, using a vector expressing BAG3 or a functional variant thereof.

BRIEF DESCRIPTION OF FIGURES

[0007] FIG. 1 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 107.

[0008] FIG. 2 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 108.

[0009] FIG. 3 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 109.

[0010] FIG. 4 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 110.

[0011] FIG. 5 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 111.

[0012] FIG. 6 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 112.

[0013] FIG. 7 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 113.

[0014] FIG. 8 is a diagram illustrating a non-limiting example of a vector genome. The full polynucleotide sequence of the vector genome is SEQ ID NO: 114.

[0015] FIG. 9 shows expression of BAG3 in CHO-Lec2 cells following transduction by the indicated vectors. The cells were transduced with 3E6 MOI for each vector, and after 6

days, the cells lysate were collected and a Western Blot performed using an anti-BAG3 polyclonal antibody (abcam ab225561 1:2,500).

DETAILED DESCRIPTION OF THE INVENTION

[0016] The present disclosure provides gene therapy vectors that deliver a polynucleotide encoding a BAG3 polypeptide or a functional fragment or variant thereof, along with methods of use, and other compositions and methods. In particular embodiments, the disclosure relates to a gene therapy vector comprising a promoter sequence operatively linked to a polynucleotide encoding a BAG3 polypeptide or a functional fragment or variant thereof. In certain embodiments, the promoter is a heterologous promoter, i.e., not the normal or endogenous promoter for the *BAG3* gene in mammalian cells or not a normal or endogenous protein for the gene delivery vector, e.g., an AAV. In some embodiments, the BAG3 is a human BAG3.

[0017] In some embodiments, the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is an MHCK7 promoter and the AAV vector is a AAVrh.74 vector. In some embodiments, the promoter is a hTNNT2 promoter. In some embodiments, the promoter is a hTNNT2 promoter and the AAV vector is a AAVrh.74 vector. In some embodiments, the promoter is a HSP70 promoter. In some embodiments, the promoter is a HSP70 promoter and the AAV vector is a AAVrh.74 vector. In some embodiments, the promoter is a Ubiquitin C (UBC) promoter. In some embodiments, the promoter is an UBC promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is a CAG promoter or a chicken β actin promoter. In some embodiments, the promoter is a CAG promoter or a chicken β actin promoter and the AAV vector is a AAVrh.74 vector. In some embodiments, the BAG3 is human BAG3.

[0018] In some embodiments, the AAV vector is an AAV9 vector. In some embodiments, the promoter is a Myosin Heavy-chain Creatine Kinase 7 (MHCK7) promoter. In some embodiments, the promoter is an MHCK7 promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is a hTNNT2 promoter. In some embodiments, the promoter is an hTNNT2 promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is a heat shock protein 70 (HSP70) promoter. In some embodiments, the promoter is an HSP70 promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is a Ubiquitin C (UBC) promoter. In some embodiments, the promoter is an UBC promoter and the AAV vector is an AAV9 vector. In some embodiments,

the promoter is a CAG promoter or a chicken β actin promoter. In some embodiments, the promoter is a CAG promoter or a chicken β actin promoter and the AAV vector is an AAV9 vector. In some embodiments, the BAG3 is human BAG3.

[0019] This disclosure further provides methods of treating a disease or disorder in a subject by administering a gene therapy vector of the disclosure to the subject. In certain embodiments, the disease or disorder is heart failure. In certain embodiments, the disease or disorder is a cardiomyopathy, e.g., a dilated cardiomyopathy. In certain embodiments, the disease or disorder is BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial isolated dilated cardiomyopathy, and cardiomyopathy, dilated, 1hh (CMD1HH).

[0020] In certain embodiments, the subject being treated is a heart failure patient having one or more mutations or truncations in a *BAG3* gene. The expression level of *BAG3* is decreased in failing hearts of multiple etiologies including human heart failure. The gene *BAG3* encodes the protein B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3). BAG3 is involved in protein quality control (PQC). PQC comprises chaperones and protein degradation systems, including the ubiquitin-proteasome system (UPS) and autophagy-lysosome system, that help minimize proteotoxicity. Chaperones function as the first line of defense by either refolding misfolded proteins or by promoting the degradation of misfolded or damaged proteins that are not suitable for refolding via the UPS or autophagy. BAG3 regulates the ATPase activity of a class of chaperones, the HSP70 family, and is predominantly expressed in striated muscles.

[0021] BAG3 is also involved in chaperone-assisted selective autophagy (CASA). CASA is a cargo-selective form of autophagy that is mediated through the HSC70-BAG3-HSPB8 complex and allows ubiquitination of selected proteins recognized by HSC70 via the CHIP ubiquitin ligase and sequestration by autophagosomes through the LC3 adapter p62/ SQSTM1 in the presence of synaptopodin 2 or DNAJB6. In muscles, BAG3 is particularly important for maintaining the structure and integrity of sarcomeres through its interaction with HSC70 and an actin-capping sarcomeric protein (actin-capping protein $\beta 1$).

[0022] Genome wide associated studies (GWAS) have identified several mutations in BAG3, such as E455K, in patients with DCM. Additionally, mouse models (e.g., BAG3 cKO or BAG3 E455K KI) demonstrated that loss of function of BAG3 induces the development of

DCM by attenuating PQC over a specific subset of proteins involved in metabolic and contractile functions in cardiomyocytes

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting.

[0024] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment, or any form of suggestion, that they constitute valid prior art or form part of the common general knowledge in any country in the world.

[0025] In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. The term “about”, when immediately preceding a number or numeral, means that the number or numeral ranges plus or minus 10%. It should be understood that the terms “a” and “an” as used herein refer to “one or more” of the enumerated components unless otherwise indicated. The use of the alternative (*e.g.*, “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. The term “and/or” should be understood to mean either one, or both of the alternatives. As used herein, the terms “include” and “comprise” are used synonymously.

[0026] As used herein, the term “in a subject over time” refers to an effect in a subject that occurs for about one day, for about one month, for about one year, for about one decade, and/or for about several decades.

[0027] As used herein, the terms “identity” and “identical” refer, with respect to a polypeptide or polynucleotide sequence, to the percentage of exact matching residues in an

alignment of that “query” sequence to a “subject” sequence, such as an alignment generated by the BLAST algorithm. Identity is calculated, unless specified otherwise, across the full length of the subject sequence. Thus, a query sequence “shares at least x% identity to” a subject sequence if, when the query sequence is aligned to the subject sequence, at least x% (rounded down) of the residues in the subject sequence are aligned as an exact match to a corresponding residue in the query sequence. Where the subject sequence has variable positions (*e.g.*, residues denoted X), an alignment to any residue in the query sequence is counted as a match. Sequence alignments may be performed using the NCBI Blast service (BLAST+ version 2.12.0).

[0028] As used herein, the term “operatively linked” refers to a functional relationship between two or more nucleic acid (*e.g.*, DNA) segments. Typically, it refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter sequence is operatively linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Generally, promoter transcriptional regulatory sequences that are operatively linked to a transcribed sequence are physically contiguous to the transcribed sequence, *i.e.*, they are *cis*-acting. However, some transcriptional regulatory sequences, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.

[0029] As used herein, an “AAV vector” or “rAAV vector” refers to a recombinant vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV inverted terminal repeat sequences (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a plasmid encoding and expressing *rep* and *cap* gene products. Alternatively, AAV vectors can be packaged into infectious particles using a host cell that has been stably engineered to express *rep* and *cap* genes.

[0030] As used herein, an “AAV virion” or “AAV viral particle” or “AAV vector particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. As used herein, if the particle comprises a heterologous polynucleotide (*i.e.*, a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an “AAV vector particle” or simply an “AAV vector.” Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.

[0031] As used herein, “promoter” refers to a polynucleotide sequence capable of promoting initiation of RNA transcription from a polynucleotide in a eukaryotic cell.

[0032] As used herein, “vector genome” refers to the polynucleotide sequence packaged by the vector (*e.g.*, an rAAV virion), including flanking sequences (in AAV, inverted terminal repeats). The terms “expression cassette” and “polynucleotide cassette” refer to the portion of the vector genome between the flanking ITR sequences. “Expression cassette” implies that the vector genome comprises at least one gene encoding a gene product operatively linked to an element that drives expression (*e.g.*, a promoter).

[0033] As used herein, the term “patient in need” or “subject in need” refers to a patient or subject at risk of, or suffering from, a disease, disorder or condition that is amenable to treatment or amelioration with a recombinant gene therapy vector or gene editing system disclosed herein. A patient or subject in need may, for instance, be a patient or subject diagnosed with a disorder associated with heart. A subject may have a mutation in an *BAG3* gene or deletion of all or a part of *BAG3* gene, or of gene regulatory sequences, that causes aberrant interaction between BAG3 and HSP70. “Subject” and “patient” are used interchangeably herein. The subject treated by the methods described herein may be an adult or a child. Subjects may range in age.

[0034] As used herein, the term “variant” refers to a protein that has one or more amino-acid substitution, insertion, or deletion as compared to a parental protein. As used herein, the term “functional variant” refers to a protein that has one or more amino-acid substitution, insertion, or deletion as compared to a parental protein, and which retains one or more desired activities of the parental protein.

[0035] As used herein “BAG3”, “BAG3 molecules”, “BCL2-associated athanogene 3 (BAG3) genes”, “BCL2-associated athanogene 3 (BAG3) molecules” are inclusive of all family members, mutants, cDNA sequences, alleles, fragments, species, coding and noncoding sequences, sense and antisense polynucleotide strands, etc. Similarly, “BAG3”, “BAG3 molecules”, “BCL2-associated athanogene 3 (BAG3) molecules” also refer to BAG3 polypeptides or fragment thereof, proteins, variants, derivatives etc. The term “molecule” encompasses both the nucleic acid sequences and amino acid sequences of BAG3, unless specified otherwise.

[0036] As used herein, the term “fragment” refers to a fragment of a protein. As used herein, the term “functional fragment” refers to a protein that has one or more deletion as compared to a parental protein, and which retains one or more desired activities of the parental protein. In particular embodiments, a fragment may be a portion of a protein lacking an N-terminal and/or C-terminal stretch of amino acids. Fragments may comprise less than 99%, less than 95%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, or less than 20% of the full-length protein.

[0037] As used herein, “treating” refers to ameliorating one or more symptoms of a disease or disorder. The term “preventing” refers to delaying or inhibiting or interrupting the onset of one or more symptoms of a disease or disorder or slowing the progression of *BAG3*-related disease or disorder, *e.g.*, a dilated cardiomyopathy (DCM).

[0038] Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including two ~145-nucleotide inverted terminal repeat (ITRs). There are multiple known variants of AAV, also sometimes called serotypes when classified by antigenic epitopes. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and Srivastava et al., J. Virol., 45: 555-564 (1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., J. Virol., 78: 6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1): 67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2): 375-383 (2004). The sequence of the AAVrh.74 genome is provided in U.S. Patent 9,434,928, incorporated herein by reference. Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the AAV ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins

(rep78, rep68, rep52, and rep40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, *Current Topics in Microbiology and Immunology*, 158: 97-129 (1992).

[0039] AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues *in vivo*. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV viral genome is inserted as cloned DNA in plasmids, which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication and genome encapsidation are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.7 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA. To generate AAV vectors, the rep and cap proteins may be provided in trans. Another significant feature of AAV is that it exhibits high thermal stability. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.

[0040] Gene delivery viral vectors useful in the practice of the present invention can be constructed utilizing methodologies well known in the art of molecular biology. Typically, viral vectors carrying transgenes are assembled from polynucleotides encoding the transgene, suitable regulatory elements and elements necessary for production of viral proteins, which mediate cell transduction. Such recombinant viruses may be produced by techniques known in the art, *e.g.*, by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of virus packaging cells include but are not limited to HeLa cells, SF9 cells (optionally with a baculovirus helper vector), HEK293 cells, etc. A Herpesvirus-based system can be used to produce AAV vectors, as described in US20170218395A1.

Detailed protocols for producing such replication-defective recombinant viruses may be found for instance in W095/14785, W096/22378, U.S. Pat. No. 5,882,877, U.S. Pat. No. 6,013,516, U.S. Pat. No. 4,861,719, U.S. Pat. No. 5,278,056 and W094/19478, the complete contents of each of which is hereby incorporated by reference.

[0041] The present disclosure contemplates compositions and methods of use related to B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3) proteins or polypeptides. In certain embodiments, the subject being treated has one or more mutations in a BAG3 gene or downregulated expression or levels of BAG3 mRNA and/or protein. Mutations or downregulations in BAG3 that disrupt interaction with HSP70 is known to be associated with cardiomyopathy and heart failure, including diseases like those described in Fang et al. *J Clin Invest.* 127(8):3189-320 (2017) and Kieserman et al. *J Am Heart Assoc.* 8(10) (2019); and in other sources. Viral vector-mediated delivery of the *BAG3* gene may therefore serve as a viable therapeutic for BAG3-related human diseases, such as dilated cardiomyopathy and heart failure.

[0042] Mutations in the *BAG3* gene have been identified in people with BAG3-related dilated cardiomyopathy (CMD1HH). (See “CMD1HH,” NCBI MedGen). This condition is a hereditary heart disorder characterized by left ventricular or biventricular heart dilatation. The symptoms include dyspnea, syncope, collapse, fatigue, and chest pain. DCM may lead to death and can affect both children and adults. In certain embodiments, BAG3 mutations include nucleotide variant in-frame insertions as compared to wild-type BAG3 gene sequence. In certain embodiments, the in-frame insertion encodes an amino acid, e.g., a non-polar amino acid. In certain embodiments, the in-frame insertion comprises a 3-nucleotide insertion that adds an alanine at position 160.

[0043] In some embodiments, BAG3 comprises one or more amino acid substitutions. For example, BAG3 may have a C151R amino acid substitution, numbered relative to SEQ ID NO: 1 (described in Villard, E. et al. *Eur Heart J.* 2011 May; 32(9):1065-1076).

[0044] The BAG3 may comprise one or more amino-acid substitutions, inserts, or deletions (collectively, mutations) that alter BAG3 protein-protein binding interactions. For example, BAG3 C151R may increase in the interaction with actin-binding protein Filamin A, hippo pathway kinase STK38, and E3 ubiquitin protein ligases DDB1 and TRIM21, while interaction with small heat shock protein HSPB7 and co-chaperone DNAJB1 may decrease.

[0045] In some embodiments, the BAG3 protein comprises one or more amino acid substitutions at position C-151 to a reference BAG3 protein.

[0046] In some embodiments, BAG3 comprises one or more amino acid modifications, e.g., substitutions, including but not limited to any disclosed in PCT Patent Application Publication Nos. WO2015117010A or WO2019237002A1, US Patent No. 11,236,389, or US Patent Application Publication Nos. US20180296703 or US20210254159, which are incorporated herein by reference in their entirety.

[0047] The polypeptide and polynucleotide coding sequences of human BAG3 are shown below:

BAG3-wild type (SEQ ID NO: 1) – 575 amino acids

MSAATHSPMMQVASGNDRDPLPPGWEIKIDPQTGWPFVVDHNSRTTWNDRVPSEGPKETPSSANG
PSREGSRLPPAREGHPVYPQLRPGYIPIPVLHEGAENRQVHPFHVYPQPGMQRFRTAAAAAPQRSQS
PLRGMPETTQPDKQCGQVAAAAAQPASHGPERSQSPAASDCSSSSSSASLPSSGRSSLGSHQLPRG
YISIPVIHEQNVTRPAAQPSFHQAQKTHYPAAQQGEYQTHQPVYHKIQGDDWEPRPLRAASPFSSVQG
ASSREGSPARSSTPLHSPSPIRVHTVVDRPQQPMTHRETAPVSQPENKPEKPGVPVGPPELPPGHIPIQ
VIRKEVDSKPVSKPPPPSEKVEVKVPPAPVPCPPSPGPSAVPSSPKSVATEERAAPSTAPAEATPP
KPGEAEAPPKHPGVKVEAILEKVQGLEQAVDNFEGKTKDKKYLMIIEEYLTKEALLALDSVDPEGRADV
RQARRDGVRKVQTILEKLEQKAIDVPGQVQVYELQPSNLEADQPLQAIMEMGAVAADKGKKNAGNAED
PHTETQQPEATAAATSNPSSMTDTFGNPAAP

BAG3-wild type (SEQ ID NO: 2) – 1728 nucleotide bases

atgagcgccg ccaccactc gccatgatg caggtggcgt ccggcaacgg tgaccgcgac 60
cctttgcccc ccggatggga gatcaagatc gaccgcgaga ccggctggcc cttcttcgtg
120
gaccacaaca gccgcaccac tacgtggaac gaccgcgcg tgccctctga gggccccaag
180
gagactccat cctctgcca tggcccttcc cgggagggct ctaggctgcc gcctgctagg
240
gaaggccacc ctgtgtaccc ccagctccga ccaggctaca ttccatttcc tgtgctccat
300
gaaggcgctg agaaccggca ggtgcaccct ttccatgtct atcccagcc tgggatgcag
360
cgattccgaa ctgaggcggc agcagcggt cctcagaggt ccagtcacc tctgcggggc
420
atgccagaaa cactcagcc agataaacag tgtggacagg tggcagcggc ggcggcagcc
480
cagccccag cctccacgg acctgagcg tccagtcctc cagctgcctc tgactgctca
540
tcctatcct cctcgccag cctgccttcc tccggcagga gcagcctggg cagtcaccag
600
ctcccgcggg ggtacatctc cattccggtg atacacgagc agaacgttac ccggccagca
660
gcccgccct ccttccacca agcccagaag acgcactacc cagcgcagca gggggagtag
720

```

cagaccacc agcctgtgta ccacaagatc caggggggatg actgggagcc cgggcccctg
780
cgggcgggcat ccccgttcag gtcattctgtc caggggtgcat cgagccggga gggctcacca
840
gccaggagca gcacgccact ccactcccc tcgcccattcc gtgtgcacac cgtgggtcgac
900
aggcctcagc agcccatgac ccatcgagaa actgcacctg tttcccagcc tgaaaacaaa
960
ccagaaagta agccaggccc agttggacca gaactccctc ctggacacat cccaattcaa
1020
gtgatccgca aagaggtgga ttctaaacct gtttcccaga agccccacc tccctctgag
1080
aaggtagagg tgaaagtcc cctgctcca gttccttgtc ctctcccag ccctggccct
1140
tctgctgtcc cctcttcccc caagagtgtg gctacagaag agagggcagc cccagcact
1200
gcccctgcag aagctacacc tccaaaacca ggagaagccg aggtccccc aaaacatcca
1260
ggagtgtga aagtggaagc catcctggag aaggtacagg ggctggagca ggctgtagac
1320
aactttgaag gcaagaagac tgacaaaaag tacctgatga tcgaagagta tttgacaaa
1380
gagctgtgg ccctggattc agtggacccc gagggacgag ccgatgtgag tcaggccagg
1440
agagacggtg tcaggaaggt tcagaccatc ttggaaaaac ttgaacagaa agccattgat
1500
gtcccaggtc aagtccagggt ctatgaactc cagcccagca accttgaagc agatcagcca
1560
ctgcaggcaa tcatggagat ggggtgccgtg gcagcagaca agggcaagaa aaatgctgga
1620
aatgcagaag atccccacac agaaaccag cagccagaag ccacagcagc agcgacttca
1680
aaccacgca gcatgacaga cacccttgtt aaccagcag caccgtag
1728

```

[0048] In some embodiments, the BAG3 protein comprises a polypeptide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1. In some embodiments, the BAG3 protein comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2. In some embodiments, the BAG3 protein is a wild-type or native BAG3 protein, *e.g.* human BAG3.

[0049] In some embodiments, the disclosure provides a recombinant adeno-associated virus (rAAV) virion, comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding an BAG3 or a functional variant thereof, operatively linked to a promoter. In some embodiments, the disclosure provides a recombinant adeno-associated virus (rAAV) virion, comprising a capsid and a vector genome, wherein the

vector genome comprises a polynucleotide sequence encoding a BAG3, operatively linked to a promoter. The polynucleotide encoding the BAG3 may comprise a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2.

[0050] The AAV virions of the disclosure comprise a vector genome. The vector genome may comprise an expression cassette (or a polynucleotide cassette for gene-editing applications not requiring expression of the polynucleotide sequence).

[0051] Optionally, the polynucleotide sequence encoding the vector genome may comprise a Kozak sequence, including but not limited to GCCACCATGG (SEQ ID NO: 11). Kozak sequence may overlap the polynucleotide sequence encoding a BAG3 protein or a functional variant thereof.

[0052] In some embodiments, the Kozak sequence is an alternative Kozak sequence comprising or consisting of any one of:

(gcc)gccRccAUGG (SEQ ID NO: 13);

AGNNAUGN; (SEQ ID NO: 45)

ANNAUGG; (SEQ ID NO: 46)

ANNAUGC; (SEQ ID NO: 47)

ACCAUGG; (SEQ ID NO: 49), and

GACACCAUGG (SEQ ID NO: 14),

or having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% to any of SEQ ID NOs: 13, 45, 46, 47, 49 or 14.

[0053] In some embodiments, the vector genome comprises no Kozak sequence.

[0054] The vector genome may comprise 5' and/or 3' inverted terminal repeats (ITRs). Any suitable ITRs may be used. The ITRs may be AAV ITRs from the same serotype as the capsid present in the AAV virion, or a different serotype from the capsid (*e.g.*, AAV2 ITRs may be used with an AAV virion having an AAV9 capsid or an AAVrh74 capsid). In each case, the serotype of the capsid determines the name applied to the virion. The ITR are

generally the most 5' and most 3' elements of the vector genome. The vector genome will also generally contain, in 5' to 3' order, a promoter, a transgene, 3' untranslated region (UTR) sequences (*e.g.*, a WPRE element), and a polyadenylation sequence. In variations, the vector genome includes an enhancer element (generally 5' to the promoter) and/or an exon (generally 3' to the promoter). In variations, the vector genome includes a Green Fluorescence Protein (GFP) protein, generally 3' to the transgene. In variations, the vector genomes of the disclosure encode a partial or complete transgene sequence used as a repair template in a gene editing system. In such variations, the vector genome may comprise an exogenous promoter, or the gene editing system may insert the transgene into a locus in the genome having an endogenous promoter, such as a cardiac- or myocyte-specific promoter.

[0055] In some embodiments, the 5' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 15.

SEQ ID NO: 15

```
cctgcaggca gctgcgcgct cgctcgtcct ctgaggccgc cggggcaaag cccgggctgc 60
gggcgacctt tggtcgccc gctcagtg gcgagcgagc gcgcagagag ggagtggcca 120
actccatcac taggggttcc t 141
```

[0056] In some embodiments, the 5' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16.

SEQ ID NO: 16

```
gcgcgctcgc tcgtcactg aggcgcgcc ggcaaagccc gggcgctcgg cgacctttgg 60
tcgcccggcc tcagtgcgc agcgagcgcg cagagagga gtggccaact ccatcactag 120
gggttccttg tagttaatga ttaaccgcc atgtactta tctacgta 168
```

[0057] In some embodiments, the 5' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17)

SEQ ID NO: 17

```
ctgcgcgctc gctcgtcac tgaggccgcc cgggcaaagc cggggcgtcg ggcgaccttt 60
ggtcgcccg cctcagtgag cgagcgagcg cgagagagg gaggggccaa ctccatcact 120
aggggttcct ttagttaat gattaaccgc ccatgtact tatctacgta 170
```

[0058] In some embodiments, the 5' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 18.

SEQ ID NO: 18

```

ttggccactc cctctctgcg cgctcgctcg ctcaactgagg ccgcccgggc aaagcccggg      60
cgtcggggcga cctttggtcg cccggcctca gtgagcgagc gagcgcgagc agagggagtg      120
gccaactcca tcactagggg ttccct                                           145

```

[0059] In some embodiments, the 3' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 19.

SEQ ID NO: 19

```

aggaaccctt agttagtgag ttggccactc cctctctgcg cgctcgctcg ctcaactgagg      60
ccgggcgacc aaaggtcgcc cgacggcccg gctttgcccg ggcggcctca gtgagcgagc      120
gagcgcgagc ctgcctgcag g                                           141

```

[0060] In some embodiments, the 3' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20.

SEQ ID NO: 20

```

tacgtagata agtagcatgg cgggttaatc attaactaca aggaaccctt agttagtgag      60
ttggccactc cctctctgcg cgctcgctcg ctcaactgagg ccgggcgacc aaaggtcgcc      120
cgacggcccg gctttgcccg ggcggcctca gtgagcgagc gagcgcgc      168

```

[0061] In some embodiments, the 3' ITR comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21.

SEQ ID NO: 21

```

aggaaccctt agttagtgag ttggccactc cctctctgcg cgctcgctcg ctcaactgagg      60
ccgggcgacc aaaggtcgcc cgacggcccg gctttgcccg ggcggcctca gtgagcgagc      120
gagcgcgagc agagggagtg gccaa                                           145

```

[0062] In some embodiments the vector genome comprises one or more filler sequences, *e.g.*, at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 22; SEQ ID NO: 23; or SEQ ID NO: 24.

SEQ ID NO: 22

```

gcggcaattc agtcgataac tataacggtc ctaaggtagc gatttaaata cgcgctctct      60
taaggtagcc ccgggacgcg tcaattgact acaaaccgag tatctgcaga gggccctgcg      120
tatg                                           124

```

SEQ ID NO: 23

```

cttctgaggg ggaaagaacc agatcctctc ttaaggtagc atcgagattt aaattagggg      60
taacagggta atggcgcggg ccgc                                           84

```

SEQ ID NO: 24

```

gttaccagg ctggagtgcg gtggcacatt tctgtcact gcaacctcct cctccctggg 60
ttc 63

```

[0063] In some embodiments, the polynucleotide sequence encoding an BAG3 protein or functional variant thereof is operatively linked to a promoter. In some embodiments, the promoter is an MHCK7 promoter. In some embodiments, the promoter is an TNNT2 promoter. In some embodiments, the promoter is a HSP70 promoter. In some embodiments, the promoter is a UBC promoter. In some embodiments, the promoter is a CAG promoter or a chicken β -actin promoter.

[0064] The present disclosure contemplates use of various promoters. Promoters useful in embodiments of the present disclosure include, without limitation, a cytomegalovirus (CMV) promoter, phosphoglycerate kinase (PGK) promoter, or a promoter sequence comprised of the CMV enhancer and portions of the chicken beta-actin promoter and the rabbit beta-globin gene (CAG). In some cases, the promoter may be a synthetic promoter. Exemplary synthetic promoters are provided by Schlabach et al. *PNAS USA*. 107(6):2538–43 (2010). In some embodiments, the promoter comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 25.

SEQ ID NO: 25.

```

acttacggta aatggcccgcc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat
60
aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga
120
gtattttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc
180
ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgccagat acatgacctt
240
atgggacttt cctacttggc agtacatcta cgtattagtc atcgtatatta ccatgggtcga
300
ggtgagcccc acgttctgct tcaactctccc catctccccc cctcccccac ccccaatttt
360
gtattttattt attttttaat tattttgtgc agcgatgggg gcgggggggg ggggggcgcg
420
cgccaggcgg gcggggcgcg ggcgaggggc ggggcggggc gaggcggaga ggtgcggcgg
480
cagccaatca gagcggcgcg ctccgaaagt ttctttttat ggcgagggcg cgcgggcgcg
540
ggccctataa aaagcgaagc gcgcggcgcg cg
573

```

[0065] In some embodiments, a polynucleotide sequence encoding an BAG3 protein or functional variant thereof is operatively linked to an inducible promoter. An inducible promoter may be configured to cause the polynucleotide sequence to be transcriptionally expressed or

not transcriptionally expressed in response to addition or accumulation of an agent or in response to removal, degradation, or dilution of an agent. The agent may be a drug. The agent may be tetracycline or one of its derivatives, including, without limitation, doxycycline. In some cases, the inducible promoter is a tet-on promoter, a tet-off promoter, a chemically-regulated promoter, a physically-regulated promoter (*i.e.*, a promoter that responds to presence or absence of light or to low or high temperature). Inducible promoters include heavy metal ion inducible promoters (such as the mouse mammary tumor virus (mMTV) promoter or various growth hormone promoters), and the promoters from T7 phage which are active in the presence of T7 RNA polymerase. This list of inducible promoters is non-limiting.

[0066] In some cases, the promoter is a tissue-specific promoter, such as a promoter capable of driving expression in a cardiac cell to a greater extent than in a non-cardiac cell. In some embodiments, tissue-specific promoter is a selected from any various cardiac tissue- or cell-specific promoters including but not limited to, desmin (Des), alpha-myosin heavy chain (α -MHC), myosin light chain 2 (MLC-2), cardiac troponin C (cTnC), cardiac troponin T (hTNNT2), muscle creatine kinase (CK) and combinations of promoter/enhancer regions thereof, such as MHCK7. In some embodiments, the promoter is inducible to environmental stimuli. In some embodiments, the promoter is a heat shock protein 70 (HSP70) promoter. In some cases, the promoter is a ubiquitous promoter. A “ubiquitous promoter” refers to a promoter that is not tissue-specific under experimental or clinical conditions. In some cases, the ubiquitous promoter is any one of Cytomegalovirus (CMV), Cytomegalovirus early enhancer element chicken beta-Actin gene intron with the splice acceptor of the rabbit beta-Globin gene (CAG), ubiquitin C (UBC), Phosphoglycerate Kinase (PGK), Eukaryotic translation elongation factor 1 alpha 1 (EF1-alpha), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), simian virus 40 (SV40), Hepatitis B virus (HBV), chicken beta-actin, and human beta-actin promoters.

[0067] In some embodiments, the promoter sequence is selected from Table 1. In some embodiments, the promoter comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 31-48, 115 or 116. In some embodiments, the promoter comprises a fragment of a polynucleotide sequence of any one of SEQ ID NOS: 31-48, e.g., a fragment comprising at least 25 %, at least 50%, at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of any one of SEQ ID NOS: 31-51, 115 or 116. For example, in some

embodiments, the promoter is a fragment of the UBC promoter consisting of about the first 400 nucleotides of the UBC promoter sequence of SEQ ID NO: 116.

Table 1

PROMOTER	SEQUENCE	SEQ ID NO:
MHCK7	ACCCTTCAGATTAAAAATAACTGAGGTAAGGGCCTGGGTAG GGGAGGTGGTGTGAGACGCTCCTGTCTCTCTCTATCTGCCC ATCGGCCCTTTGGGGAGGAGGAATGTGCCCAAGGACTAAAA AAAGGCCATGGAGCCAGAGGGGCGAGGGCAACAGACCTTTC ATGGGCAAACCTTGGGGCCCTGCTGTCTAGCATGCCCCACTA CGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGAC ACCCGAGATGCCTGGTTATAATTAACCCAGACATGTGGCTGC CCCCCCCCCCAACACCTGCTGCCTCTAAAAATAACCCTGT CCCTGGTGGATCCCCTGCATGCGAAGATCTTCGAACAAGGCT GTGGGGGACTGAGGGCAGGCTGTAACAGGCTTGGGGGCCAG GGCTTATACGTGCCTGGGACTCCCAAAGTATTACTGTTCCAT GTTCCCGGCGAAGGGCCAGCTGTCCCCGCCAGCTAGACTCA GCACTTAGTTTATAGGAACCAAGTGAGCAAGTCAGCCCTTGGGGC AGCCCATACAAGGCCATGGGGCTGGGCAAGCTGCACGCCTG GGTCGGGGTGGGCACGGTGCCCGGGCAACGAGCTGAAAGC TCATCTGCTCTCAGGGGGCCCCTCCCTGGGGACAGCCCCTCCT GGCTAGTCACACCCTGTAGGCTCCTCTATATAACCCAGGGGC ACAGGGGCTGCCCTCATTCTACCACCACCTCCACAGCACAGA CAGACACTCAGGAGCCAGCCAG	31
Human cardiac troponin T promoter (without exon 1) hTnnT2 / HTNNT2	CTCAGTCCATTAGGAGCCAGTAGCCTGGAAGATGTCTTTACC CCCAGCATCAGTTCAAGTGAGCAGCACATAACTCTTGCCCT CTGCCTTCCAAGATTCTGGTGCTGAGACTTATGGAGTGTCTT GGAGGTTGCCTTCTGCCCCCAACCCTGCTCCCAGCTGGCCC TCCCAGGCCTGGGTTGCTGGCCTCTGCTTTATCAGGATTCTCA AGAGGGACAGCTGGTTTATGTTGCATGACTGTTCCCTGCATA TCTGCTCTGGTTTTAAATAGCTTATCTGAGCAGCTGGAGGAC CACATGGGCTTATATGGCGTGGGGTACATGTTCCCTGTAGCCT TGTCCCTGGCACCTGCCAAAATAGCAGCCAACACCCCCACC	33

PROMOTER	SEQUENCE	SEQ ID NO:
	CCCACCGCCATCCCCCTGCCCCACCCGTCCCCTGTCGCACAT TCCTCCCTCCGCAGGGCTGGCTCACCAGGCCCCAGCCCACAT GCCTGCTTAAAGCCCTCTCCATCCTCTGCCTCACCCAGT	
Human cardiac troponin T promoter (with exon 1, underlined) hTnnT2 / HTNNT2	CTCAGTCCATTAGGAGCCAGTAGCCTGGAAGATGTCTTTACC CCCAGCATCAGTTCAAGTGGAGCAGCACATAACTCTTGCCCT CTGCCTTCCAAGATTCTGGTGCTGAGACTTATGGAGTGTCTT GGAGGTTGCCTTCTGCCCCCAACCCGTCTCCAGCTGGCCC TCCCAGGCCTGGGTTGCTGGCCTCTGCTTTATCAGGATTCTCA AGAGGGACAGCTGGTTTATGTTGCATGACTGTTCCCTGCATA TCTGCTCTGGTTTTAAATAGCTTATCTGAGCAGCTGGAGGAC CACATGGGCTTATATGGCGTGGGGTACATGTTCCCTGTAGCCT TGTCCTGGCACCTGCCAAAATAGCAGCCAACACCCCCCACC CCCACCGCCATCCCCCTGCCCCACCCGTCCCCTGTCGCACAT TCCTCCCTCCGCAGGGCTGGCTCACCAGGCCCCAGCCCACAT GCCTGCTTAAAGCCCTCTCCATCCTCTGCCTCACCCAGT <u>CCCC</u> <u>GCTGAGACTGAGCAGACGCCTCCAGGATCTGTCTGGCAG</u>	32
Mouse α -cardiac myosin heavy chain promoter (α MHC)	GGTACCGGATCCTGCAAGGTCACACAAGGGTCTCCACCCACC AGGTGCCCTAGTCTCAATTTTCAGTTTCCATGCCTTGTTCTCAC AATGCTGGCCTCCCCAGAGCTAATTTGGACTTTGTTTTTATTT CAAAAGGGCCTGAATGAGGAGTAGATCTTGTGCTACCCAGC TCTAAGGGTGCCCGTGAAGCCCTCAGACCTGGAGCCTTTGCA ACAGCCCTTTAGGTGGAAGCAGAATAAAGCAATTTTCCTTAA AGCCAAAATCCTGCCTCTAGACTCTTCTTCTCTGACCTCGGTC CCTGGGCTCTAGGGTGGGGAGGTGGGGCTTGGAAGAAGAAG GTGGGGAAGTGGCAAAAGCCGATCCCTAGGGCCCTGTGAAG TTCGGAGCCTTCCCTGTACAGCACTGGCTCATAGATCCTCCT CCAGCCAAACATAGCAAGAAGTGATACCTCCTTTGTGACTTC CCCAGGCCCAGTACCTGTCAGGTTGAAACAGGATTTAGAGA AGCCTCTGAACCTCACCTGAACTCTGAAGCTCATCCACCAAGC AAGCACCTAGGTGCCACTGCTAGTTAGTATCCTACGCTGATA ATATGCAGAGCTGGGCCACAGAAGTCCTGGGGTGTAGGAAC TGACCAGTGACTTTTCAGTCGGCAAAGGTATGACCCCTCAG	34

PROMOTER	SEQUENCE	SEQ ID NO:
	CAGATGTAGTAATGTCCCCTTAGATCCCATCCCAGGCAGGTC TCTAAGAGGACATGGGATGAGAGATGTAGTCATGTGGCATT CCAAACACAGCTATCCACAGTGTCCCTTGCCCCCTCCACTTA GCCAGGAGGACAGTAACCTTAGCCTATCTTTCTTCCTCCCCA TCCTCCCAGGACACACCCCCTGGTCTGCAGTATTCATTTCTTC CTTCACGTCCCCTCTGTGACTTCCATTTGCAAGGCTTTTGACC TCTGCAGCTGCTGGAAGATAGAGTTTGGCCCTAGGTGTGGCA AGCCATCTCAAGAGAAAGCAGACAACAGGGGGACCAGATTT TGGAAGGATCAGGAATAAATCACTGGCGGGCCTGGGGGTA GAAAAAAGAGTGAGTGAGTCCGCTCCAGCTAAGCCAAGCTA GTCCCCGAGATACTCTGCCACAGCTGGGCTGCTCGGGGTAGC TTTAGGAATGTGGGTCTGAAAGACAATGGGATTGGAAGACA TCTCTTTGAGTCTCCCCTCAACCCACCTACAGACACACTCGT GTGTGGCCAGACTCCTGTTCAACAGCCCTCTGTGTTCTGACC ACTGAGCTAGGCAACCAGAGCATGGGCCCTGTGCTGAGGAT GAAGAGTTGGTTACCAATAGCAAAAACAGCAGGGGAGGGAG AACAGAGAACGAAATAAGGAAGGAAGAAGGAAAGGCCAGT CAATCAGATGCAGTCAGAAGAGATGGGAAGCCAACACACAG CTTGAGCAGAGGAAACAGAAAAGGGAGAGATTCTGGGCATA AGGAGGCCACAGAAAGAAGAGCCCAGGCCCCCAAGTCTCC TCTTTATACCCTCATCCCGTCTCCCAATTAAGCCCACTCTTCT TCCTAGATCAGACCTGAGCTGCAGCGAAGAGACCCGTAGGG AGGATCACACTGGATGAAGGAGATGTGTGGAGAAGTCCAGG GAACCTAAGAGCCAGAGCCTAAAAGAGCAAGAGATAAAGGT GCTTCAAAGGTGGCCAGGCTGTGCACACAGAGGGTCGAGGA CTGGTGGTAGAGCCTCAAGATAAGGATGATGCTCAGAAATGG GCGGGGGGGGGGATTCTGGGGGGGGGAGAGAGAAGGTGAG AAGGAGCCTGGAACAGAGAATCTGGAAGCGCTGGAAACGAT ACCATAAAGGGAAGAACCAGGCTACCTTTAGATGTAAATC ATGAAAGACAGGGAGAAGGGAAGCTGGAGAGAGTAGAAGG ACCCCGGGGCAAGACATTGAAGCAAGGACAAGCCAGGTTGA GCGCTCCGTGAAATCAGCCTGCTGAAGGCAGAGCCCTGGTAT GAGCACCAGAACAGCAGAGGCTAGGGTTAATGTGAGACAG GGAACAGAAGGTAGACACAGGAACAGACAGAGACGGGGGA	

PROMOTER	SEQUENCE	SEQ ID NO:
	GCCAGGTAACAAAGGAATGGTCCTTCTCACCTGTGGCCAGA GCGTCCATCTGTGTCCACATACTCTAGAATGTTTCATCAGACT GCAGGGCTGGCTTGGGAGGCAGCTGGAAAGAGTATGTGAGA GCCAGGGGAGACAAGGGGGCCTAGGAAAGGAAGAAGAGGG CAAACCAGGCCACACAAGAGGGCAGAGCCCAGAACTGAGTT AACTCCTTCCTTGTTCATCTTCCATAGGAGGCAGTGGGAAC TCTGTGACCACCATCCCCCATGAGCCCCCACTACCCATACCA AGTTTGGCCTGAGTGGCATTCTAGGTTCCCTGAGGACAGAGC CTGGCCTTTGTCTCTTGGACCTGACCCAAGCTGACCCAATGT TCTCAGTACCTTATCATGCCCTCAAGAGCTTGAGAACCAGGC AGTGACATATTAGGCCATGGGCTAACCCTGGAGCTTGCACAC AGGAGCCTCAAGTGACCTCCAGGGACACAGCTGCAGACAGG TGGCCTTTATCCCCAAAGAGCAACCATTGTCATAGGTGGCT GCAAATGGGAATGCAAGGTTGAATCAGGTCCCTTCAAGAAT ACTGCATGCAAGACCTAAGACCCCTGGAGAGAGGGGTATGC TCCTGCCCCCACCACCATAAGGGGAGTGAAGTATCCTAGGG GGCTGGCGACCTTGGGGAGACACCACATTACTGAGAGTGCT GAGCCCAGAAAACTGACCGCCCTGTGTCCTGCCCACCTCCA CACTCTAGAGCTATATTGAGAGGTGACAGTAGATAGGGTGG GAGCTGGTAGCAGGGAGAGTGTTCTGGGTGTGAGGGTGTA GGGGAAAGCCAGAGCAGGGGAGTCTGGCTTTGTCTCCTGAA CACAATGTCTACTTAGTTATAACAGGCATGACCTGCTAAAGA CCCAACATCTACGACCTCTGAAAAGACAGCAGCCCTGGAGG ACAGGGGTGTCTCTGAGCCTTGGGTGCTTGATGGTGCCACA AAGGAGGGCATGAGTGTGAGTATAAGGCCCCAGGAGCGTTA GAGAAGGGCACTTGGGAAGGGGTCAGTCTGCAGAGCCCCTA TCCATGGAATCTGGAGCCTGGGGCCAACTGGTGTAATCTCT GGGCCTGCCAGGCATTCAAAGCAGCACCTGCATCCTCTGGCA GCCTGGGGAGGCGGAAGGGAGCAACCCCCCACTTATACCCT TTCTCCCTCAGCCCCAGGATTAACACCTCTGGCCTTCCCCCTT CCCACCTCCCATCAGGAGTGGAGGGTTGCAGAGGGAGGGTA AAAACCTACATGTCCAAACATCATGGTGCACGATATATGGAT CAGTATGTGTAGAGGCAAGAAAGGAAATCTGCAGGCTTAAC TGGGTTAATGTGTAAAGTCTGTGTGCATGTGTGTGTGTCTGA	

PROMOTER	SEQUENCE	SEQ ID NO:
	CTGAAAACGGGCATGGCTGTGCAGCTGTTTCAGTTCTGTGCGT GAGGTTACCAGACTGCAGGTTTGTGTGTAAATTGCCCAAGGC AAAGTGGGTGAATCCCTTCCATGGTTTAAAGAGATTGGATGA TGGCCTGCATCTCAAGGACCATGGAAAATAGAATGGACACT CTATATGTGTCTCTAAGCTAAGGTAGCAAGGTCTTTGGAGGA CACCTGTCTAGAGATGTGGGCAACAGAGACTACAGACAGTA TCTGTACAGAGTAAGGAGAGAGAGGAGGGGGTGTAGAATTC TCTTACTATCAAAGGGAACTGAGTCGTGCACCTGCAAAGTG GATGCTCTCCCTAGACATCATGACTTTGTCTCTGGGGAGCCA GCACTGTGGAACCTTCAGGTCTGAGAGAGTAGGAGGCTCCCCCT CAGCCTGAAGCTATGCAGATAGCCAGGGTTGAAAGGGGGAA GGGAGAGCCTGGGATGGGAGCTTGTGTGTTGGAGGCAGGGG ACAGATATTAAGCCTGGAAGAGAAGGTGACCCTTACCCAGT TGTTCAACTCACCTTCAGATTAAAAATAACTGAGGTAAGGG CCTGGGTAGGGGAGGTGGTGTGAGACGCTCCTGTCTCTCCTC TATCTGCCCATCGGCCCTTTGGGGAGGAGGAATGTGCCCAAG GACTAAAAAAAGGCCATGGAGCCAGAGGGGCGAGGGCAAC AGACCTTTCATGGGCAAACCTTGGGGCCCTGCTGTCCTCCTG TCACCTCCAGAGCCAAGGGATCAAAGGAGGAGGAGCCAGGA CAGGAGGGAAGTGGGAGGGAGGGTCCCAGCAGAGGACTCC AAATTTAGGCAGCAGGCATATGGGATGGGATATAAAGGGG TGGAGCACTGAGAGCTGTCAGAGATTTCTCCAACCCAGGTAA GAGGGAGTTTCGGGTGGGGGCTCTTCACCCACACCAGACCTC TCCCCACCTAGAAGGAACTGCCTTTCCTGGAAGTGGGGTTC AGGCCGGTCAGAGATCTGACAGGGTGGCCTTCCACCAGCCT GGGAAGTTCTCAGTGGCAGGAGGTTTCCACAAGAAACACTG GATGCCCCTTCCCTTACGCTGTCTTCTCCATCTTCCTCCTGGG GATGCTCCTCCCCGTCTTGGTTTATCTTGGCTCTTCGTCTTCA GCAAGATTTGCCCTGTGCTGTCCACTCCATCTTCTCTACTGT CTCCGTGCCTTGCCTTGCCTTCTTGCCTGTCTTCCTTCCAC CCATTTCTCACTTCACCTTTTCTCCCCCTTCTCATTTGTATTCAT CCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTC CTTTCTCCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTC TTCTGTGTGTCAGAGTGCTGAGAATCACACCTGGGGTTCCCAC	

PROMOTER	SEQUENCE	SEQ ID NO:
	CCTTATGTAAACAATCTTCCAGTGAGCCACAGCTTCAGTGCT GCTGGGTGCTCTCTTACCTTCCTCACCCCTGGCTTGTCTGT TCCATCCTGGTCAGGATCTCTAGATTGGTCTCCAGCCTCTGC TACTCCTCTTCCTGCCTGTTCTCTCTGTCCAGCTGCGCCA CTGTGGTGCCTCGTTCAGCTGTGGTCCACATTCTTCAGGATT CTCTGAAAAGTTAACCAGGTGAGAATGTTTCCCCTGTAGACA GCAGATCACGATTCTCCCGGAAGTCAGGCTTCCAGCCCTCTC TTTCTCTGCCAGCTGCCCCGCACTCTTAGCAAACCTCAGGC ACCCCTACCCACATAGACCTCTGACAGAGAAGCAGGCACTT TACATGGAGTCCTGGTGGGAGAGCCATAGGCTACGGTGTA AAGAGGCAGGGAAGTGGTGGTGTAGGAAAGTCAGGACTTCA CATAGAAGCCTAGCCCACACCAGAAATGACAGACAGATCCC TCCTATCTCCCCCATAAGAGTTTGAGTCGACCCGCGGCCCCG AATTG	
Chicken cardiac troponin T promoter (cTnT)	GGGATAAAAGCAGTCTGGGCTTTCACATGACAGCATCTGGG GCTGCGGCAGAGGGTTCGGGTCCGAAGCGCTGCCTTATCAGC GTCCCCAGCCCTGGGAGGTGACAGCTGGCTGGCTTGTGTCAG CCCCTCGGGCACTCACGTATCTCCGTCCGACGGGTTTAAAT AGCAAACTCTGAGGCCACACAATAGCTTGGGCTTATATGG GCTCCTGTGGGGGAAGGGGGAGCACGGAGGGGGCGGGGCC GCTGCTGCCAAAATAGCAGCTCACAAGTGTTCATTCTCTC TGGGCGCCGGGCACATTCTGCTGGCTCTGCCCCCCCCGGG TGGGCGCCGGGGGACCTTAAAGCCTCTGCCCCCAAGGAG CCCTTCCCAGACAGCCGCCGGCACCCACCGCTCCGTGGGA	35
Human Creatine Kinase M (hCKM)	CTCTCAGCCCTGGAAGTCCTTGCTCACAGCCGAGGCGCCGAG AGCGCTTGCTCTGCCCAGATCTGCGCGAGTCTGGCGCCCGCG CTCTGAACGGCGTCGCTGCCCAGCCCCCTTCCCCGGGAGGTG GGAGCGGCCACCCAGGGCCCCGTGGCTGCCCTTGTAAGGAG GCGAGGCCCCGAGGACACCCGAGACGCCCCGTTATAATTAAC CAGGACACGTGGCGAACCCCCCTCCAACACCTGCCCCGAA CCCCCCCATAACCCAGCGCCTCGGGTCTCGGCCTTTCGGGCAG AGGAGACAGCAAAGCGCCCTCTAAAAATAACTCCTTTCCCG	36

PROMOTER	SEQUENCE	SEQ ID NO:
	GCGACCGAGACCCTCCCTGTCCCCCGCACAGCGGAAATCTCC CAGTGGCACCGAGGGGGCGAGGGTTAAGTGGGGGGGAGGGT GACCACCGCCTCCCACCCTTGCCCTGAGTTTGAATCTCTCCA ACTCAGCCAGCCTCAGTTTCCCCTCCACTCAGTCCCTAGGAG GAAGGGGCGCCCAAGCGCGGGTTTCTGGGGTTAGACTGCCC TCCATTGCAATTGGTCCTTCTCCCGGCCTCTGCTTCCTCCAGC TCACAGGGTATCTGCTCCTCCTGGAGCCACACCTTGGTTCCC CGAGGTGCCGCTGGGACTCGGGTAGGGGTGAGGGCCCAGGG GGCACAGGGGGAGCCGAGGGCCACAGGAAGGGCTGGTGGCT GAAGGAGACTCAGGGGCCAGGGGACGGTGGCTTCTACGTGC TTGGGACGTTCCCAGCCACCGTCCCATGTTCCCGGCGGGGGG CCAGCTGTCCCCACCGCCAGCCCAACTCAGCACTTGGTCAGG GTATCAGCTTGGTGGGGGGGCGTGAGCCCAGCCCCTGGGGC GGCTCAGCCCATACAAGGCCATGGGGCTGGGCGCAAAGCAT GCCTGGGTTCAGGGTGGGTATGGTGCGGGAGCAGGGAGGTG AGAGGCTCAGCTGCCCTCCAGAACTCCTCCCTGGGGACAACC CCTCCCAGCCAATAGCACAGCCTAGGTCCCCCTATATAAGGC CACGGCTGCTGGCCCTTCCTTTGGGTCAGTGTCACCTCCAGG ATACAGACA	
Human beta-actin (HuBa)	GCCCAGCACCCCAAGGCGGCCAACGCCAAAACCTCTCCCTCCT CCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTTTCGAAAA GGAGGGGAGAGGGGGTAAAAAATGCTGCACTGTGCGGCGA AGCCGGTGAGTGAGCGGCGCGGGCCAATCAGCGTGCGCCG TTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCCGCGGCGGCG CCCTATAAAACCCAGCGGCGCGACGCGCCACCACCGCCGAG TC	37
Chicken beta-actin (CBA)	GGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTC CCCCCCTCCCCACCCCAATTTTGTATTTATTTATTTTAAAT TATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGCGCGC GCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCG AGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT	38

PROMOTER	SEQUENCE	SEQ ID NO:
	CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGGCGGGCGGCC CTATAAAAAGCGAAGCGCGCGGGCGGGCGGGA	
Cytomegalovirus (CMV)	TGGTGATGCGGTTTTTGGCAGTACACCAATGGGCGTGGATAGC GGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTTGACG TCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTC CAAAATGTCTAATAACCCCGCCCCGTTGACGCAAATGGGC GGTAGGCGGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCG TTTAGTGAACCG	39
Cytomegalovirus (CMV) (second version)	TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGG CCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTC AATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTT CCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA CTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCC TATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGC CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACAT CTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTG GCAGTACATCAATGGGCGTGGATAGCGGTTTGAATCACGGG GATTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGT TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCTGTAACA ACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT GGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGT	40
Cytomegalovirus (CMV) (third version)	CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCC CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGT GTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGG TAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATG GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT ATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGT GGATAGCGGTTTGAATCACGGGGATTTCCAAGTCTCCACCC ATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGG	41

PROMOTER	SEQUENCE	SEQ ID NO:
	GACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAA ATGGGCGGTAGGCGGTGTACGGTGGGAGGTCTATATAAGCAG AGCT	
CAG promoter (first version)	ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAAC GCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTT ACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCC CGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCC TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCAT GGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTC CCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAAT TATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGCGCGC GCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCG AGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGC CTATAAAAGCGAAGCGCGCGGCGGGCGG	42
CAG promoter (second version)	CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGT GTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGG TAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATG GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT ATTACCATGTGAGGTGAGCCCCACGTTCTGCTTCACTCTCC CCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTAT TTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGG GGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGG CGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGC GGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGG CGGCGGCCCTATAAAAGCGAAGCGCGCGGCGGGCGG	43

PROMOTER	SEQUENCE	SEQ ID NO:
Human EF1-alpha (EF1- α)	CAACCTTTGGAGCTAAGCCAGCAATGGTAGAGGGAAGATTC TGCACGTCCCTTCCAGGCGGCTCCCCGTCACCACCCCCCCC AACCCGCCCCGACCGGAGCTGAGAGTAATTCATACAAAAGG ACTCGCCCCCTGCCTTGGGGAATCCCAGGGACCGTCGTTAAAC TCCCCTAACGTAGAACCCAGAGATCGCTGCGTTCCCGCCCC CTCACCCGCCCCGCTCTCGTCATCACTGAGGTGGAGAATAGCA TGCGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACAT CGCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTTCGGCAAT TGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGA AAGTGATGTCGTGTACTGGCTCCGCCTTTTCCCGAGGGTGG GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTT	44
Human CamKIIa (CaMKIIa)	ACTTGTGGACAAAGTTTGCTCTATTCCACCTCCTCCAGGCCCT CCTTGGGTCCATCACCCCAGGGGTGCTGGGTCCATCCCACCC CCAGGCCACACAGGCTTGCAAGTATTGTGTGCGGTATGGTCA GGGCGTCCGAGAGCAGGTTTCGCAGTGGAAGGCAGGCAGGT GTTGGGGAGGCAGTTACCGGGGCAACGGGAACAGGGCGTTT TGGAGGTGGTTGCCATGGGGACCTGGATGCTGACGAAGGCT CGCGAGGCTGTGAGCAGCCACAGTGCCCTGC	48
HSP70	CCTGCAGGGCCGCCCCTCCCCCTTCCTCTCAGGGTCCCTGT CCCCCTCAGTGAATCCCAGAAGACTCTGGAGAGTTCTGAGCA GGGGGCGGCACTCTGGCCTCTGATTGGTCCAAGGAAGGCTG GGGGGCAGGACGGGAGGCGAAAACCCTGGAATATTCCTGAC CTGGCAGCCTCATCGAGCTCGGTGATTGGCTCAGAAGGGAA AAGGCGGGTCTCCGTGACGACTTATAAAAGCCCAGGGGCAA GCGGTCCGGATAACGGCTAGCCTGAGGAGCTGCTGCGACAG TCCACTACCTTTTTTCGAGAGTGAAGTCCCGTTGTCCAAGGCTT CCCAGAGCGAACCTGTGCGGCTGCAGGCACCGGCGCGTCA GTTTCCGGCGTCCGGAAGGACCGAGCTCTTCTCGCGGATCCA GTGTTCCGTTTCCAGCCCCCAATCTCAGAGCGGAGCCGACAG AGAGCAGGGAACCC	115
UBC	GATCTGGCCTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCC CCTCCTCACGGCGAGCGCTGCCACGTGAGACGAAGGGCGCAGGAG	116

PROMOTER	SEQUENCE	SEQ ID NO:
	CGTCCTGATCCTTCCGCCCCGACGCTCAGGACAGCGGCCCGCTGC TCATAAGACTCGGCCTTAGAACCCCAAGTATCAGCAGAAGGACATT TTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTTCCA GAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCT GCGGAGGGATCTCCGTGGGGCGGTGAACGCCGATGATTATATAAG GACGCGCCGGGTGTGGCACAGCTAGTTCCGTGCGAGCCGGGATTT GGGTGCGGGTTCTTGTTGTGGATCGCTGTGATCGTCACTTGGTG AGTAGCGGGCTGCTGGGCTGGCCGGGGCTTTCGTGGCCGCCGGGC CGCTCGGTGGGACGGAAGCGTGTGGAGAGACGCCAAGGGCTGTA GTCTGGGTCCGCGAGCAAGGTTGCCCTGAACTGGGGGTTGGGGGG AGCGCAGCAAAATGGCGGCTGTTCCCGAGTCTTGAATGGAAGACG CTTGTGAGGCGGGCTGTGAGGTCGTTGAAACAAGGTGGGGGGCAT GGTGGGCGGCAAGAACCCAAGGTCTTGAGGCCTTCGCTAATGCGG GAAAGCTCTTATTCGGGTGAGATGGGCTGGGGCACCATCTGGGGA CCCTGACGTGAAGTTTGTCACTGACTGGAGAACTCGGTTTGTCTG CTGTTGCGGGGGCGGCAGTTATGCGGTGCCGTTGGGCAGTGCACC CGTACCTTTGGGAGCGCGGCCCTCGTCTGTCTGTGACGTCACCC GTTCTGTTGGCTTATAATGCAGGGTGGGGCCACCTGCCGGTAGGT GTGCGGTAGGCTTTTCTCCGTGCGAGGACGCAGGGTTCGGGCCTA GGGTAGGCTCTCCTGAATCGACAGGCGCCGGACCTCTGGTGAGGG GAGGGATAAGTGAGGCGTCAGTTTCTTTGGTCGGTTTTATGTACC TATCTTCTTAAGTAGCTGAAGCTCCGGTTTTGAACTATGCGCTCG GGGTTGGCGAGTGTGTTTTGTGAAGTTTTTTAGGCACCTTTTGAA ATGTAATCATTTGGGTCAATATGTAATTTTCAGTGTTAGACTAGT AAATTGTCCGCTAAATTCTGGCCGTTTTTTGGCTTTTTTTGTTAGAC GAAG	

[0068] In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 32. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identical to SEQ ID NO: 33. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 34. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 35. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 37. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 38. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 42. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115. In a certain embodiment, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116.

[0069] Further illustrative examples of promoters are the SV40 late promoter from simian virus 40, the Baculovirus polyhedron enhancer/promoter element, Herpes Simplex Virus

thymidine kinase (HSV tk), the immediate early promoter from cytomegalovirus (CMV) and various retroviral promoters including LTR elements. A large variety of other promoters are known and generally available in the art, and the sequences of many such promoters are available in sequence databases such as the GenBank database.

[0070] In some cases, vectors of the present disclosure further comprise one or more regulatory elements selected from the group consisting of an enhancer, an intron, a poly-A signal, a 2A peptide encoding sequence, a WPRE (Woodchuck hepatitis virus posttranscriptional regulatory element), and a HPRE (Hepatitis B posttranscriptional regulatory element). In certain embodiments, the vectors comprise a mutant or modified WPRE (collectively referred to as WPRE(x), e.g., a WPRE or mutant or modified WPRE disclosed in any of SEQ ID NOs: 62-67 or 70, optionally the modified WPRE disclosed in SEQ ID NO: 63 (WPRE Mut6; see Zanta-Boussif, M., Charrier, S., Brice-Ouzet, A. *et al.* Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. *Gene Ther* **16**, 605–619 (2009). <https://doi.org/10.1038/gt.2009.3>). In particular embodiments, the modified WPRE comprises a modification of the start codon of the WHV-X protein, thus preventing its expression.

[0071] In some embodiments, the vector comprises a CMV enhancer.

[0072] In certain embodiments, the vectors comprise one or more enhancers. In particular embodiments, the enhancer is a CMV enhancer sequence, a GAPDH enhancer sequence, a β -actin enhancer sequence, or an EF1- α enhancer sequence. Sequences of the foregoing are known in the art. For example, the sequence of the CMV immediate early (IE) enhancer is SEQ ID NO: 50.

SEQ ID NO: 50

```

acttacggta aatggcccg cttggctgacc gcccaacgac ccccgcccat tgacgtcaat      60
aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga      120
gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc      180
ccctattgac gtcaatgacg gtaaatggcc cgctggcat tatgccagc acatgacctt      240
atgggacttt cctacttggc agtacatcta cgtattagtc atcgtatta cca                293

```

[0073] In certain embodiments, the vectors comprise one or more introns. In particular embodiments, the intron is a rabbit globin intron sequence, a chicken β -actin intron sequence, a synthetic intron sequence, an SV40 intron, or an EF1- α intron sequence.

[0074] In certain embodiments, the vectors comprise a polyA sequence. In particular embodiments, the polyA sequence is a rabbit globin polyA sequence, a human growth hormone polyA sequence, a bovine growth hormone polyA sequence, a PGK polyA sequence, an SV40 polyA sequence, or a TK polyA sequence. In some embodiments, the poly-A signal may be a bovine growth hormone polyadenylation signal (bGHpA).

[0075] In certain embodiments, the vectors comprise one or more transcript stabilizing element. In particular embodiments, the transcript stabilizing element is a WPRE sequence, a HPRE sequence, a scaffold-attachment region, a 3' UTR, or a 5' UTR. In particular embodiments, the vectors comprise both a 5' UTR and a 3' UTR.

[0076] In some embodiments, the vector comprises a 5' untranslated region (UTR) selected from Table 2. In some embodiments, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS 51-61.

Table 2

5' UNTRANSLATED REGION	SEQUENCE	SEQ ID NO:
Human beta-actin exon/intron	CGCGTCCGCCCCGCGAGCACAGAGCCTCGCCTTTGCCGATC CGCCGCCCCGTCCACACCCGCGCCAGGTAAGCCCGGCCAG CCGACCGGGGCATGCGGCCGCGGCCCTTCGCCCCGTGCAGA GCCGCCGTCTGGGCCGCGAGCGGGGGCGCATGGGGCGGA ACCGGACCGCCGTGGGGGGCGCGGGAGAAGCCCCCTGGGC CTCCGGAGATGGGGGACACCCACGCCAGTTCGACAGGCG CGAGGCCGCGCTCGGGCGGGCGCGCTCCGGGGGTGCCGC TCTCGGGGCGGGGGCAACCGGCGGGGTCTTTGTCTGAGCC GGGCTCTTGCCAATGGGGATCGCACGGTGGGCGCGGCGTA GCCCCCGTCAGGCCCCGTGGGGGCTGGGGCGCCATGCGC GTGCGCGCTGGTCCTTTGGGCGCTAACTGCGTGCGCGCTG GGAATTGGCGCTAATTGCGCGTGCGCGCTGGGACTCAATG GCGCTAATCGCGCGTGCGTTCTGGGGCCCCGGGCGCTTGCG CCACTTCCTGCCCCAGCCGCTGGCGCCCCGAGGGTGTGGCC GCTGCGTGCGCGCGCGACCCGGTCGCTGTTTGAACCGG GCGGAGGCGGGGCTGGCGCCCCGGTTGGGAGGGGGTTGGG GCCTGGCTTCCTGCCGCGCGCCGCGGGGACGCCTCCGACC AGTGTTTGCCCTTTATGGTAATAACGCGGCCGGCCCCGGCT TCCTTTGTCCCCAATCTGGGCGCGCGCCGGCGCCCCCTGG CGGCCTAAGGACTCGGCGCGCCGGAAGTGGCCAGGGCGG CAGCGGCTGCTCTTGGCGGCCCCGAGGTGACTATAGCCTT CTTTGTGTCTTGATAGTTCGCCAGCCTCTGCTAACCATGT	51

	TCATGCCTTCTTCTTTTTCTACAGCTCCTGGGCAACGTGC TGGTTATTGTGCTGTCTCATCATTTTGGCAAAGAATTC	
Chicken beta-actin exon/intron + rabbit globin intron	GTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGCTCCGCCG CCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTT ACTCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCG GGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGTTCCTT TCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGGGC CCTTTGTGCGGGGGAGCGGCTCGGGGGGTGCGTGCGTGT GTGTGTGCGTGGGGAGCGCCGCGTGCGGCTCCGCGCTGCC CGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGT GCGCTCCGCAGTGTGCGCGAGGGGAGCGCGGCCGGGGC GGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAACAAA GGCTGCGTGCGGGGTGTGTGCGTGCGGGGGGTGAGCAGGG GGTGTGGGCGCGTTCGGTTCGGGCTGCAACCCCCCTGCACC CCCCCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGC GGGGCTCCGTACGGGGCGTGCGCGGGGCTCGCCGTGCC GGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGC GGGGCCGCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCG CGGCGGCCCCCGAGCGCCGGCGGCTGTCGAGGCGCGGC GAGCCGACGCCATTGCCTTTATGGTAATCGTGCGAGAGG GCGCAGGGACTTCCTTTGTCCCAAATCTGTGCGGAGCCGA AATCTGGGAGGCGCCGCCGCACCCCTCTAGCGGGCGCGG GGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGG GGAGGGCCTTCGTGCGTTCGCCGCGCCGCGCTCCCTTCTC CCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGGCGC TTCGGGGGGGACGGGGCAGGGCGGGGTTGCGCTTCTGGC GTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCA TGCCTTCTTCTTTTTCTACAGCTCCTGGGCAACGTGCTGG TTATTGTGCTGTCTCATCATTTTGGCAAAGAATTC	52
SV40 intron (Chimeric intron sequence)	GGTAAGTTTAGTCTTTTGTCTTTTATTTACAGGTCCCGGAT CCGGTGGTGGTGCAAATCAAAGAACTGCTCCTCAGTGGAT GTTGCCTTTACTTCTAGGCCTGTACGGAAGTGTTACTTCTG CTCTAAAAGCTGCGGAATTGTACCCGC	53
5' UTR-Syn1 Hs	AGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCTGCTGAG AGCGCAGCTGTGCTCCTGGGCACCGCGCAGTCCGCCCCCG CGGCTCCTGGCCAGACCACCCCTAGGACCCCTGCCCAA GTCGCA	54
CMV IE exon	TCAGATCGCCTGGAGAGGCCATCCACGCTGTTTTGACCTC CATAGTGGACACCGGGACCGATCCAGCCTCCGCGGCCGG GAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTG AC	55
TPL-eBAG3 (adenovirus derived enhancer element)	CTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTT GGGCTCGCGGTGAGGACAACTCTTCGCGGTCTTTCCAG TACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGGTACT CCGCCACCGAGGGACCTGAGCGAGTCCGCATCGACCGGA TCGGAACCTCTCGAGAAAGGCGTCTAACCAAGTCACAGT CGCAAGGTAGGCTGAGCACCGTGGCGGGCGGCAGCGGGT GGCGGTGCGGGTTGTTTCTGGCGGAGGTGCTGCTGATGAT GTAATTAAAGTAGGCGGTCTTGAGACGGCGGATGGTCA GGTGAGGTGTGGCAGGCTTGAGATCCAGCTGTTGGGGTGA	56

	GTACTCCCTCTCAAAAGCGGGCATTACTTCTGCGCTAAGA TTGTCAGTTTCCAAAAACGAGGAGGATTTGATATTCACCT GGCCCGATCTGGCCATACACTTGAGTGACAATGACATCCA CTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAG	
Human EF1- α intron/exon	CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTG CCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTAT GGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTCCAGTA CGTGATTCTTGATCCCGAGCTGGAGCCAGGGGCGGGCCTT GCGCTTTAGGAGCCCCCTTCGCCTCGTGCTTGAGTTGAGGC CTGGCCTGGGCGCTGGGGCCCGCGCTGCGAATCTGGTGG CACCTTCGCGCCTGTCTCGCTGCTTTGATAAGTCTCTAGC CATTTAAATTTTTGATGACGTGCTGCGACGCTTTTTTTCT GGCAAGATAGTCTTGTAATGCGGGCCAGGATCTGCACAC TGGTATTTTCGGTTTTTGGGCCCCGCGGCCGCGACGGGGCC CGTGCGTCCCAGCGCACATGTTGCGCGAGGCGGGGCTGC GAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAG CTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTG TATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCCGGTCCGCA CCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTG CTCCAGGGGGCTCAAAATGGAGGACGCGGCGCTCGGGAG AGCGGGCGGGTGAGTACCCACACAAAGGAAAAGGGCCT TTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTAC CGGGCGCCGTCCAGGCACCTCGATTAGTTCTGGAGCTTTT GGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGC GATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTT AGGCCAGCTTGGCACTTGATGTAATTCTCCTTGAATTG GCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAG ACAGTGGTTCAAAGTTTTTTTTCTTCCATTTTCAG	57
Human EF1- α , intron A	GTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTA CGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGG CTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTGGAA GTGGGTGGGAGAGTTTCGAGGCCTTGCCTTAAGGAGCCCC TTCGCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGG GGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTC TCGCTGCTTTGATAAGTCTCTAGCCATTTAAATTTTTGA TGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGT AAATGCGGGCCAAGATCTGCACACTGGTATTTTCGGTTTTT GGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGC ACATGTTGCGCGAGGCGGGGCCTGCGAGCGCGGCCACCG AGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTC TGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTG GGCGGCAAGGCTGGCCCCGGTCGGCACCAAGTTGCGTGAGC GGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCA AAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAG TCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCG TCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAG GCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTT TAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCA CACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCAC TTGATGTAATTCTCCTTGAATTTGCCCTTTTGGAGTTTGG ATCTTGGTTCAATTCTCAAGCCTCAGACAGTGGTTCAAAGTT TTTTCTTCCATTTTCAG	58

5' UTR human CamKIIa	TCAGAAGCCCCGGGCTCGTCAGTCAAACCGGTTCTCTGTT TGCACTCGGCAGCACGGGCAGGCAAGTGGTCCCTAGGTTC GGG	59
B-globin intron	GTGAGTCTATGGGACCCTTGATGTTTTCTTTCCCTTCTTTT CTATGGTTAAGTTCATGTCATAGGAAGGGGAGAAGTAACA GGGTACACATATTGACCAAATCAGGGTAATTTTGCATTTG TAATTTTAAAAATGCTTTCTTCTTTTAATATACTTTTTTGT TTATCTTATTTCTAATACTTTCCCTAATCTCTTTCTTTTCAGG GCAATAATGATACAATGTATCATGCCTCTTTGCACCATCT AAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCA ATATTTCTGCATATAAATATTTCTGCATATAAATTGTAAC GATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCC AGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAGGCTG GATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGT TCATACCTCTTATCTTCTCCACAG	60
SV40 intron (long form; underlined 5' and 3' extensions)	<u>TCTAGAGGATCCGGTACTCGAGGAACTGAAAAACCAGAA</u> <u>AGTTAACTGGTAAGTTTAGTCTTTTTGTCTTTTATTTTCAGG</u> TCCCGGATCCGGTGTTGGTGCAAATCAAAGAAGTGTCTCT CAGTGGATGTTGCCTTTACTTCTAGGCCCTGTACGGAAGTG TTACTTCTGCTCTAAAGCTGCGGAATTGTACCCGC	61

[0077] In some embodiments, the vector comprises a 3' untranslated region selected from Table 3. In some embodiments, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS 62-70.

Table 3

3' UNTRANSLATED REGION	SEQUENCE	SEQ ID NO:
WPRE(x) (mutated woodchuck hepatitis regulatory element – version 1)	AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACT GGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGAT ACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGT ATGGCTTTTCATTTTCTCCTCCTTGATAAATCCTGGTTGCT GTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGT GGCGTGTTGTGCACTGTGTTTGCTGACGCAACCCCCACTG GTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGAC TTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAATCATC GCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGT TGGGCACTGACAATCCGTGGTGTGTCGGGGAAATCAT	62

	CGTCCTTTCTTGGCTGCTCGCCTGTGTTGCCACCTGGATT CTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCA ATCCAGCGGACCTTCTTCCCGCGGCCTGCTGCCGGCTCT GCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGT CGGATCTCCCTTTGGGCGCGCTCCCCGC	
WPRE(x) (mutated woodchuck hepatitis regulatory element – version 2; WPRE Mut6)	TCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGT ATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACG CTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATG GCTTTTCATTTCTCCTCCTTGTATAAATCCTGGTTGCTGTC TCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGC GTGGTGTGCACTGTGTTTGTGACGCAACCCCCACTGGTT GGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTT CGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCC GCCTGCCCTGCCCCGCTGCTGGACAGGGGCTCGGCTGTTGG GCACTGACAATTCCGTGGTGTGTCGGGGAAATCATCGTC CTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGC GCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCC AGCGGACCTTCTTCCCGCGGCCTGCTGCCGGCTCTGCGG CCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGA TCTCCCTTTGGGCGCGCTCCCCGCA	63
WPRE(x) (mutated woodchuck hepatitis regulatory element – version 3)	TTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAG ATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTAT GTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGC TTCCCGTATGGCTTTTCATTTTCTCCTCCTTGTATAAATCCT GGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAG GCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAAC CCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTT TCCGGGACTTTTCGCTTTCCCCCTCCCTATTGCCACGGCGG AACTCATCGCCGCCTGCCCTGCCCCGCTGCTGGACAGGGG CTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTCGGG GAAGCTGACGTCTTTCCGCGGCTGCTCGCCTGTGTTGCC ACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTT CGGCCCTCAATCCAGCGGACCTTCTTCCCGCGGCCTGCT GCCGGCTCTGCGGCCTCTTCCGCCTCTTCGCCTTCGCCCT CAGACGAGTCGGATCTCCCTTTGGGCGCGCTCCCCGCCCA	64

	TGTATCTTTTTACCTGTGCCTTGTTTTTGCCTGTGTTCCG CGTCCTACTTTTCAAGCCTCCAAGCTGTGCCCTGGGCGGC TTTGGGGCATGGACATAGATCCCTATAAAGAATTTGGTTC ATCTTATCAGTTGTTGAATTTTCTTCCTTTGGAC	
CAAX	TGTGTGATAATG	65
EES	CTGTTCTCATCACATCATATCAAGGTTATATACCATCAAT ATTGCCACAGATGTTACTTAGCCTTTTAATTTTCTCTAAT TTAGTGTATATGCAATGATAGTTCTCTGATTTCTGAGATT GAGTTTCTCATGTGTAATGATTATTTAGAGTTTCTCTTTCA TCTGTTCAAATTTTTGTCTAGTTTTATTTTTACTGATTTG TAAGACTTCTTTTTATAATCTGCATATTACAATTCCTTTA CTGGGGTGTGCAAATTTTTCTGTCAATTCTATGGCCTGA CTTTTCTTAATGGTTTTTTAATTTTAAAAATAAGTCTTAAT ATTCATGCAATCTAATTAACAATCTTTTCTTTGTGGTTAG GACTTTGAGTCATAAGAAATTTTTCTCTACACTGAAGTCA TGATGGCATGCTTCTATATTATTTTCTAAAAGATTTAAAG TTTTGCCTTCTCCATTAGACTTATAATTCACCTGGAATTTT TTTGTGTGTATGGTATGACATATGGGTTCCCTTTATTTTT TACATATAAATATATTTCCCTGTTTTTCTAAAAAGAAAA AGATCATCATTTTCCCATTGTAAAATGCCATATTTTTTTCA TAGGTCACCTACATATATCAATGGGTCTGTTTCTGAGCTC TACTCTATTTTATCAGCCTCACTGTCTATCCCCACACATCT CATGCTTTGCTCTAAATCTTGATATTTAGTGGAACATTCT TTCCCATTTTGTCTACAAGAATATTTTGTATTGTCTTT GGGCTTCTATATACATTTTGAAATGAGGTTGACAAGTTA	66
HPRE	ATAACAGGCCTATTGATTGGAAAGTTTGTCAACGAATTGT GGGTCTTTTGGGGTTTGTGCCCCTTTTACGCAATGTGGA TATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAA AACAGGCTTTTACTTTCTCGCCAACCTACAAGGCCTTTCT CAGTAAACAGTATATGACCCTTTACCCCGTTGCTCGGCAA CGGCCTGGTCTGTGCCAAGTGTGTGCTGACGCAACCCCCA CTGGTTGGGGCTTGGCCATAGGCCATCAGCGCATGCGTG GAACCTTTGTGTCTCCTCTGCCGATCCATACTGCGGAACT CCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAC CTCATCGGGACCGACAATTCTGTCTGACTCTCCCCGAAAGT ATACATCGTTTCCATGGCTGCTAGGCTGTGCTGCCAACTG GATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCG CTGAATCCCGCGGACGACCCCTCCCGGGGCGCTTGGGG CTCTACCGCCCGCTTCTCCGTCTGCCGTACCGTCCGACCA CGGGGCGCACCTCTCTTTACGCGGACTCCCCGTCTGTGCC TTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTG CACGTCGCATGGAGGCCACCGTGAACGCCACCGGAACC TGCCCAAGGTCTTGATAAGAGGACTCTTGGAATTCAGC AATGTCATC	67
R2V17 (<i>HepB</i> derived enhancer element)	TTCCTGTAAACAGGCCTATTGATTGGAAAGTTTGTCAACG AATTGTGGGTCTTTTGGGGTTTGTGCCCCTTTTACGCAA	68

	TGTGGATATCCTGCTTTAATGCCTTTATATGCATGTATAC AAGCAAAACAGGCTTTTACTTTCTCGCCAACTTACAAGGC CTTTCTCAGTAAACAGTATATGACCCTTTACCCCGTTGCT CGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCA ACCCCCACTGGTTGGGGCTTGGCCATAGGCCATCAGCGC ATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCATACTG CGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCTGGACTGG AGCAAACCTCATCGGGACCGACAATTCTGTCTACTCTCC CGCAAGCACTCACCGTTTCCGCGGCTGCTCGCCTGTGTTG CCACCTGGATTCTGCGCGGGACGTCCCTTCTGCTACGTCCC TTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTG CTGCCGGCTCTGCGGCCTCTTCCGCCTCTTCGCCTTCGCC CTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCC CATGTATCTTTTTACCTGTGCCTTGTTTTGCCTGTGTTT CGCGTCCTACTTTTCAAGCCTCCAAGCTGTGCCTTGGGCG GCTTTGGGGCATGGACATAGATCCCTATAAAGAATTTGG TTCATCTTATCAGTTGTTGAATTTTCTTCCTTTGGAC	
3'UTR(globin)	GCTGGAGCCTCGGTAGCCGTTCTCCTGCCCGCTGGGCCT CCCAACGGGCCCTCCTCCCCTCCTTGCAACGGCCCTTCCT GGTCTTTGAATAAA	69
WPRE(r)	ATTCGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTG TTTTCTTGATTTGGGTATACATTTAAATGTTAATAAAAC AAAATGGTGGGGCAATCATTTACATTTTATAGGGATATGTA ATTACTAGTTTCAGGTGTATTGCCACAAGACAAACATGTTA AGAAACTTTCCCGTTATTTACGCTCTGTTCTGTTAATCA ACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATT CTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTG CTTAAATGCCTCTGTATCATGCTATTGCTTCCCGTACGGCT TTCGTTTTCTCCTCCTTGATAAATCCTGGTTGCTGTCTCT TTATGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTG GTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGG GCATTGCCACCACCTGTCAACTCCTTTCTGGGACTTTTCGC TTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCC TGCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGC ACTGATAATTCCGTGGTGTGTGCGGGGAAGGGCC	70

[0078] In some embodiments, the vector comprises a polyadenylation (polyA) signal selected from Table 4. In some embodiments, the polyA signal comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS 71-75.

Table 4

POLY-ADENYLATION SITE	SEQUENCE	SEQ ID NO:
Rabbit globin (pAGlobin-Oc)	TGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTG TTGGAATTTTTTGTGTCTCTCACTCGGAAGAACATATGG GAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGT TTAGAGTTTGGCAACATATGCCCATATGCTGGCTGCCAT GAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGA AACAGCCCCCTGCTGTCCATTCTTATTCCATAGAAAAG CCTTGACTTGAGGTTAGATTTTTTTTATATTTTGTTTTGTG TTATTTTTTCTTTAACATCCCTAAAATTTTCTTACATGT TTTACTAGCCAGATTTTTCTCCTCTCCTGACTACTCCCA GTCATAGCTGTCCCTCTTCTCTTATGGAGATC	71
Bovine growth hormone (pAGH-Bt – version 1)	TTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCC TTGACCCTGGAAGGTGCCACTCCCCTGTCCTTTCCTAA TAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGT CATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAA GGGGGAGGATTGGGAATACAATAGCAGGCATGCTGGGG ATGCGGTGGGCTCTATGGGTACCCAGGTGCTGAAGAATT GACCCGGTTCCTCCTGGG	72
Bovine growth hormone (pAGH-Bt – version 2)	TTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCC TTGACCCTGGAAGGTGCCACTCCCCTGTCCTTTCCTAA TAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGT CATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAA GGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGG ATGCGGTGGGCTCTATGGGTACCCAGGTGCTGAAGAATT GACCCGGTTCCTCCTGGG	73

Bovine growth hormone (pAGH-Bt – version 3)	CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCAC TGTCCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTG TCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGG GCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC AGGCATGCTGGGGATGCGGTGGGCTCTATGG	74
Human growth hormone (pAGH-Hs)	CTGCCCCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCT CTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCACCAGC CTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACT AGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGG TATGGAGCAAGGGGGCCCAAGTTGGGAAGAAACCTGTAG GGCCTGC	75

[0079] Illustrative vector genomes are depicted in FIGs. 1-8; and provided as SEQ ID NOs: 107-114. In some embodiments, the vector genome comprises, consists essentially of, or consists of a polynucleotide sequence that shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of SEQ ID NOs: 26-30 and 76-95, optionally with or without the ITR sequences.

[0080] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an MHCK7 promoter; an SV-40 Chimeric Intron, a BAG3 transgene; an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 107; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 107

```

ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgcccgggc aaagcccggg 60
cgtcggggcga cctttggtcg cccggcctca gtgagcgagc gagcgcgag agagggagtg
120
gccaaactcca tcaactagggg ttcctcctga ggacgcgtac cttcagatt aaaaataact
180
gaggtaaggg cctgggtagg ggaggtggtg tgagacgctc ctgtctctcc tctatctgcc
240
catcgccct ttggggagga ggaatgtgcc caaggactaa aaaaaggcca tggagccaga
300

```

ggggcgaggg caacagacct ttcatgggca aaccttgggg ccttgctgtc tagcatgccc
360
cactacgggt ctaggctgcc catgtaagga ggcaaggcct ggggacaccc gagatgcctg
420
gttataatta acccagacat gtggctgccc ccccccccc aacacctgct gcctctaaaa
480
ataacctgt ccttggtgga tcccctgcat gcgaagatct tcgaacaagg ctgtggggga
540
ctgagggcag gctgtaacag gcttgggggc cagggttat acgtgcctgg gactcccaaa
600
gtattactgt tccatgttcc cggcgaaggg ccagctgtcc cccgccagct agactcagca
660
cttagtttag gaaccagtga gcaagtcagc ctttggggca gccatacaa ggccatgggg
720
ctgggcaagc tgcacgcctg ggtccggggg gggcacggtg cccgggcaac gagctgaaag
780
ctcatctgct ctacggggcc cctccctggg gacagcccct cctggctagt cacacctgt
840
aggctcctct atataaccca ggggcacagg ggctgccctc attctaccac cacctccaca
900
gcacagacag aactcagga gccagccagg gtaagttag tctttttgtc ttttatttca
960
ggtcccggat ccggtggtgg tgcaaatcaa agaactgctc ctacgtggat gttgccttta
1020
cttctaggcc tgtacggaag tgttacttct gctctaaaag ctgcggaatt gtaccgcgc
1080
caccATGagc gccgccacc actcgcccat gatgcagggt gcgtccggca acggtgaccg
1140
cgacctttg cccccggat gggagatcaa gatcgaccgc cagaccggct ggcccttctt
1200
cgtggaccac aacagccgca ccactacgtg gaacgaccgc gcgtgccct ctgagggccc
1260
caaggagact ccacctctg ccaatggccc ttcccgggag ggctctaggc tgccgcctgc
1320
tagggaaggc caccctgtgt acccccagct ccgaccaggc tacattccca ttctgtgct
1380
ccatgaaggc gctgagaacc ggcaggtgca ccctttccat gtctatcccc agcctgggat
1440
gcagcgattc cgaactgagg cggcagcagc ggctcctcag aggtcccagt cacctctgcg
1500
gggcatgcca gaaaccactc agccagataa acagtgtgga caggtggcag cggcggcggc
1560
agcccagccc ccagcctccc acggacctga gcggtcccag tctccagctg cctctgactg
1620
ctcatcctca tcctcctcgg ccagcctgcc ttctccggc aggagcagcc tgggcagtca
1680
ccagctcccg cgggggtaca tctccattcc ggtgatacac gagcagaacg ttaccgggc
1740
agcagcccag ccctccttcc accaagcca gaagacgcac taccagcgc agcaggggga
1800
gtaccagacc caccagcctg tgtaccacaa gatccagggg gatgactggg agccccggc
1860
cctgcgggcg gcatccccgt tcaggctatc tgtccagggt gcatcgagcc gggagggctc
1920
accagccagg agcagcacgc cactccactc ccctcgccc atccgtgtgc acaccgtggt
1980

cgacaggcct cagcagccca tgacccatcg agaaactgca cctgtttccc agcctgaaaa
2040
caaaccagaa agtaagccag gccagttgg accagaactc cctcctggac acatcccaat
2100
tcaagtgatc cgcaaagagg tggattctaa acctgtttcc cagaagcccc cacctccctc
2160
tgagaaggta gaggtgaaag ttccccctgc tccagttcct tgtcctcctc ccagccctgg
2220
cccttctgct gtccccctct cccccaagag tgtggctaca gaagagaggg cagccccag
2280
cactgcccct gcagaagcta cacctccaaa accaggagaa gccgaggctc ccccaaaaca
2340
tccaggagtg ctgaaagtgg aagccatcct ggagaaggta caggggctgg agcaggctgt
2400
agacaacttt gaaggcaaga agactgacaa aaagtacctg atgatcgaag agtatttgac
2460
caaagagctg ctggccctgg attcagtggc ccccgaggga cgagccgatg tgcgtcaggc
2520
caggagagac ggtgtcagga aggttcagac catcttgaa aaacttgaa agaaagccat
2580
tgatgtccca ggtcaagtcc aggtctatga actccagccc agcaaccttg aagcagatca
2640
gccactgcag gcaatcatgg agatgggtgc cgtggcagca gacaagggca agaaaaatgc
2700
tggaatgca gaagatcccc acacagaaac ccagcagcca gaagccacag cagcagcgac
2760
ttcaaacccc agcagcatga cagacacccc tggtaaccca gcagcacgT AGtcaacctc
2820
tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct ccttttaacgc
2880
tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt atggctttca
2940
ttttctcctc cttgtataaa tcctgggtgc tgtctcttta tgaggagtgt tggcccgttg
3000
tcaggcaacg tggcgtggtg tgcaactgtg ttgctgacgc aacccccact ggttggggca
3060
ttgccaccac ctgtcagctc ctttcgggga ctttcgcttt cccctccct attgccacgg
3120
cggaactcat cgccgcctgc cttgcccgt gctggacagg ggctcggctg ttgggcactg
3180
acaattccgt ggtgttgctg gggaaatcat cgtcctttcc ttggctgctc gcctgtgttg
3240
ccactggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc aatccagcgg
3300
accttccttc ccgcggcctg ctgcggctc tgcggcctct tccgcgtctt cgccttcgcc
3360
ctcagacgag tcggatctcc ctttgggccc cctccccgca ctgcccgggt ggcatccctg
3420
tgacccctcc ccagtgcctc tcctggccct ggaagttgcc actccagtgc ccaccagcct
3480
tgtcctaata aaattaagtt gcatcatttt gtctgactag gtgtccttct ataataattat
3540
ggggtggagg ggggtggtat ggagcaagg gcccaagttg ggaagaaacc tgtagggcct
3600
gccctaagga ggaacccta gtgatggagt tggccactcc ctctctgcgc gctcgtcgc
3660

tcactgaggc cgggcgacca aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag
 3720
 tgagcgagcg agcgcgaga gagggagtgg ccaa
 3754

[0081] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an hTNNT2 promoter; a BAG3 transgene; an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 108; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 108

ttggccaatc cctctctgcg cgtctgctcg ctactgagg ccgcccgggc aaagcccggg 60
 cgtcggggcga cctttggtcg ccgggcctca gtgagcgagc gagcgcgag agagggagtg
 120
 gccaaactca tcactagggg ttctctctga ggacgcgtct cagtccatta ggagccagta
 180
 gcctggaaga tgtctttacc ccagcatca gttcaagtgg agcagcacat aactcttgcc
 240
 ctctgccttc caagattctg gtgctgagac ttatggagtg tcttgagggt tgcttctctg
 300
 cccccaaccc tgctcccagc tggccctccc aggcctgggt tgctggcctc tgctttatca
 360
 ggattctcaa gagggacagc tggtttatgt tgcattgactg ttccctgcat atctgctctg
 420
 gttttaaata gcttatctga gcagctggag gaccacatgg gcttatatgg cgtgggggtac
 480
 atgttctctg agccttgctc ctggcacctg caaaaatagc agccaacacc cccaccccc
 540
 accgccatcc ccctgcccc cccgtcccct gtcgcacatt cctccctccg cagggtggtg
 600
 tcaccaggcc ccagcccaca tgcttgctta aagccctctc catcctctgc ctcaccagt
 660
 cccgctgag actgagcaga cgcctccagg atctgtcggc aggccaccAT Gaggcgccgc
 720
 acccactcgc ccatgatgca ggtggcgtcc ggcaacggtg accgcgaccc tttgcccccc
 780
 ggatgggaga tcaagatcga ccgcagacc ggctggccct tcttcgtgga ccacaacagc
 840
 cgcaccacta cgtggaacga ccgcgcgtg ccctctgagg gcccacagga gactccatcc
 900
 tctgccaatg gcccttccc ggagggctct aggtgcccgc ctgctaggga aggccaccct
 960
 gtgtaccccc agctccgacc aggtacatt ccattcctg tgctccatga aggcgtgag
 1020
 aaccggcagg tgcacccttt ccatgtctat cccagcctg ggatgcagcg attccgaact
 1080

gaggcggcag cagcggctcc tcagaggtcc cagtcacctc tgcggggcat gccagaaacc
1140
actcagccag ataaacagtg tggacaggtg gcagcggcgg cggcagccca gccccagcc
1200
tcccacggac ctgagcggtc ccagtctcca gctgcctctg actgctcatc ctcatcctcc
1260
tcggccagcc tgccttcctc cggcaggagc agcctgggca gtcaccagct cccgcggggg
1320
tacatctcca ttccggtgat acacgagcag aacgttacc ggccagcagc ccagccctcc
1380
ttccaccaag cccagaagac gcactacca gcgcagcagg gggagtacca gaccaccag
1440
cctgtgtacc acaagatcca gggggatgac tgggagcccc ggcccctgcg ggcggtatcc
1500
ccgttcaggt catctgtcca ggggtgcatcg agccgggagg gctcaccagc caggagcagc
1560
acgccactcc actccccctc gcccatccgt gtgcacaccg tggtcgacag gcctcagcag
1620
cccattgaccc atcgagaaac tgcacctgtt tcccagcctg aaaacaaacc agaaagtaag
1680
ccaggcccag ttggaccaga actccctcct ggacacatcc caattcaagt gatccgcaaa
1740
gaggtggatt ctaaacctgt tcccagaag cccccacctc cctctgagaa ggtagaggtg
1800
aaagttcccc ctgctccagt tccttgtcct cctcccagcc ctggcccttc tgetgtcccc
1860
tcttccccca agagtgtggc tacagaagag agggcagccc ccagcactgc ccctgcagaa
1920
gctacacctc caaaaccagg agaagccgag gctcccccaa aacatccagg agtgctgaaa
1980
gtggaagcca tcctggagaa ggtacagggg ctggagcagg ctgtagacaa ctttgaaggc
2040
aagaagactg acaaaaagta cctgatgatc gaagagtatt tgaccaaaga gctgctggcc
2100
ctggattcag tggaccccgga gggacgagcc gatgtgctgc aggccaggag agacggtgtc
2160
aggaaggttc agaccatctt ggaaaaactt gaacagaaag ccattgatgt cccagggtcaa
2220
gtccaggctc atgaactcca gccagcaac cttgaagcag atcagccact gcaggcaatc
2280
atggagatgg gtgccgtggc agcagacaag ggcaagaaaa atgctggaaa tgcagaagat
2340
ccccacacag aaaccagca gccagaagcc acagcagcag cgacttcaaa cccagcagc
2400
atgacagaca cccctggtaa cccagcagca ccgTAGtcaa cctctggatt acaaaatttg
2460
tgaaagattg actggtattc ttaactatgt tgctcctttt acgctatgtg gatacgtgc
2520
tttaatgcct ttgtatcatg ctattgcttc ccgtatggct ttcattttct cctccttgta
2580
taaatacctg ttgctgtctc tttatgagga gttgtggccc gttgtcaggc aacgtggcgt
2640
ggtgtgcaact gtgtttgctg acgcaacccc cactggttgg ggcatgcca ccacctgtca
2700
gtccttttcc gggactttcg ctttccccct ccctattgcc acggcggaac tcatcgccgc
2760

ctgccttgcc cgctgctgga caggggctcg gctgttgggc actgacaatt ccgtggtggt
 2820
 gtcggggaaa tcatcgctct ttccttggct gctcgccctgt gttgccacct ggattctgcg
 2880
 cgggacgtcc ttctgctacg tcccttcggc cctcaatcca gcggaccttc cttcccgcgg
 2940
 cctgtgccc gctctgcggc ctcttcgcg tcttcgcctt cgccctcaga cgagtcggat
 3000
 ctcccttttg gccgcctccc cgcactgcc ggttgcatc cctgtgaccc ctccccagt
 3060
 cctctcctgg ccctggaagt tgccactcca gtgcccacca gccttgcctt aataaaatta
 3120
 agttgcatca ttttgtctga ctaggtgtcc ttctataata ttatgggggtg gaggggggtg
 3180
 gtatggagca agggggccaa gttgggaaga aacctgtagg gcctgcccta aggaggaacc
 3240
 cctagtgatg gagttggcca ctccctctct gcgcgctcgc tcgctcactg aggcggggcg
 3300
 accaaaggtc gcccgacgcc cgggctttgc ccgggcggcc tcagtgcgcg agcgagcgcg
 3360
 cagagaggga gtggccaa
 3378

[0082] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an HSP70 promoter; a BAG3 transgene; an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 109; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 109

ttggcactc cctctctgcg cgctcgctcg ctactgagg ccgcccgggc aaagcccggg 60
 cgtcgggcga cctttggtcg cccggcctca gtgagcgagc gagcgcgag agagggagtg
 120
 gccaaactcca tcaactagggg ttctctctga ggacgcgtcc tgcagggccg cccactcccc
 180
 cttctctca gggtcctgt cccctccagt gaatcccaga agactctgga gagttctgag
 240
 cagggggcg cactctggcc tctgattggt ccaaggaagg ctgggggggca ggacgggagg
 300
 cgaaaaccct ggaatattcc cgacctggca gcctcatcga gctcggtgat tggctcagaa
 360
 gggaaaaggc gggctctcgt gacgacttat aaaagcccag gggcaagcgg tccggataac
 420
 ggctagcctg aggagctgct gcgacagtcc actacctttt tcgagagtga ctcccgttgt
 480
 cccaaggctt ccagagcgga acctgtgcgg ctgcaggcac cggcgcgctc agtttccggc
 540

gtccggaagg accgagctct tctcgcggat ccagtgttcc gtttccagcc cccaatctca
600
gagcggagcc gacagagagc agggaaacccg ccaccATGag cgccgccacc cactcgccca
660
tgatgcaggt ggcgtccggc aacggtgacc gcgacccttt gccccccgga tgggagatca
720
agatcgaccc gcagaccggc tggcccttct tcgtggacca caacagccgc accactacgt
780
ggaacgaccc gcgcgtgccc tctgagggcc ccaaggagac tccatcctct gccaatggcc
840
cttcccggga gggctctagg ctgccgcctg ctagggaagg ccaccctgtg tacccccagc
900
tccgaccagg ctacattccc attcctgtgc tccatgaagg cgctgagaac cggcaggtgc
960
accctttcca tgtctatccc cagcctggga tgcagcgatt ccgaactgag gcggcagcag
1020
cggctcctca gaggtcccag tcacctctgc ggggcatgcc agaaaccact cagccagata
1080
aacagtgtgg acaggtggca gggcgggcgg cagcccagcc ccagcctcc cacggacctg
1140
agcggtccca gtctccagct gcctctgact gctcatcctc atcctcctcg gccagcctgc
1200
cttcctccgg caggagcagc ctgggcagtc accagctccc gcgggggtac atctccattc
1260
cggtgataca cgagcagaac gttaccggc cagcagccca gccctccttc caccaagccc
1320
agaagacgca ctaccagcg cagcaggggg agtaccagac ccaccagcct gtgtaccaca
1380
agatccaggg ggatgactgg gagccccggc ccctgcgggc ggcatccccg ttcaggtcat
1440
ctgtccaggg tgcacgagc cgggagggct caccagccag gagcagcacg cactccact
1500
cccctcgcc catccgtgtg cacaccgtgg tcgacaggcc tcagcagccc atgaccatc
1560
gagaaaactgc acctgtttcc cagcctgaaa acaaaccaga aagtaagcca ggcccagttg
1620
gaccagaact ccctcctgga cacatcccaa ttcaagtgat ccgcaaagag gtggattcta
1680
aacctgtttc ccagaagccc ccacctccct ctgagaaggt agaggtgaaa gttccccctg
1740
ctccagttcc ttgtcctcct ccagccctg gcccttctgc tgtccccctt tcccccaaga
1800
gtgtggctac agaagagagg gcagccccc gactgcccc tgcagaagct acacctcaa
1860
aaccaggaga agccgaggct cccccaaaac atccaggagt gctgaaagtg gaagccatcc
1920
tggaagaagt acaggggctg gagcaggctg tagacaactt tgaaggcaag aagactgaca
1980
aaaagtacct gatgatcgaa gagtatttga ccaaagagct gctggccctg gattcagttg
2040
accccaggg acgagccgat gtgcgtcagg ccaggagaga cgggtgcagg aaggttcaga
2100
ccatcttga aaaacttgaa cagaaagcca ttgatgtccc aggtcaagtc caggtctatg
2160
aactccagcc cagcaacctt gaagcagatc agccactgca ggcaatcatg gagatgggtg
2220

[0083] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an MHCK7 promoter; an SV-40 Chimeric Intron; a BAG3 transgene; enhanced green fluorescent protein (eGFP); an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 110; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

ttggccactccctctctgcgcgctcgctcgctcactgaggcgcccgggcaagcccgggcgctcgggcgacctttggtcgccc
ggcctcagtgagcgagcgagcgcgagagggagtgqgcgaactccatcactaggggttctctctgaggaacgctaccctca

gattaaaaataactgaggttaagggcctgggtaggggaggtggtgtgagacgctcctgtctctcctctatctgccatcgccccc
 tttggggaggaggaatgtgcccaggactaaaaaaggccatggagccagagggcgagggaacagacctttcatggggcaaa
 ccttggggccctgctgtctagcatgcccactacgggtctaggctgcccatgtaaggaggcaaggcctgggggaccccgagat
 gcttggttataattaaccacagacatgtggctgcccccccccccccaacacctgctgctctaaaaataaccctgtccctggtg
 gatccctgtcatgcaagatcttcgaacaaggctgtgggggactgagggcaggctgtaacaggcttgggggcccagggttata
 cgtgctgggactcccaaagtattactgttccatgttccggcgcaagggccagctgtccccgccagctagactcagcactta
 gtttaggaaccagtgagcaagtcagcccttggggcagcccatacaaggccatggggctgggcaagctgcacgctgggtccgg
 ggtggcgacggtgccccgggcaacgagctgaaagctcatctgactcaggggccccctccctggggacagccccctcctggtagt
 cacacctgtaggctcctctatataaccaggggcacagggtgccccattctaccaccacctccacagcacagacagaca
 ctgaggagccagccagggttaagtttagtctttttgtcttttatttcagggtcccgatccgggtggtgtaaatacaagaact
 gctcctcagtggtgtgtcctttacttctaggcctgtacggaagtgtacttctgctctaaaagctggggaattgtaccgcg
 ccaccATGagcctcctccaccactcccccagtgatgaggtggcgctccggcaacggtgaccgcgacctttggccctcctggtacg
 gagatcaagatcgacccgcagacggctggcccttctctgtggaccacaacagccgacccactacgtggaacgacccgcgct
 gcccctgagggcccccaaggagactccatcctctgccaatggcccttccccggagggtcttaggtgcccctgttagggaag
 gccacctgtgtacccccagctccgaccaggtacattcccatctctgtgctccatgaaggcgctgagaacgggcagggtgcac
 aacttccctcctgttccaccagcctgggatgacgagctgagggcagcagcggtcctccagacccctcctggtaccc
 tctgcggggcatgccagaaacctcagccagataaacagtgtggacaggtggcagcgggcgggcagccagcccccagcct
 cccacggacctgagcggtccagctccagctgctctgactgctcatcctcatcctcctcgccagcctgcttccctcggc
 aggagcagcctgggcagtcaccagctcccgcggggtacatctccattccggtgatacacgagcagaacgttaccggccagc
 agccacATGagcctcctccaccagcctcccaagccagacgactacccagcagcagggggagtaaccagaccccccaggtacc
 acaagatccagggggatgactgggagccccggccctgcgggcggtacccccgttcagggtcatctgtccagggtgcatcgagc
 cgggagggtcaccagccaggagcagcagccactccactccccctcgccatccgtgtgcacacggtgtgcagggcctca
 gcagcccatgacccatcgagaaaactgcacctgttccagcctgaaaacaaaccagaaagtaagccaggccaggtggaccag
 aacttccctcctgttccaccagcctcccaatccaagtgtccgcaaaaggtggattctaaacctgttcccaagccccctccc
 tctgagaaggtagaggtgaaagtccccctgctccagttccttgtcctcctccagccctggcccttctgctgtccccctcttc
 ccccaagagtgtggtacagaaagagagggcagccccagcactgcccctgcagaagctacacctccaaaaccaggagaagccg
 aggtccccccaaaacatccaggagtgtgaaagtggaaagccatcctggagaaggtacaggggctggagcaggtgttagacaac
 tttgaaggcaagaagactgacaaaaagtacctgatgatcgaaaggtatttgaccaaagagctgctggccctggattcagtgga
 ccccgagggaacgagccgatgtgctgagggcaggagagacggtgtcaggaaggttcagaccatcttgaaaaacttgaacaga
 aagccattgatgtccaggtcaagtcaggtctatgaactccagccagcaacccctgaagcagatcagccactgcaggcaatc
 atggagatgggtgcccgtggcagcagacaagggcaagaaaaatgctggaaatgcagaagatccccacacagaaaccagcagcc
 agaagccacagcagcagcagcttcaaacccccagcagcatgacagacacccctggttaacccagcagcaacgggtaccggcagtg
 gagagggcagaggaagtctgtaacatgcggtgacgtcgaggagaatcctggcccaATGAGCAAGGGCGAGGAGCTGTTACCC
 GGCCTGGTGCCATCTTGGTGGAGCTGGACGGCGACGTGAACGGCCACAAGTTACGCGTGAGAGGCGAGGGCGAGGGCGACGC
 CACCAACGGCAAGCTGACCTGAAGTTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTGGTGACCACTTGA
 CCTACGGCGCTGTGCTTACGACAGATACCCCGACCATGAAGAGACACGACTTCTTCAAGAGCGCCACTTCCGAGGGGTAC
 GTGCAGGAGAGAACCATCAGCTTCAAGGACGACGGCACCTACAAGACCAGAGCCGAGGTGAAGTTCAAGGGCGACACCTGGT
 GAACAGAATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCTGGGCCACAAGCTGGAGTACAACCTCAACAGCC
 ACAACGTGTACATCACCGCCGACAGCAGAGAAGACGGCATCAAGGCCTACTTCAAGATCAGACACAACGTGGAGGACGGCAGC
 GTGCAGCTGGCCGACCACTACAGCAGAACACCCCATCGGCGACGGCCCGTGTGCTGCTGCCCCGACAACCACTACTTGAACAC
 CCAGAGCGTGTGAGCAAGGACCCCAACGAGAAGAGAGACCACATGGTGTGCTGAGGAGCGTGACCGCCCGCGCATCACCC
 ACGGCATGGACGAGCTGTACAGTGATcaaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgc
 tccctttacgctatgtggatacgtgctttaaagcctttgtatcatgtctattgcttcccgtatggctttcattttctcctcct
 tgtataaatcctggttctgtctctttatgaggagtttgggcccgttgtcaggcaacggtggcggtgtgcaactgtgttctgct
 gacgcaacccccactggttggggcattgtccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcccac
 ggccgaaactcatcgccgctgcttggccgctgtgtgacaggggctcggtgtgtgggcaatccggtggtgtgtcgg
 ggaaatcatcgctccttccctggctgctcgctgtgttgcacactggattctgcgcggaacgtccttctgctacgtccctcg
 gccctcaatccagcggacccctccttcccgcgccctgctgcccgtctgcggcctcttcccgctcttccgcttccgctccagac
 gactcggtatctcccttggggccgctccccgactgcccgggtggcatccctgtgacccctccccagtgctctcctggccct
 ggaagttgccactccagtgccaccagccttgcctaataaaattaggtgcatcattttgtctgactaggtgtcctctctata
 atattatggggtggaggggggtggtatggagcaagggcccaagttgggaagaaacctgtagggcctgcctaaggaggaacc
 cctagtgtggagttggccactcctctctgcgctcgtcgctcactgagggcgggcgaccaaaggtcgcccgacgcccgg
 gctttgccccggcgccctcagtgagcgagcgagcgagagagggtggccaa

[0084] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an TNNT2 promoter; a BAG3 transgene; enhanced green fluorescent protein (eGFP); an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 111; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged

in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

[0085] SEQ ID NO: 111

```

ttggccactc cctctctgcg cgtctgctcg ctactgagg ccgcccgggc aaagcccggg 60
cgtcgggcga cctttggtcg cccggcctca gtgagcgagc gagcgcgagc agagggagtg
120
gccaaactcca tcactagggg ttctctctga ggacgcgtct cagtccatta ggagccagta
180
gcctggaaga tgtctttacc ccagcatca gttcaagtgg agcagcacat aactcttgcc
240
ctctgccttc caagattctg gtgctgagac ttatggagtg tcttgagggt tgctttctgc
300
cccccaacc tgctcccagc tggccctccc aggctgggt tgctggcctc tgctttatca
360
ggattctcaa gagggacagc tggtttatgt tgcagtactg ttccctgcat atctgctctg
420
gttttaaata gcttatctga gcagctggag gaccacatgg gcttatatgg cgtgggggtac
480
atgttctgtg agccttgtcc ctggcacctg caaaatagc agccaacacc cccaccccc
540
accgccatcc ccctgcccc cccgtcccct gtcgcacatt cctccctccg cagggtggc
600
tcaccaggcc ccagcccaca tgctgctta aagccctctc catcctctgc ctacccagt
660
ccccgctgag actgagcaga cgcctccagg atctgtcggc aggccaccAT Gagcgccggc
720
accactcgc ccatgatgca ggtggcgtcc ggcaacgggt accgcgaccc ttgcccccc
780
ggatgggaga tcaagatcga cccgcagacc ggctggccct tcttcgtgga ccacaacagc
840
cgcaccacta cgtggaacga cccgcgcgtg ccctctgagg gcccgaagga gactocatcc
900
tctgccaatg gcccttccc ggagggctct aggtgcccgc ctgctaggga aggccaccct
960
gtgtaccccc agctccgacc aggctacatt cccattcctg tgctccatga aggcgtgag
1020
aaccggcagg tgcacccttt ccatgtctat cccagcctg ggatgcagcg attccgaact
1080
gaggcggcag cagcggtcc tcagaggtcc cagtcacctc tgcggggcat gccagaaacc
1140
actcagccag ataaacagtg tggacaggtg gcagcggcgg cggcagccca gccccagcc
1200
tcccacggac ctgagcggtc ccagtctcca gctgcctctg actgctcatc ctcatcctcc
1260
tcggccagcc tgcttctctc cggcaggagc agcctgggca gtcaccagct cccgcggggg
1320
tacatctcca ttccggtgat acacgagcag aacgttacc ggccagcagc ccagccctcc
1380
ttccaccaag cccagaagac gcactacca gcgcagcagg gggagtacca gaccaccag
1440
cctgtgtacc acaagatcca gggggatgac tgggagcccc ggcccctgcg ggcggcatcc
1500

```

ccgttcaggt catctgtcca ggggtgcatcg agccgggagg gctcaccagc caggagcagc
1560
acgccactcc actccccctc gcccatccgt gtgcacaccg tggtcgacag gcctcagcag
1620
cccatgaccc atcgagaaac tgcacctgtt tcccagcctg aaaacaaacc agaaagtaag
1680
ccaggcccag ttggaccaga actccctcct ggacacatcc caattcaagt gatccgcaaa
1740
gaggtggatt ctaaacctgt ttcccagaag cccccacctc cctctgagaa ggtagaggtg
1800
aaagttcccc ctgctccagt tccttgtcct cctcccagcc ctggcccttc tgctgtcccc
1860
tcttccccca agagtgtggc tacagaagag agggcagccc ccagcactgc ccctgcagaa
1920
gctacacctc caaaaccagg agaagccgag gctcccccaa aacatccagg agtgctgaaa
1980
gtggaagcca tcctggagaa ggtacagggg ctggagcagg ctgtagacaa ctttgaaggc
2040
aagaagactg aaaaaagta cctgatgatc gaagagtatt tgaccaaaga gctgctggcc
2100
ctggattcag tggaccccga gggacgagcc gatgtgctgc aggccaggag agacggtgtc
2160
aggaaggttc agaccatctt ggaaaaactt gaacagaaag ccattgatgt cccagggtcaa
2220
gtccagggtc atgaactcca gccagcaac cttgaagcag atcagccact gcaggcaatc
2280
atggagatgg gtgccgtggc agcagacaag ggcaagaaaa atgctggaaa tgcagaagat
2340
ccccacacag aaaccagca gccagaagcc acagcagcag cgacttcaaa cccagcagc
2400
atgacagaca cccctggtaa cccagcagca ccgggatccg gcagtggaga gggcagagga
2460
agtctgctaa catgcggtga cgtcgaggag aatcctggcc caATGAGCAA GGGCGAGGAG
2520
CTGTTACCG GCGTGGTGCC CATCCTGGTG GAGCTGGACG GCGACGTGAA CGGCCACAAG
2580
TTCAGCGTGA GAGGCGAGGG CGAGGGCGAC GCCACCAACG GCAAGCTGAC CCTGAAGTTC
2640
ATCTGCACCA CCGGCAAGCT GCCCGTGCCC TGGCCACCC TGGTGACCAC CCTGACCTAC
2700
GGCGTGCTGT GCTTCAGCAG ATACCCCGAC CACATGAAGA GACACGACTT CTTCAAGAGC
2760
GCCATGCCCC AGGGCTACGT GCAGGAGAGA ACCATCAGCT TCAAGGACGA CGGCACCTAC
2820
AAGACCAGAG CCGAGGTGAA GTTCGAGGGC GACACCCTGG TGAACAGAAT CGAGCTGAAG
2880
GGCATCGACT TCAAGGAGGA CGGCAACATC CTGGGCCACA AGCTGGAGTA CAACTTCAAC
2940
AGCCACAACG TGTACATCAC CGCCGACAAG CAGAAGAACG GCATCAAGGC CTACTTCAAG
3000
ATCAGACACA ACGTGGAGGA CGGCAGCGTG CAGCTGGCCG ACCACTACCA GCAGAACACC
3060
CCCATCGGCG ACGGCCCCGT GCTGCTGCCC GACAACCACT ACCTGAGCAC CCAGAGCGTG
3120
CTGAGCAAGG ACCCCAACGA GAAGAGAGAC CACATGGTGC TGCTGGAGGA CGTGACCGCC
3180

```

GCCGGCATCA CCCACGGCAT GGACGAGCTG TACAAGTGAT caacctctgg attacaaaat
3240
ttgtgaaaga ttgactggta ttcttaacta tgttgctcct tttacgctat gtggatacgc
3300
tgctttaatg cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt
3360
gtataaatcc tggttgctgt ctctttatga ggagttgtgg cccgttggtca ggcaacgtgg
3420
cgtggtgtgc actgtgtttg ctgacgcaac cccactgggt tggggcattg ccaccacctg
3480
tcagctcctt tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc
3540
cgctgcctt gcccgctgct ggacaggggc tcggctgttg ggactgaca attccgtgggt
3600
gttgctcggg aaatcatcgt cctttccttg gctgctcgcc tgtgttgcca cctggattct
3660
gcgcgggacg tccttctgct acgtcccttc ggccctcaat ccagcggacc ttccttcccg
3720
cggcctgctg ccggtctctg ggccctcttc gcgtcttcgc ctcgccctc agacgagtcg
3780
gatctccctt tgggccgcct ccccgactg cccgggtggc atccctgtga cccctcccca
3840
gtgcctctcc tggccctgga agttgccact ccagtgccca ccagccttgt cctaataaaa
3900
ttaagttgca tcattttgtc tgactagggtg tccttctata atattatggg gtggaggggg
3960
gtggtatgga gcaagggggc caagttggga agaaacctgt agggcctgcc ctaaggagga
4020
accctagtg atggagttgg ccactccctc tctgcgcgct cgctcgctca ctgaggccgg
4080
gcgaccaaag gtcgcccgcg gcccgggcct tggccgggcg gcctcagtga gcgagcgagc
4140
gcgcagagag ggagtggcca a
4161

```

[0086] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an HSP70 promoter; a BAG3 transgene; enhanced green fluorescent protein (eGFP); an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 112; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 112

```

ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgcccgggc aaagcccggg 60
cgtcgggcga cctttggtcg cccggcctca gtgagcgagc gagcgcgag agagggagtg
120
gccaactcca tcaactagggg ttcctcctga ggacgcgtcc tgcagggccg cccactcccc
180

```

cttcctctca ggggtccctgt cccctccagt gaatcccaga agactctgga gagttctgag
240
cagggggcgg cactctggcc tctgattggg ccaaggaagg ctgggggggca ggacgggagg
300
cgaaaaccct ggaatattcc cgacctggca gcctcatcga gctcgggtgat tggctcagaa
360
gggaaaaggc ggggtctccgt gacgacttat aaaagcccag gggcaagcgg tccggataac
420
ggctagcctg aggagctgct gcgacagtcc actacctttt tcgagagtga ctcccgttgt
480
cccaaggctt cccagagcga acctgtgcgg ctgcaggcac cggcgcgtcg agtttccggc
540
gtccggaagg accgagctct tctcgcggat ccagtgttcc gtttccagcc cccaatctca
600
gagcggagcc gacagagagc agggaaacccg ccaccATGag cgccgccacc cactcgccca
660
tgatgcaggt ggcgtccggc aacggtgacc gcgacccttt gccccccgga tgggagatca
720
agatcgaccc gcagaccggc tggcccttct tcgtggacca caacagccgc accactacgt
780
ggaacgaccc gcgcgtgcc tctgagggcc ccaaggagac tccatcctct gccaatggcc
840
cttcccggga gggctctagg ctgccgcctg ctagggaagg ccaccctgtg tacccccagc
900
tccgaccagg ctacattccc attcctgtgc tccatgaagg cgctgagaac cggcaggtgc
960
accctttcca tgtctatccc cagcctggga tgcagcgatt ccgaactgag gcggcagcag
1020
cggctcctca gaggtcccag tcacctctgc ggggcatgcc agaaaccact cagccagata
1080
aacagtgtgg acaggtggca gcggcggcgg cagcccagcc cccagcctcc cacggacctg
1140
agcggtccca gtctccagct gcctctgact gctcatcctc atcctcctcg gccagcctgc
1200
cttcctccgg caggagcagc ctgggcagtc accagctccc gcgggggtac atctccattc
1260
cggtgataca cgagcagaac gttaccggc cagcagccca gccctccttc caccaagccc
1320
agaagacgca ctaccagcg cagcaggggg agtaccagac ccaccagcct gtgtaccaca
1380
agatccaggg ggatgactgg gagccccggc ccctgcgggc ggcatccccg ttcaggteat
1440
ctgtccaggg tgcacgagc cgggagggct caccagccag gagcagcacg cactccact
1500
cccctcgcc catccgtgtg cacaccgtgg tcgacaggcc tcagcagccc atgaccatc
1560
gagaaaactgc acctgtttcc cagcctgaaa acaaaccaga aagtaagcca ggcccagttg
1620
gaccagaact ccctcctgga cacatcccaa ttcaagtgat ccgcaaagag gtggattcta
1680
aacctgtttc ccagaagccc ccacctccct ctgagaaggt agaggtgaaa gttccccctg
1740
ctccagttcc ttgtcctcct cccagccctg gcccttctgc tgtccccctt tcccccaaga
1800
gtgtggctac agaagagagg gcagccccc gactgcccc tgcagaagct acacctccaa
1860

aaccaggaga agccgaggct cccccaaaac atccaggagt gctgaaagtg gaagccatcc
1920
tggagaaggt acaggggctg gagcaggctg tagacaactt tgaaggcaag aagactgaca
1980
aaaagtacct gatgatcgaa gagtatttga ccaaagagct gctggccctg gattcagtg
2040
accccagagg acgagccgat gtgcgtcagg ccaggagaga cgggtgcagg aaggttcaga
2100
ccatcttgga aaaacttgaa cagaaagcca ttgatgtccc aggtcaagtc caggtctatg
2160
aactccagcc cagcaacctt gaagcagatc agccactgca ggcaatcatg gagatgggtg
2220
ccgtggcagc agacaagggc aagaaaaatg ctggaaatgc agaagatccc cacacagaaa
2280
cccagcagcc agaagccaca gcagcagcga cttcaaacc cagcagcatg acagacaccc
2340
ctggtaaccc agcagcaccg ggatccggca gtggagaggg cagaggaagt ctgctaacat
2400
gcggtgacgt cgaggagaaat cctggcccaA TGAGCAAGGG CGAGGAGCTG TTCACCGGCG
2460
TGGTGCCCAT CCTGGTGGAG CTGGACGGCG ACGTGAACGG CCACAAGTTC AGCGTGAGAG
2520
GCGAGGGCGA GGGCGACGCC ACCAACGGCA AGCTGACCCT GAAGTTCATC TGCACCACCG
2580
GCAAGCTGCC CGTGCCCTGG CCCACCCTGG TGACCACCCT GACCTACGGC GTGCTGTGCT
2640
TCAGCAGATA CCCCACCAC ATGAAGAGAC ACGACTTCTT CAAGAGCGCC ATGCCCGAGG
2700
GCTACGTGCA GGAGAGAACC ATCAGCTTCA AGGACGACGG CACCTACAAG ACCAGAGCCG
2760
AGGTGAAGTT CGAGGGCGAC ACCCTGGTGA ACAGAATCGA GCTGAAGGGC ATCGACTTCA
2820
AGGAGGACGG CAACATCCTG GGCCACAAGC TGGAGTACAA CTTCAACAGC CACAACGTGT
2880
ACATCACCGC CGACAAGCAG AAGAACGGCA TCAAGGCCTA CTTCAAGATC AGACACAACG
2940
TGGAGGACGG CAGCGTGCAG CTGGCCGACC ACTACCAGCA GAACACCCCC ATCGGCGACG
3000
GCCCCGTGCT GCTGCCCGAC AACCACTACC TGAGCACCCA GAGCGTGCTG AGCAAGGACC
3060
CCAACGAGAA GAGAGACCAC ATGGTGCTGC TGGAGGACGT GACCGCCGCC GGCATCACCC
3120
ACGGCATGGA CGAGCTGTAC AAGTGAtcaa cctctggatt acaaaaatttg tgaaagattg
3180
actggtattc ttaactatgt tgctcctttt acgctatgtg gatacgtgc tttaatgcct
3240
ttgtatcatg ctattgcttc ccgtatggct ttcatTTTTt ctccttgta taaatcctgg
3300
ttgctgtctc tttatgagga gttgtggccc gttgtcaggc aacgtggcgt ggtgtgcact
3360
gtgtttgctg acgcaacccc cactggttgg ggcatgtcca ccacctgtca gtccttttcc
3420
gggactttcg ctttccccct ccctattgcc acggcggaac tcatcgccgc ctgccttgcc
3480
cgctgctgga caggggctcg gctgttgggc actgacaatt ccgtgggtgtt gtcggggaaa
3540

```

tcacgtcct ttccttggct gctcgctgt gttgccacct ggattctgcg cgggacgtcc
3600
ttctgctacg tcccttcggc cctcaatcca gcggaccttc cttcccgcgg cctgctgccc
3660
gctctgcggc ctcttcgcgg tcttcgcctt cgccctcaga cgagtcggat ctccctttgg
3720
gccgctccc cgcactgccc ggggtggcatc cctgtgacct ctcccagtg cctctcctgg
3780
ccctggaagt tgccactcca gtgcccacca gccttgtcct aataaaatta agttgcatca
3840
ttttgtctga ctaggtgtcc ttctataata ttatgggggtg gaggggggtg gtatggagca
3900
aggggcccaa gttggaaga aacctgtagg gcctgcccta aggaggaacc ctagtgatg
3960
gagttggcca ctccctctct gcgcgctcgc tcgctcactg aggccgggcg accaaaggtc
4020
gcccgacgcc cgggctttgc ccgggcgggc tcagtgagcg agcgagcgcg cagagagggg
4080
gtggccaa
4088

```

[0087] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; a CMV enhancer, a chicken β -actin promoter; a chimeric intron; a BAG3 transgene; enhanced green fluorescent protein (eGFP); an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 113; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 113

```

ttggcactc cctctctgcg cgctcgctcg ctactgagg ccgcccgggc aaagcccggg 60
cgtcggggcg cctttggtcg ccgggcctca gtgagcgagc gagcgcgagc agagggagtg
120
gccaaactca tcaactagggg ttctctctga ggacgcgtta cataacttac ggtaaattggc
180
ccgcttggtg gaccgcccga cgacccccgc ccattgacgt caataatgac gtatgttccc
240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaaact
300
gccacttggt cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat
360
gacggtaaatt ggcccgccctg gcattatgcc cagtacatga ctttatggga ctttctact
420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tcgaggtgag ccccaagttc
480
tgcttcactc tcccctctc cccccctcc ccacccccaa ttttgtattt atttattttt
540

```

taattatttt gtgcagcgat gggggcgggg gggggggggg cgcgcgccag gcggggcggg
600
gcggggcgag gggcggggag gggcgaggcg gagaggtgcg gcggcagcca atcagagcgg
660
cgcgctccga aagtttcctt ttatggcgag gcggcgggcg cgcgggccct ataaaaagcg
720
aagcgcgcg cgggcgggag tcgctgcgcg ctgccttcgc cccgtgcccc gctccgcgcg
780
cgctcgcgc cgcccgcccc ggctctgact gaccgcgtta ctccacaggg tgagcggggc
840
ggacggccct tctcctccgg gctgtaatta gcgcttggtt taatgacggc ttgtttcttt
900
tctgtggctg cgtgaaagcc ttgaggggct ccgggagggc ctttgtgcg gggggagcgg
960
ctcggggggt gcgtgcgtgt gtgtgtgcgt ggggagcgcc gcgtgcggct ccgcgctgcc
1020
cggcggtgt gagcgctgcg ggcgcggcgc ggggctttgt gcgctccgca gtgtgcgcga
1080
ggggagcgcg gccgggggag gtgccccgcg gtgcgggggg ggctgcgagg ggaacaaagg
1140
ctgcgtgcgg ggtgtgtgcg tgggggggtg agcagggggt gtgggcgcgt cggtcgggct
1200
gcaaccccc ctgcaccccc ctccccgagt tgctgagcac ggcccggtt cgggtgcggg
1260
gctccgtacg gggcggtggc cggggctcgc cgtgccgggc ggggggtggc ggcaggtggg
1320
ggtgccgggc ggggcggggc cgctcgggc cggggagggc tcgggggagg ggcgcggcgg
1380
ccccggagc gccggcggt gtgcaggcgc ggcgagccgc agccattgcc ttttatggta
1440
atcgtgcgag agggcgaggg gacttccttt gtcccaaatac tgtgcggagc cgaaatctgg
1500
gaggcgccg cgacccccct ctacggggcg cggggcgaag cgggtgcggc cgggcaggaa
1560
ggaaatgggc ggggaggggc ttcgtgcgtc gccgcgccgc cgtccccctt tccctctcca
1620
gcctcggggc tgtccgcggg gggacggctg cttcggggg ggacggggca gggcggggtt
1680
cggcttctgg cgtgtgaccg gcggctctag agcctctgct aaccatgttc atgccttctt
1740
cttttctta cagctcctgg gcaacgtgct ggttattgtg ctgtctcatc attttgga
1800
agaattcATG agcgccgcca cccactcgcc catgatgcag gtggcgtccg gcaacgggtga
1860
ccgcgaccct ttgcccccg gatgggagat caagatcgac ccgcagaccg gctggccctt
1920
cttcgtggac cacaacagcc gcaccactac gtggaacgac ccgcgcgtgc cctctgaggg
1980
ccccaaggag actccatcct ctgccaatgg cccttcccgg gagggctcta ggctgcgcgc
2040
tgctagggaa ggccaccctg tgtaccccca gctccgacca ggctacattc ccattcctgt
2100
gctccatgaa ggcgctgaga accggcaggc gcacccttct catgtctatc ccagcctgg
2160
gatgcagcga ttccgaactg agggcgagc agcggtcctt cagaggtccc agtcacctct
2220

gcggggcatg ccagaaacca ctcagccaga taaacagtgt ggacaggtgg cagcggcggc
2280
ggcagcccag cccccagcct ccacaggacc tgagcgggcc cagtctccag ctgcctctga
2340
ctgctcatcc tcctcctcct cggccagcct gccttcctcc ggacaggaga gcctgggcag
2400
tcaccagctc ccgcgggggt acatctccat tccggtgata cacgagcaga acgttacccg
2460
gccagcagcc cagccctcct tccaccaagc ccagaagacg cactaccag cgcagcaggg
2520
ggagtaccag acccaccagc ctgtgtacca caagatccag ggggatgact gggagccccg
2580
gccctgcgg gcggcatccc cgttcaggtc atctgtccag ggtgcatcga gccgggaggg
2640
ctcaccagcc aggagcagca cggcactcca ctccccctcg cccatccgtg tgcacaccgt
2700
ggtcgacagg cctcagcagc ccatgacca tcgagaaact gcacctgttt ccagcctga
2760
aaacaaacca gaaagtaagc caggcccagt tggaccagaa ctccctcctg gacacatccc
2820
aattcaagtg atccgcaaag aggtggattc taaacctgtt tcccagaagc cccacctcc
2880
ctctgagaag gtagaggaga aagttcccc tgctccagtt ccttgtcctc ctcccagccc
2940
tggcccttct gctgtccctt cttcccccaa gagtgtggct acagaagaga gggcagcccc
3000
cagcactgcc cctgcagaag ctacacctcc aaaaccagga gaagccgagg ccccccaaa
3060
acatccagga gtgctgaaag tggagccat cctggagaag gtacaggggc tggagcaggc
3120
tgtagacaac tttgaaggca agaagactga caaaaagtac ctgatgatcg aagagtattt
3180
gaccaagag ctgctggccc tggattcagt ggaccccgag ggacgagccg atgtgctca
3240
ggccaggaga gacggtgtca ggaagggtca gaccatcttg gaaaaacttg aacagaaagc
3300
cattgatgtc ccagggtcaag tccagggtcta tgaactccag cccagcaacc ttgaagcaga
3360
tcagccactg caggcaatca tggagatggg tgccgtggca gcagacaagg gcaagaaaaa
3420
tgctggaaat gcagaagatc cccacacaga aaccagcag ccagaagcca cagcagcagc
3480
gacttcaaac cccagcagca tgacagacac ccctggtaac ccagcagcac cgggatccgg
3540
cagtggagag ggcagaggaa gtctgctaac atgcggtgac gtcgaggaga atcctggccc
3600
aATGAGCAAG GGCGAGGAGC TGTTACCGG CGTGGTGCCC ATCCTGGTGG AGCTGGACGG
3660
CGACGTGAAC GGCCACAAGT TCAGCGTGAG AGGCGAGGGC GAGGGCGACG CCACCAACGG
3720
CAAGCTGACC CTGAAGTTCA TCTGCACCAC CGGCAAGCTG CCCGTGCCCT GGCCACCCCT
3780
GGTGACCACC CTGACCTACG GCGTGCTGTG CTTGAGCAGA TACCCGACC ACATGAAGAG
3840
ACACGACTTC TTCAAGAGCG CCATGCCCCG GGGCTACGTG CAGGAGAGAA CCATCAGCTT
3900

CAAGGACGAC GGCACCTACA AGACCAGAGC CGAGGTGAAG TTCGAGGGCG ACACCCCTGGT
 3960
 GAACAGAATC GAGCTGAAGG GCATCGACTT CAAGGAGGAC GGCAACATCC TGGGCCACAA
 4020
 GCTGGAGTAC AACTTCAACA GCCACAACGT GTACATCACC GCCGACAAGC AGAAGAACGG
 4080
 CATCAAGGCC TACTTCAAGA TCAGACACAA CGTGGAGGAC GGCAGCGTGC AGCTGGCCGA
 4140
 CCACTACCAG CAGAACACCC CCATCGGCGA CGGCCCCGTG CTGCTGCCCCG ACAACCACTA
 4200
 CCTGAGCACC CAGAGCGTGC TGAGCAAGGA CCCCAACGAG AAGAGAGACC ACATGGTGCT
 4260
 GCTGGAGGAC GTGACCGCCG CCGGCATCAC CCACGGCATG GACGAGCTGT ACAAGTGATc
 4320
 aacctctgga ttacaaaatt tgtgaaagat tgactggtat tcttaactat gttgctcctt
 4380
 ttacgctatg tggatacgct gctttaatgc ctttgtatca tgctattgct tcccgatagg
 4440
 ctttcatttt ctccctccttg tataaatcct ggttgctgtc tctttatgag gagttgtggc
 4500
 ccgttgctcag gcaacgtggc gtggtgtgca ctgtgtttgc tgacgcaacc cccactggtt
 4560
 ggggcattgc caccacctgt cagctccttt ccgggacttt cgctttcccc ctccctattg
 4620
 ccacggcgga actcatcgcc gcctgccttg cccgctgctg gacaggggct cggtgttg
 4680
 gcactgacaa ttccgtggtg ttgtcgggga aatcatcgct ctttccttggt ctgctcgcct
 4740
 gtgttgccac ctggattctg cgcgggacgt ccttctgcta cgtcccttcg gccctcaatc
 4800
 cagcggacct tccttcccgc ggctgctgc cggctctgct gcctcttccg cgtcttcgcc
 4860
 ttgcacctca gacgagtcgg atctcccttt gggccgcctc cccgcactgc ccgggtggca
 4920
 tccctgtgac ccctccccag tgctctcct ggccctggaa gttgccactc cagtgccac
 4980
 cagccttgct ctaataaaat taagttgcat cttttgtct gactaggtgt cttctataa
 5040
 tattatgggg tggagggggg tggatatggag caagggggcc aagtgggaa gaaacctgta
 5100
 gggcctgccc taaggaggaa cccctagtga tggagtggc cactccctct ctgcgcgtc
 5160
 gctcgctcac tgaggccggg cgaccaaagg tcgcccgcg cccgggcttt gcccgggcgg
 5220
 cctcagtgag cgagcgagcg cgcagagagg gagtggccaa
 5260

[0088] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR; an UBC promoter; a BAG3 transgene; an WPRE(x) element; a Human GH poly(A) signal (hGH) sequence; and a 3' ITR. The vector genome may comprise, in 5' to 3' order, the polynucleotide sequences SEQ ID NO: 114; or polynucleotide sequences sharing 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to each of the foregoing. In

certain embodiments, this vector genome is packaged in an AAV9 or AAVrh74 vector. In certain embodiments, this vector genome is packaged in an AAVrh74 vector.

SEQ ID NO: 114

ttggccactccctctctgcgcgctcgctcgctcactgagggcgcccgggcaaagcccgggcgctcgggcgaccttt
ggcgcccgccctcagtgagcgagcgagcgcgagagagggagtgcccaactccatcactaggggttcctcctga
ggacgcgtgatctggcctccgcgccgggttttggcgccctcccgcgggcgccccctcctcacggcgagcgctgcc
acgtcagacgaagggcgagggcgagcgctcctgatccttccgcccggacgctcaggacagcgggcccgctgctcataag
actcgcccttagaaccacagtatcagcagaaggacatcttaggacgggacttggtgactctagggcactgggtt
tctttccagagcggaacaggcgaggaagtaagtccttctcgcgattctcgaggaggtatcccggtggcg
gtgaacgcgatgattatataaggacgcgcgggtgtggcacagctagttccgtcgagccgggatttggtcg
gggtcttgtttgtggatcgctgtgatcgctcacttggtgagtagcggtcgctgggtcgccggggtttctgtggc
cgccgggcccgtcggtgggacggaagcggtgtggagagacggccaagggtgtagctcggtccgagcaaggtt
gcccgaactgggggttggggggagcgagcaaaatggcggtgttcccgagcttgaatggaagacgcttgtga
ggcggtgtgaggtcggttgaacaaggtggggggcatggtggcggaagaaccaaggtcttgagcccttcgc
taagtgcgggaagctcttattcggtgagatgggtggggcaccatctggggaccctgacgtgaagttgtcact
gactggagaactcggtttgtcgtctgttgcggggcgcgagttatgcggtgccgttgggcagtgacccgtacct
ttgggagcgcgccctcgtcgtgtcgtgacgtcacccgttctgttggcttataatgcagggtggggccacctgc
cggtaggtgtcggttaggtcttttctccgtcgagacgcaggggtcgggcctagggtaggtctcctgaatcgac
aggcgccggacctctggtgaggggagggataagtgagcgctcagtttcttgggtcggtttatgtacctatcttc
ttaagtagctgaagctccggttttgaactatgcgctcggttggcgagtggttttgtgaagtttttaggcac
cttttgaatgtaatcatttgggtcaatatgtaatttccagtgttagactagtaaatgtccgctaaattctggc
cgtttttggcttttttgttagacgaaggccaccATGagcgccgccacccactcgcccatgatgcaggtggcgctcc
ggcaacggtgacccgcgaccccttggcccccggtgggagatcaagatcgaccgcagaccggtggcccttcttc
gtggaccacaacagccgcacccactacgtggaacgacccgcgctgcctctgagggcccaaggagactccatcc
tctgccaatggcccttcccgagggtcttaggtcgccgctgctaggggaaggccacccctgtgtacccccagctc
cgaccaggctacattcccatctcgtgtccatgaaggcgctgagaacccggcaggtgcaccttccatgtctat
ccccagcctgggatgcagcgattccgaactgaggcggcagcagcggtcctcagaggtcccagtcacctctgcgg
ggcatgccagaaccactcagccagataaacagtggtggacaggtggcagcgggcgggcagccagcccccagcc
tcccacggacctgagcggtcccagctctccagctgcctctgactgctcatcctcatcctcctcgccagcctgcct
tccctccggcaggagcagcctgggcagtcaccagctcccggggggtacatctccattccggtgatacacgagcag
aacgttaccggccagcagccagccctccttccaccaagccagaagacgcactaccagcgagcagggggag
taccagaccacccagcctgtgtaccacaagatccagggggatgactgggagccccggccctcgggcgggcatcc
ccgttcaggtcatctgtccagggtgcacgagccgggaggggtcaccagccaggagcagcagccactccactcc
ccctcgcccatccgtgtgcacacgtggtcgacaggcctcagcagcccatgaccatcgagaaatgcacctgtt
tcccagcctgaaaacaaaccagaaagtaagccaggccagttggaccagaactccctcctggacacatcccaatt
caagtgatccgcaaagaggtggattctaaacctgttcccagaagccccacctccctctgagaaggtagaggtg
aaagttccccctgctccagttccttctcctcctccagccctggcccttctgctgtccctcttcccccaagag
gtggctacagaagagagggcagccccagcactgcctcgcagaaagctacacctccaaaccagagagaagccgag
gctcccccaaaacatccaggagtgctgaaagtggaaagccatcctggagaaggtacaggggtggagcaggtgta
gacaactttgaaggcaagaagactgacaaaagtaacctgatgatcgaagagtatttgaccaaaagagctgctggcc
ctggattcagtggaaccccgaggacgagccgatgtgcgtcaggccaggagagacggtgtcaggaaaggttcagacc
atcttgaaaaacttgaaacagaagccattgatgtccagggtcaagtccagggtctatgaactccagccagcaac
ctggaagcagatcagccactgcaggcaatcatggagatgggtgcccgtggcagcagacaagggcaagaaaaatgct
ggaaatgcagaagatccccacacagaaacccagcagccagaagccacagcagcagcgacttcaaacccagcagc
atgacagacacccctggttaaccagcagcaccgTAGtcaacctctggattacaaaatttgtgaaagattgactgg
tattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttc
ccgtatggcttcattttctcctcctgtataaatcctgggtgtgtctctttatgaggagttgtggccggtgt
caggcaacgtggcggtgtgcaactgtgttctgacgcaacccccactgggtggggcattggccaccactgtca
gtccttttccgggacttttgccttccccctccctattgccacggcggaactcatcgccgctgcttggccgctg
ctggacaggggtcggctgttgggcactgacaattccgtgggtgttgcgggaaatcatcgtccttctcctggct
gctcgctgtgttgccacctggattctgcggggacgtccttctgctaegtccttccggccctcaatccagcgga
ccttccctcccgggcctgtgcgggtctgcggcctcttccgctcttccgctcgcctcagacagagtcggat
ctccctttggcgccctcccgcaactgcccgggtggcatccctgtgacccctcccagtgctcctcctggccctg
gaagtgtgcaactccagtgcccaccagccttgcctaataaaattaagttgcatcattttgtctgactaggtgtcc
ttctataatattatgggtggaggggggtggtatggagcaagggggcccaagttgggaagaaacctgagggcctg
ccctaaggaggaacccctagtgatggagttggccactccctctctgcgctcgctcactgagggcgggcg

accaaaggtcgcccgacgcccgggctttgcccgggcgccctcagtgagcgagcgagcgcgagagagggagtggc
caa

[0089] In each case the optionally WPRE element may be present or absent.

ADENO-ASSOCIATED VIRUS VECTOR

[0090] AAV vectors useful in the practice of the present invention can be packaged into AAV virions (viral particles) using various systems including adenovirus-based and helper-free systems. Standard methods in AAV biology include those described in Kwon and Schaffer. *Pharm Res.* (2008) 25(3):489-99; Wu et al. *Mol. Ther.* (2006) 14(3):316-27. Burger et al. *Mol. Ther.* (2004) 10(2):302-17; Grimm et al. *Curr Gene Ther.* (2003) 3(4):281-304; Deyle DR, Russell DW. *Curr Opin Mol Ther.* (2009) 11(4):442-447; McCarty et al. *Gene Ther.* (2001) 8(16):1248-54; and Duan et al. *Mol Ther.* (2001) 4(4):383-91. Helper-free systems included those described in US 6,004,797; US 7,588,772; and US 7,094,604;

[0091] AAV DNA in the rAAV genomes may be from any AAV variant or serotype for which a recombinant virus can be derived including, but not limited to, AAV variants or serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAVrh.74, and AAVrh10. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. *See, for example*, Marsic et al., *Molecular Therapy*, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.

[0092] In some cases, the rAAV comprises a self-complementary genome. As defined herein, an rAAV comprising a “self-complementary” or “double stranded” genome refers to an rAAV which has been engineered such that the coding region of the rAAV is configured to form an intra-molecular double-stranded DNA template, as described in McCarty et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors promoter efficient transduction independently of DNA synthesis. *Gene Therapy*. 8 (16): 1248–54 (2001). The present disclosure contemplates the use, in some cases, of an rAAV comprising a self-complementary genome because upon infection (such transduction), rather than waiting for cell mediated synthesis of the second strand of the rAAV genome, the two complementary halves of scAAV will associate to form one double stranded DNA (dsDNA) unit that is ready for

immediate replication and transcription. It will be understood that instead of the full coding capacity found in rAAV (4.7-6kb), rAAV comprising a self-complementary genome can only hold about half of that amount (≈ 2.4 kb).

[0093] In other cases, the rAAV vector comprises a single stranded genome. As defined herein, a “single standard” genome refers to a genome that is not self-complementary. In most cases, non-recombinant AAVs have singled stranded DNA genomes. There have been some indications that rAAVs should be scAAVs to achieve efficient transduction of cells. The present disclosure contemplates, however, rAAV vectors that maybe have singled stranded genomes, rather than self-complementary genomes, with the understanding that other genetic modifications of the rAAV vector may be beneficial to obtain optimal gene transcription in target cells.

[0094] In some cases, the rAAV vector is of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh10, or AAVrh74. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. *See, for example*, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). In certain embodiments, the rAAV vector is of serotype AAVrh74. In some cases, the rAAV vector is of the serotype AAV9. In some embodiments, said rAAV vector is of serotype AAV9 and comprises a single stranded genome. In some embodiments, said rAAV vector is of serotype AAV9 and comprises a self-complementary genome. In some embodiments, a rAAV vector comprises the inverted terminal repeat (ITR) sequences of AAV2. In some embodiments, the rAAV vector comprises an AAV2 genome, such that the rAAV vector is an AAV-2/9 vector, an AAV-2/6 vector, or an AAV-2/8 vector.

[0095] Full-length sequences and sequences for capsid genes for most known AAVs are provided in US Patent No. 8,524,446, which is incorporated herein in its entirety.

[0096] AAV vectors may comprise wild-type AAV sequence or they may comprise one or more modifications to a wild-type AAV sequence. In certain embodiments, an AAV vector comprises one or more amino acid modifications, optionally substitutions, deletions, or insertions, within a capsid protein, optionally VP1, VP2 and/or VP3. In particular embodiments, the modification provides for reduced immunogenicity when the AAV vector is provided to a subject.

[0097] Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as cardiomyocytes. In some embodiments, the rAAV is directly injected into the intracerebroventricular space of the subject.

[0098] In some embodiments, the rAAV virion is an AAVrh.74 rAAV virion. The capsid may be an AAVrh.74 capsid or functional variant thereof. In some embodiments, the AAVrh.74 capsid shares at least 98%, 99%, or 100% identity to a reference AAVrh.74 capsid, *e.g.*, SEQ ID NO: 100. In particular embodiments, the rAAVrh.74 rAAV virion is preferred for targeting adults with DCM and has greater safety and/or efficacy than other AAV serotypes.

[0099] In some embodiments, the rAAV virion is an AAV2 rAAV virion. The capsid may be an AAV2 capsid or functional variant thereof. In some embodiments, the AAV2 capsid shares at least 98%, 99%, or 100% identity to a reference AAV2 capsid, *e.g.*, SEQ ID NO: 96.

SEQ ID NO: 96

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser
 Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro
 Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 Leu Gly Leu Val Glu Glu Pro Val Lys Thr Ala Pro Gly Lys Lys Arg
 Pro Val Glu His Ser Pro Val Glu Pro Asp Ser Ser Ser Gly Thr Gly
 Lys Ala Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
 Gly Asp Ala Asp Ser Val Pro Asp Pro Gln Pro Leu Gly Gln Pro Pro
 Ala Ala Pro Ser Gly Leu Gly Thr Asn Thr Met Ala Thr Gly Ser Gly
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr
 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp
 Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val
 Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu
 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr
 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala As
 Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser
 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu
 Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg
 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr
 Asn Thr Pro Ser Gly Thr Thr Thr Gln Ser Arg Leu Gln Phe Ser Gln
 Ala Gly Ala Ser Asp Ile Arg Asp Gln Ser Arg Asn Trp Leu Pro Gly
 Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ser Ala Asp Asn Asn
 Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly
 Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp
 Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly Val Leu Ile Phe Gly Lys
 Gln Gly Ser Glu Lys Thr Asn Val Asp Ile Glu Lys Val Met Ile Thr
 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr
 Gly Ser Val Ser Thr Asn Leu Gln Arg Gly Asn Arg Gln Ala Ala Thr
 Ala Asp Val Asn Thr Gln Gly Val Leu Pro Gly Met Val Trp Gln Asp
 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys
 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn
 Pro Ser Thr Thr Phe Ser Ala Ala Lys Phe Ala Ser Phe Ile Thr Gln
 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
 Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr
 Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu

[0100] In some embodiments, the rAAV virion is an AAV9 rAAV virion. The capsid may be an AAV9 capsid or functional variant thereof. In some embodiments, the AAV9

capsid shares at least 98%, 99%, or 100% identity to a reference AAV9 capsid, *e.g.*, SEQ ID NO: 97.

SEQ ID NO: 97

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
 Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
 Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
 Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
 Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
 Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
 Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
 Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
 Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
 Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
 Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
 Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
 Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
 Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
 Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
 Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
 Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
 Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
 Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
 Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
 Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
 Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
 Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
 Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
 Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu

[0101] In some embodiments, the rAAV virion is an AAV6 rAAV virion. The capsid may be an AAV6 capsid or functional variant thereof. In some embodiments, the AAV6 capsid shares at least 98%, 99%, or 100% identity to a reference AAV6 capsid, *e.g.*, SEQ ID NO: 98.

SEQ ID NO: 98

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
Asp Asp Lys Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
Phe Gly Thr Val Ala Val Asn Leu Gln Ser Ser Ser Thr Asp Pro Ala
Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu

[0102] In some embodiments, the rAAV virion is an AAVrh.10 rAAV virion. The capsid may be an AAVrh.10 capsid or functional variant thereof. In some embodiments, the AAVrh.10 capsid shares at least 98%, 99%, or 100% identity to a reference AAVrh.10 capsid, *e.g.*, SEQ ID NO: 99.

SEQ ID NO: 99

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile
 Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln
 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro
 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly
 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser
 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp
 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn
Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn
Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala
Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln
Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe
Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn
Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr
Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr
Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser
Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu
Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu
Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp
Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser
Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met
Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val
Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr
Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala
Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val
Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile
Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe
Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val
Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe
Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu
Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr
Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp
Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg
Asn Leu

[0103] In some embodiments, the capsid protein is encoded by a polynucleotide supplied on a plasmid *in trans* to the transfer plasmid. The polynucleotide sequence of wild-type AAVrh74 *cap* is provided as SEQ ID NO: 100.

SEQ ID NO: 100

atggctgccc	atggttatct	tccagattgg	ctcgaggaca	acctctctga	gggcattcgc	6
gagtgggtgg	acctgaaacc	tggagccccc	aaacccaaag	ccaaccagca	aaagcaggac	120
aacggccggg	gtctggtgct	tcctggttac	aagtacctcg	gacccttcaa	cggactcgac	180
aagggggagc	cgtccaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctcc	aagcgggtga	caatccgtac	ctgcggtata	atcacgccga	cgcgagttt	300
caggagcgtc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggcgcgc	agtcttccag	360
gccaaaaagc	gggttctcga	acctctgggc	ctggttgaat	cgccggttaa	gacggctcct	420
ggaaagaaga	gaccggtaga	gccatcaccc	cagcgctctc	cagactcctc	tacgggcatc	480
ggcaagaaag	gccagcagcc	cgcaaaaaag	agactcaatt	ttgggcagac	tggcgactca	540
gagtcagtc	cgcaccccca	accaatcgga	gaaccaccag	caggccctcc	tggctctggga	600
tctggtacaa	tggttcgagg	cgggtggcgt	ccaatggcag	acaataacga	aggcgccgac	660
ggagtgggta	gttcctcagg	aaattggcat	tgcgattcca	catggctggg	cgacagagtc	720
atcaccacca	gcacccgcac	ctgggcccctg	cccacctaca	acaaccacct	ctacaagcaa	780
atctccaacg	ggacctcggg	aggaagcacc	aacgacaaca	cctacttcgg	ctacagcacc	840
ccctgggggt	atcttgactt	caacagattc	cactgccact	tttcaccacg	tgactggcag	900
cgaactcatca	acaacaactg	gggattccgg	cccaagaggc	tcaacttcaa	gctcttcaac	960
atccaagtca	aggaggtcac	gcagaatgaa	ggcaccaaga	ccatcgccaa	taaccttacc	1020
agcacgattc	aggtctttac	ggactcggaa	taccagctcc	cgtacgtgct	cggtctggcg	1080
caccagggct	gcctgcctcc	gttcccggcg	gacgtcttca	tgattctcca	gtacgggtac	1140
ctgactctga	acaatggcag	tcaggctgtg	ggccggtcgt	ccttctactg	cctggagtag	1200
tttcccttct	aatgctgag	aacgggcaac	aactttgaat	tcagctacaa	cttcgaggac	1260
gtgcccctcc	acagcagcta	cgcgcacagc	cagagcctgg	accggctgat	gaaccctctc	1320
atcgaccagt	acttgtacta	cctgtcccgg	actcaaagca	cgggcgggtac	tgcaggaaat	1380
cagcagttgc	tattttctca	ggccgggcct	aacaacatgt	cggctcaggc	caagaactgg	1440
ctaccccggtc	cctgctaccg	gcagcaacgc	gtctccacga	cactgtcgca	gaacaacaac	1500
agcaactttg	cctggacggg	tgccaccaag	tatcatctga	atggcagaga	ctctctggtg	1560
aatccctggc	ttgccatggc	taccacaag	gacgacgaag	agcgattttt	tccatccagc	1620
ggagctctaa	tggttgggaa	acaggagact	ggaaaagaca	acgtggacta	tagcagctgt	1680
atgctaacca	gcgaggaaga	aataaagacc	accaaccag	tgccacaga	acagtacggc	1740
gtggtggccg	ataacctgca	acagcaaaac	gccgctccta	ttgtaggggc	cgtcaatagt	1800
caaggagcct	tacctggcat	ggtgtggcag	aaccgggacg	tgtacctgca	gggtcccatc	1860
tgggccaaga	ttcttcatac	ggacggcaac	tttcatccct	cgcgctgat	gggaggcttt	1920
ggactgaagc	atccgcctcc	tcagatcctg	attaaaaaca	cacctgttcc	cgcggatcct	1980
ccgaccacct	tcaatcagcg	caagctggct	tctttcatca	cgcagtagag	taccggccag	2040
gtcagcgctg	agatcgagtg	ggagctgcag	aaggagaaca	gcaaacgctg	gaaccagag	2100
attcagtaga	cttccaacta	ctacaaatct	acaaatgtgg	actttgctgt	caatactgag	2160
ggtacttatt	cgcagcctcg	ccccattggc	accggttacc	tcaccctgaa	tctgtaa	2217

[0104] The disclosure further provides protein sequences for AAVrh74 VP1, VP2, and VP3, including SEQ ID NOs: 101-103, and homologs or functional variants thereof.

SEQ ID NO: 101

MAADGYLPDWLEDNLSEGIREWDDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEH
 DKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESPVKTA PGKKRPVEPSP
 QRSPDSSTGIGKKGQQPAKKRLNFGQTDGSESVDPQPIGEPPAGPSGLSGTMAAGGGAPMADNNEGADGVGSS
 SGNWHCDSTWLGDRVITSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDNRFHCHFS PRDWQ
 RLINNNWGFPRKRLNFKLFNIQVKEVTQNEGKTIANNLSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMI
 PQYGYLTLNNGSQAVGRSSFYCLEYFSPQMLRTGNNEFFSYNFEDVPFHSSYAHSQSLDRLMNP LIDQYLYLRSR
 TQSTGGTAGTQQLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVPNGVA
 MATHKDDEERFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTNPVATEQYGVVADNLQQQNAAPIVGAVNS
 QGALPGMVWQNRDVYLQGP I WAKI PHTDGNFHPSPLMGGFGLKHP PPQ I L I K N T P V P A D P P T T F N Q A K L A S F I T Q
 YSTGQVSVEIEWELQKENS KRWNPEIQYTSNYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL

SEQ ID NO: 102

TAPGKKRPVEPSQSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVDPDQPIGEPPAGPSGLSGTMAAGGGAPM
 ADNNEGADGVGSSSGNWHCDSTWLGDRTVTTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDF
 NREHCHFSRDPWQRLINNNWGFPRKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQ
 GCLPPFPADVFMIPOYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPPHSSYAHSQSLDRIM
 NPLIDQYLYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTSLQNNNSNFAWTGATKYH
 LNGRDSLVPVAMATHKDDEERFFPSSGVLMTFGKQAGKDNVDYSSVMTSEEEIKTTNPVATEQYGVVADNLQ
 QQNAAPIVGAVNSQAGALPGMVWQNRDVYLQGGPIWAKIPHTDGNFHPSPMLGGFGLKHPPPQILIKNTVPVADPPT
 TFNQAKLASFITQYSTGQVSVEIEWELQKENS KRWNPEIQYTSNYKSTNVDFAVNTEGTYSERPIGTRYLTRNL

SEQ ID NO: 103

MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRTVTTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGY
 STPWGYFDFNREHCHFSRDPWQRLINNNWGFPRKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQL
 PYVLGSAHQGCLPPFPADVFMIPOYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPPHSSYA
 HSQSLDRIMNPLIDQYLYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTSLQNNNSN
 AWTGATKYHLNGRDSLVPVAMATHKDDEERFFPSSGVLMTFGKQAGKDNVDYSSVMTSEEEIKTTNPVATEQ
 YGVVADNLQQNAAPIVGAVNSQAGALPGMVWQNRDVYLQGGPIWAKIPHTDGNFHPSPMLGGFGLKHPPPQILIK
 NTPVPADPPTTFNQAKLASFITQYSTGQVSVEIEWELQKENS KRWNPEIQYTSNYKSTNVDFAVNTEGTYSERPI
 GTRYLTRNL

[0105] In certain cases, the AAVrh74 capsid comprises the amino acid sequence set forth in SEQ ID NO: 101. In some embodiments, the rAAV vector comprises a polypeptide that comprises, or consists essentially of, or yet further consists of a sequence, *e.g.*, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to amino acid sequence of AAVrh74 VP1 which is set forth in SEQ ID NO: 101. In some embodiments, the rAAV vector comprises a polypeptide that comprises, or consists essentially of, or yet further consists of a sequence, *e.g.*, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to amino acid sequence of AAVrh74 VP2 which is set forth in SEQ ID NO: 102. In some embodiments, the rAAV vector comprises a polypeptide that comprises, or consists essentially of, or yet further consists of a sequence, *e.g.*, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to amino acid sequence of AAVrh74 VP3 which is set forth in SEQ ID NO: 103.

[0106] In some embodiments, the rAAV virion is an AAV-PHP.B rAAV virion or a neutrotrophic variant thereof, such as, without limitation, those disclosed in Int'l Pat. Pub. Nos. WO 2015/038958 A1 and WO 2017/100671 A1. For example, the AAV capsid may comprise at least 4 contiguous amino acids from the sequence TLAVPFK (SEQ ID NO: 105)

or KFPVALT (SEQ ID NO: 106), *e.g.*, inserted between a sequence encoding for amino acids 588 and 589 of AAV9.

[0107] The capsid may be an AAV-PHP.B capsid or functional variant thereof. In some embodiments, the AAV-PHP.B capsid shares at least 98%, 99%, or 100% identity to a reference AAV-PHP.B capsid, *e.g.*, SEQ ID NO: 104.

SEQ ID NO: 104

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
 Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
 Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly

 Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
 Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
 Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
 Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
 Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
 Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
 Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
 Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp

Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
 Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
 Arg Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
 Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
 Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
 Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
 Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
 Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
 Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
 Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
 Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Thr Leu Ala Val
 Pro Phe Lys Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
 Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
 Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
 Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
 Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
 Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
 Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
 Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
 Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
 Arg Tyr Leu Thr Arg Asn Leu

[0108] Further AAV capsids used in the rAAV virions of the disclosure include those disclosed in Pat. Pub. Nos. WO 2009/012176 A2 and WO 2015/168666 A2.

[0109] Without being bound by theory, the present inventors have determined that an AAVrh.74, AAV9 vector, or an AAVrh.10 vector will confer desirable cardiac tropism on the vector. Without being bound by theory, the present inventors have further determined that an AAVrh.74, AAV9 vector, or an AAVrh.10 vector may provide desired specificity to cardiac cells.

[0110] In an aspect, the disclosure provides pharmaceutical compositions comprising the rAAV virion of the disclosure and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0111] For purposes of administration, optionally by injection, various solutions can be employed, such as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as Poloxamer 188, *e.g.*, at 0.001% or 0.01%. A dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

[0112] The pharmaceutical forms suitable for injectable use include but are not limited to sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form is sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0113] Sterile injectable solutions may be prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium

and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the certain methods of preparation are vacuum drying and the freeze-drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.

[0114] In another aspect, the disclosure comprises a kit comprising an rAAV virion of the disclosure and instructions for use.

[0115] In an aspect, the disclosure provides a method of increasing BAG3 activity in a cell, comprising contacting the cell with an rAAV of the disclosure. In another aspect, the disclosure provides a method of increasing BAG3 activity in a subject, comprising administering to the subject an rAAV of the disclosure. In some embodiments, the cell and/or subject is deficient in BAG3 messenger RNA or BAG3 protein expression levels and/or activity and/or comprises a loss-of-function mutation in BAG3. In some embodiments, the cell and/or subject is deficient in BAG3 messenger RNA or BAG3 protein expression levels and/or activity. The cell may be a cardiac cell, *e.g.* a cardiomyocyte cell. In particular embodiments, the subject is a mammal, *e.g.*, a human.

[0116] In some embodiments, the method promotes survival of cardiac cell, *e.g.* a cardiomyocyte cell, in cell culture and/or *in vivo*. In some embodiments, the method promotes and/or restores function of the heart.

[0117] In another aspect, the disclosure provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of an rAAV virion of the disclosure. In some embodiments, the disease or disorder is a cardiac disease or disorder. Illustrative cardiac disorders include heart failure, dilated cardiomyopathy (DCM), such as such as BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial isolated dilated cardiomyopathy, or cardiomyopathy, dilated, 1hh (CMD1HH), hypertrophic cardiomyopathy, atrial fibrillation, arrhythmia, sinus node disease, hypertensive heart disease, cardiac hypertrophy, atrial fibrosis, myocardial infarction, symptomatic sick sinus syndrome, atrial disease, and myocardial infarction. In certain embodiments, the subject suffers from or is at risk for DCM. In particular embodiments, the subject has a cardiomyopathy *e.g.*, dilated cardiomyopathy (DCM), such as BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial isolated dilated cardiomyopathy, or cardiomyopathy, dilated, 1hh (CMD1HH). In particular embodiments, the

subject is a mammal, e.g., a human, having a loss-of-function mutation in a *BAG3* gene. In particular embodiments, the subject is a mammal, e.g., a human, having a mutation in *BAG3*; e.g., E455K. In particular methods, treatment with the rAAV virion results in expression of the *BAG3* protein encoded by the rAAV virion in the subject, e.g., in the subject's heart or cardiac tissue. In certain embodiments, treatment with the rAAV virion results in at least two-fold, at least five-fold, at least ten-fold, or more *BAG3* protein levels detectable in the subject's heart.

[0118] The AAV-mediated delivery of *BAG3* protein to the heart may increase life span, prevent or attenuate cardiac cell degeneration, heart failure, scarring, reduced ejection fraction, arrhythmia, angina, exercise intolerance, angina (chest pain), sudden cardiac death, exertional myalgias and cramps. The AAV-mediated delivery of *BAG3* protein to the heart may show improvement from, or prevent normal disease course detected by use of echocardiography, pathological electrocardiogram, cardiac MRI, heart biopsy, decrease in paroxysmal ventricular arrhythmias, and/or decrease in sudden cardiac death.

[0119] The methods disclosed herein may provide efficient biodistribution in the heart. They may result in sustained expression in all, or a substantial fraction of, cardiac cells, e.g., cardiomyocytes. Notably, the methods disclosed herein may provide long-lasting expression of *BAG3* protein throughout the life of the subject following AAV vector administration. In some embodiments, *BAG3* protein expression in response to treatment lasts at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40 years.

[0120] Combination therapies are also contemplated by the invention. Combinations of methods of the invention with standard medical treatments (e.g., corticosteroids or topical pressure reducing medications) are specifically contemplated, as are combinations with novel therapies. In some cases, a subject may be treated with a steroid and/or combination of immune suppressing agents to prevent or to reduce an immune response to administration of a rAAV described herein.

[0121] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of between about 1×10^{12} and 5×10^{14} vector genomes (vg) or between about 1×10^{12} and 6×10^{14} vg of the AAV vector per kilogram (vg) of total body mass of the subject (vg/kg). In some embodiments, the AAV vector is administered at a dose of between about 1×10^{13} and 5×10^{14} vg/kg. In some embodiments, the AAV vector is administered at a dose of between about 5×10^{13} and 3×10^{14} vg/kg. In some embodiments, the

AAV vector is administered at a dose of between about 5×10^{13} and 1×10^{14} vg/kg. In some embodiments, the AAV vector is administered at a dose of less than about 1×10^{12} vg/kg, less than about 3×10^{12} vg/kg, less than about 5×10^{12} vg/kg, less than about 7×10^{12} vg/kg, less than about 1×10^{13} vg/kg, less than about 3×10^{13} vg/kg, less than about 5×10^{13} vg/kg, less than about 7×10^{13} vg/kg, less than about 1×10^{14} vg/kg, less than about 3×10^{14} vg/kg, less than about 5×10^{14} vg/kg, less than about 7×10^{14} vg/kg, less than about 1×10^{15} vg/kg, less than about 3×10^{15} vg/kg, less than about 5×10^{15} vg/kg, or less than about 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector. In some cases, it may be advantageous to use a higher dose for an AAV rh74 vector than for an AAV9 vector. In some embodiments, the AAV vector, e.g., an AAVrh.74 vector, is administered at a dosage of at least about 5×10^{13} vg/kg, at least about 6×10^{13} vg/kg, at least about 7×10^{13} vg/kg, at least about 8×10^{13} vg/kg, at least about 9×10^{13} vg/kg, at least about 1×10^{14} vg/kg, at least about 2×10^{14} vg/kg, at least about 3×10^{14} vg/kg, at least about 4×10^{14} vg/kg, at least about 5×10^{14} vg/kg, at least about 6×10^{14} vg/kg, or at least about 7×10^{14} vg/kg.

[0122] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of about 1×10^{12} vg/kg, about 3×10^{12} vg/kg, about 5×10^{12} vg/kg, about 7×10^{12} vg/kg, about 1×10^{13} vg/kg, about 3×10^{13} vg/kg, about 5×10^{13} vg/kg, about 7×10^{13} vg/kg, about 1×10^{14} vg/kg, about 3×10^{14} vg/kg, about 5×10^{14} vg/kg, about 7×10^{14} vg/kg, about 1×10^{15} vg/kg, about 3×10^{15} vg/kg, about 5×10^{15} vg/kg, or about 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0123] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of 1×10^{12} vg/kg, 3×10^{12} vg/kg, 5×10^{12} vg/kg, 7×10^{12} vg/kg, 1×10^{13} vg/kg, 3×10^{13} vg/kg, 5×10^{13} vg/kg, 7×10^{13} vg/kg, 1×10^{14} vg/kg, 3×10^{14} vg/kg, 5×10^{14} vg/kg, 7×10^{14} vg/kg, 1×10^{15} vg/kg, 3×10^{15} vg/kg, 5×10^{15} vg/kg, or 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0124] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered systemically at a dose of between about 1×10^{12} and 5×10^{14} vector genomes (vg) of the AAV vector per kilogram (vg) of total body mass of the subject (vg/kg). In some embodiments, the AAV vector is administered systemically at a dose of between about

1×10^{13} and 5×10^{14} vg/kg. In some embodiments, the AAV vector is administered systemically at a dose of between about 5×10^{13} and 3×10^{14} vg/kg. In some embodiments, the AAV vector is administered systemically at a dose of between about 5×10^{13} and 1×10^{14} vg/kg. In some embodiments, the AAV vector is administered systemically at a dose of less than about 1×10^{12} vg/kg, less than about 3×10^{12} vg/kg, less than about 5×10^{12} vg/kg, less than about 7×10^{12} vg/kg, less than about 1×10^{13} vg/kg, less than about 3×10^{13} vg/kg, less than about 5×10^{13} vg/kg, less than about 7×10^{13} vg/kg, less than about 1×10^{14} vg/kg, less than about 3×10^{14} vg/kg, less than about 5×10^{14} vg/kg, less than about 7×10^{14} vg/kg, less than about 1×10^{15} vg/kg, less than about 3×10^{15} vg/kg, less than about 5×10^{15} vg/kg, or less than about 7×10^{15} vg/kg. In some embodiments, the AAV vector, e.g., an AAVrh.74 vector, is administered at a dosage of at least about 5×10^{13} vg/kg, at least about 6×10^{13} vg/kg, at least about 7×10^{13} vg/kg, at least about 8×10^{13} vg/kg, at least about 9×10^{13} vg/kg, at least about 1×10^{14} vg/kg, at least about 2×10^{14} vg/kg, at least about 3×10^{14} vg/kg, at least about 4×10^{14} vg/kg, at least about 5×10^{14} vg/kg, at least about 6×10^{14} vg/kg, or at least about 7×10^{14} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0125] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered systemically at a dose of about 1×10^{12} vg/kg, about 3×10^{12} vg/kg, about 5×10^{12} vg/kg, about 7×10^{12} vg/kg, about 1×10^{13} vg/kg, about 3×10^{13} vg/kg, about 5×10^{13} vg/kg, about 7×10^{13} vg/kg, about 1×10^{14} vg/kg, about 3×10^{14} vg/kg, about 5×10^{14} vg/kg, about 7×10^{14} vg/kg, about 1×10^{15} vg/kg, about 3×10^{15} vg/kg, about 5×10^{15} vg/kg, or about 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0126] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered systemically at a dose of 1×10^{12} vg/kg, 3×10^{12} vg/kg, 5×10^{12} vg/kg, 7×10^{12} vg/kg, 1×10^{13} vg/kg, 3×10^{13} vg/kg, 5×10^{13} vg/kg, 7×10^{13} vg/kg, 1×10^{14} vg/kg, 3×10^{14} vg/kg, 5×10^{14} vg/kg, 7×10^{14} vg/kg, 1×10^{15} vg/kg, 3×10^{15} vg/kg, 5×10^{15} vg/kg, or 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0127] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered intravenously at a dose of between about 1×10^{12} and 5×10^{14} vector genomes (vg) of the AAV vector per kilogram (vg) of total body mass of the subject (vg/kg). In some embodiments, the AAV vector is administered intravenously at a dose of between

about 1×10^{13} and 5×10^{14} vg/kg. In some embodiments, the AAV vector is administered intravenously at a dose of between about 5×10^{13} and 3×10^{14} vg/kg. In some embodiments, the AAV vector is administered intravenously at a dose of between about 5×10^{13} and 1×10^{14} vg/kg. In some embodiments, the AAV vector is administered intravenously at a dose of less than about 1×10^{12} vg/kg, less than about 3×10^{12} vg/kg, less than about 5×10^{12} vg/kg, less than about 7×10^{12} vg/kg, less than about 1×10^{13} vg/kg, less than about 3×10^{13} vg/kg, less than about 5×10^{13} vg/kg, less than about 7×10^{13} vg/kg, less than about 1×10^{14} vg/kg, less than about 3×10^{14} vg/kg, less than about 5×10^{14} vg/kg, less than about 7×10^{14} vg/kg, less than about 1×10^{15} vg/kg, less than about 3×10^{15} vg/kg, less than about 5×10^{15} vg/kg, or less than about 7×10^{15} vg/kg. In some embodiments, the AAV vector, e.g., an AAVrh.74 vector, is administered at a dosage of at least about 5×10^{13} vg/kg, at least about 6×10^{13} vg/kg, at least about 7×10^{13} vg/kg, at least about 8×10^{13} vg/kg, at least about 9×10^{13} vg/kg, at least about 1×10^{14} vg/kg, at least about 2×10^{14} vg/kg, at least about 3×10^{14} vg/kg, at least about 4×10^{14} vg/kg, at least about 5×10^{14} vg/kg, at least about 6×10^{14} vg/kg, or at least about 7×10^{14} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0128] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered intravenously at a dose of about 1×10^{12} vg/kg, about 3×10^{12} vg/kg, about 5×10^{12} vg/kg, about 7×10^{12} vg/kg, about 1×10^{13} vg/kg, about 3×10^{13} vg/kg, about 5×10^{13} vg/kg, about 7×10^{13} vg/kg, about 1×10^{14} vg/kg, about 3×10^{14} vg/kg, about 5×10^{14} vg/kg, about 7×10^{14} vg/kg, about 1×10^{15} vg/kg, about 3×10^{15} vg/kg, about 5×10^{15} vg/kg, or about 7×10^{15} vg/kg.

[0129] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered intravenously at a dose of 1×10^{12} vg/kg, 3×10^{12} vg/kg, 5×10^{12} vg/kg, 7×10^{12} vg/kg, 1×10^{13} vg/kg, 3×10^{13} vg/kg, 5×10^{13} vg/kg, 7×10^{13} vg/kg, 1×10^{14} vg/kg, 3×10^{14} vg/kg, 5×10^{14} vg/kg, 7×10^{14} vg/kg, 1×10^{15} vg/kg, 3×10^{15} vg/kg, 5×10^{15} vg/kg, or 7×10^{15} vg/kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAV rh74 vector.

[0130] Evidence of functional improvement, clinical benefit or efficacy in patients may be revealed by improvements in New York Heart Association functional classification (NYHA Class), echocardiography (stabilized or improved cardiac output, left ventricle ejection fraction, fractional shortening, left ventricular outflow tract obstruction, left ventricular wall

thickness, left or right ventricular volumes, velocity time integral, time constant of ventricular relaxation, regurgitant volume, and decrease in left ventricular end diastolic diameter, LVEDD and decreased right ventricular area), electrocardiography (stabilized or improved ST-segment alterations, T-wave inversion, Q waves, atrial fibrillation, and/or supraventricular tachycardia), cardiac MRI, heart biopsy, decrease in paroxysmal ventricular arrhythmias, decrease in sudden cardiac death, and/or decrease in or lack of further development myocardial disarray.

[0131] Administration of an effective dose of the compositions may be by routes standard in the art including, but not limited to, systemic, local, direct injection, intravenous, intracardiac administration. In some cases, administration comprises systemic, local, direct injection, intravenous, intracardiac injection. Administration may be performed by cardiac catheterization.

[0132] In some embodiments, the disclosure provides for local administration and systemic administration of an effective dose of rAAV and compositions of the invention. For example, systemic administration may be administration into the circulatory system so that the entire body is affected. Systemic administration includes parental administration through injection, infusion or implantation. Routes of administration for the compositions disclosed herein include intravenous ("IV") administration, intraperitoneal ("IP") administration, intramuscular ("IM") administration, intralesional administration, or subcutaneous ("SC") administration, or the implantation of a slow-release device, *e.g.*, a mini-osmotic pump, a depot formulation, etc. In some embodiments, the methods of the disclosure comprise administering an AAV vector of the disclosure, or pharmaceutical composition thereof by intravenous, intramuscular, intraarterial, intrarenal, intraurethral, intracardiac, intracoronary, intramyocardial, intradermal, epidural, subcutaneous, intraperitoneal, intraventricular, or ionophoretic administration.

[0133] In particular, administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal. Administration includes, but is not limited to, injection into the heart. In some embodiments, the methods include administering the rAAV into a blood vessel of the coronary circulation *in vivo*, such as retrograde coronary sinus infusion.

[0134] In some embodiments, the methods of the disclosure comprise intracardiac delivery. Infusion may be performed using specialized cannula, catheter, syringe/needle using an infusion pump. Administration may comprise delivery of an effective amount of the rAAV

virion, or a pharmaceutical composition comprising the rAAV virion, to the heart. These may be achieved, *e.g.*, via intravenous, intramuscular, intraarterial, intrarenal, intraurethral, intracardiac, intracoronary, intramyocardial, intradermal, epidural, subcutaneous, intraperitoneal, intraventricular, or ionophoretic administration. The compositions of the disclosure may further be administered intravenously.

EFFECTS OF rAAV ADMINISTRATION

[0135] In some embodiments, administration of rAAV of the present disclosure has beneficial effects for the subject.

Lifespan

[0136] In some embodiments, administration of rAAV of the present disclosure may increase lifespan of the subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0137] In some embodiments, administration of rAAV of the present disclosure increases lifespan by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, or at least about 500% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0138] In some embodiments, administration of rAAV of the present disclosure increases lifespan by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 95% to about 100%, about 100% to about 200%,

about 200% to about 300%, about 300% to about 400%, or by about 400% to about 500% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

Ejection Fraction

[0139] In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases the ejection fraction in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases the ejection fraction in a subject over time.

[0140] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the ejection fraction by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0141] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the ejection fraction to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0142] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the ejection fraction by at least about 1% , at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least

about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0143] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the ejection fraction to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% in a subject over time.

[0144] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the ejection fraction by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0145] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the ejection fraction by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to

about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

[0146] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the ejection fraction to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0147] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the ejection fraction to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than

about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% in a subject over time.

Left Ventricular Ejection Fraction (LVEF)

[0148] In some embodiments, administration of rAAV of the present disclosure prevents a decrease in, restores, and/or increases in the LVEF in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the LVEF in a subject over time.

[0149] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0150] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0151] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0152] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% in a subject over time.

[0153] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LVEF by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0154] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LVEF by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about

6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

[0155] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0156] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less

than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% in a subject over time.

Right Ventricular Ejection Fraction (RVEF)

[0157] In some embodiments, administration of rAAV of the present disclosure prevents a decrease in, restores, and/or increases in the RVEF in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the LVEF in a subject over time.

[0158] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0159] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less

than about 95%, or less than about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0160] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0161] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% in a subject over time.

[0162] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RVEF by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0163] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RVEF by about 1% to about 90%, about 20% to about 80%, about 30% to

about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

[0164] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0165] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about

6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% in a subject over time.

Right Ventricle (RV) Area

[0166] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area in a subject over time.

[0167] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0168] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%,

about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0169] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0170] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Left Ventricle (LV) Area

[0171] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the LV area in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the RV area in a subject over time.

[0172] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the LV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0173] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the LV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0174] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the LV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0175] In some embodiments, administration of rAAV of the present disclosure prevents an increase in, restores, and/or decreases the LV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about

1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Right Ventricle (RV) Velocity Time Integral (VTI)

[0176] In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the RV VTI in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the RV VTI in a subject over time.

[0177] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0178] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about

90%, less than about 95%, or less than about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0179] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0180] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% in a subject over time.

[0181] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RV VTI by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0182] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the RV VTI by about 1% to about 90%, about 20% to about 80%, about 30%

to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

[0183] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0184] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the RV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than

about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% in a subject over time.

Left Ventricle (LV) Velocity Time Integral (VTI)

[0185] In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the LV VTI in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure limits a decrease in, restores, and/or increases in the LV VTI in a subject over time.

[0186] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0187] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about

70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0188] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0189] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% in a subject over time.

[0190] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LV VTI by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0191] In some embodiments, administration of rAAV of the present disclosure restores and/or increases the LV VTI by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

[0192] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0193] In some embodiments, administration of rAAV of the present disclosure limits a decrease in the LV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than

about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% to less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or by less than about 95% to about 100% in a subject over time.

Left Ventricle (LV) Fibrosis

[0194] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis in a subject over time.

[0195] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0196] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1%

to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0197] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0198] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the LV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Right Ventricle (RV) Fibrosis

[0199] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis in a subject compared to a subject that is not

administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis in a subject over time.

[0200] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0201] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0202] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0203] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases the RV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Premature Ventricular Contractions (PVC)

[0204] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC in a subject over time.

[0205] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0206] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25%

to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0207] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0208] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases PVC by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Non-sustained Ventricular Tachycardia (NSVT)

[0209] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT in a subject over time.

[0210] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0211] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0212] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0213] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases NSVT by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to

about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

Ectopic Beats

[0214] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats in a subject compared to a subject that is not administered the rAAV of the present disclosure or to baseline. In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats in a subject over time.

[0215] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0216] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60%

to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% compared to a subject that is not administered the rAAV of the present disclosure or to baseline.

[0217] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% in a subject over time.

[0218] In some embodiments, administration of rAAV of the present disclosure prevents an increase in and/or decreases ectopic beats by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or by about 95% to about 100% in a subject over time.

NUMBERED EMBODIMENTS

[0219] Embodiment 1. A polynucleotide, comprising an expression cassette and optionally flanking adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the polynucleotide comprises a polynucleotide sequence encoding a B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3), or a functional variant thereof, operatively linked to a promoter, optionally wherein the promoter is a heterologous promoter.

[0220] Embodiment 2. The polynucleotide of embodiment 1, wherein the promoter is a cardiac-specific promoter.

[0221] Embodiment 3. The polynucleotide of embodiment 1 or embodiment 2, wherein the promoter is a muscle-specific promoter.

[0222] Embodiment 4. The polynucleotide of any one of embodiments 1 to 3, wherein the promoter is a cardiomyocyte-specific promoter.

[0223] Embodiment 5. The polynucleotide of any one of embodiments 1 to 4, wherein the promoter is a Myosin Heavy-chain Creatine Kinase 7 (MHCK7) promoter.

[0224] Embodiment 6. The polynucleotide of embodiment 5, wherein the MHCK7 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 31.

[0225] Embodiment 7. The polynucleotide of any one of embodiments 1 to 4, wherein the promoter is a cardiac troponin T (hTNNT2) promoter.

[0226] Embodiment 8. The polynucleotide of embodiment 7, wherein the hTNNT2 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 32.

[0227] Embodiment 9. The polynucleotide of any one of embodiments 1 to 4, wherein the promoter is a human heat shock factor 70 (hHSP70) promoter.

[0228] Embodiment 10. The polynucleotide of embodiment 9, wherein the hHSP70 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 115.

[0229] Embodiment 11. The polynucleotide of any one of embodiments 1 to 10, wherein the expression cassette comprises exon 1 of the cardiac troponin T (hTNNT2) gene, wherein optionally the hTNNT2 promoter and exon 1 together share at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 32.

[0230] Embodiment 12. The polynucleotide of any one of embodiments 1 to 4, wherein the promoter is a ubiquitous promoter, optionally a CMV promoter or a CAG promoter or a chicken β -globin promoter or a UBC promoter (SEQ ID NO: 116).

[0231] Embodiment 13. The polynucleotide of any one of embodiments 1 to 12, wherein the expression cassette comprises a polyA signal.

[0232] Embodiment 14. The polynucleotide of embodiment 13, wherein the polyA signal is a human growth hormone (hGH) polyA.

[0233] Embodiment 15. The polynucleotide of any one of embodiments 1 to 14, wherein the expression cassette comprises a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE), optionally a mutant or modified WPRE (WPRE(x)), optionally WPRE Mut6 (SEQ ID NO:63).

[0234] Embodiment 16. The polynucleotide of any one of embodiments 1 to 15, wherein the expression cassette comprises a polynucleotide sequence encoding a Green Fluorescence Protein (GFP).

[0235] Embodiment 17. The polynucleotide of any one of embodiments 1 to 16, wherein the B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3) or functional fragment or variant thereof is a full length or wild-type BAG3.

[0236] Embodiment 18. The polynucleotide of any one of embodiments 1-17, wherein the BAG3 is a human BAG3.

[0237] Embodiment 19. The polynucleotide of any one of embodiments 1 to 18, wherein the polynucleotide sequence encoding BAG3 shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 2.

[0238] Embodiment 20. The polynucleotide of any one of embodiments 1 to 19, wherein the polynucleotide sequence encoding BAG3 is a human BAG3 polynucleotide.

[0239] Embodiment 21. The polynucleotide of any one of embodiments 1 to 20, wherein the polynucleotide comprises at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, at least about 3.5 kb, at least about 3.7 kb, at least about 4.0 kb, at least about 4.1 kb, at least about 4.2 kb, at least about 4.3 kb, at least about 4.4 kb, at least about 4.5 kb, at least about 4.6 kb, at least about 4.7 kb, at least about 4.8 kb, or at least about 5.0 kb.

[0240] Embodiment 22. The polynucleotide of any one of embodiments 1 to 21, wherein the polynucleotide comprises at most about 3.1 kb, at most about 3.3 kb, at most about 3.5 kb,

at most about 3.7 kb, at most about 3.9 kb, at most about 4.1 kb, at most about 4.2 kb, at most about 4.3 kb, at most about 4.4 kb, at most about 4.5 kb, at most about 4.6 kb, at most about 4.7 kb, at most about 4.8 kb, at most about 4.9 kb, or at most about 5.0 kb.

[0241] Embodiment 23. The polynucleotide of any one of embodiments 1 to 22, wherein the polynucleotide comprises 4.4 kb to 5.0 kb, 4.4 kb to 4.9 kb, or 4.4 kb to 4.8 kb, wherein the polynucleotide comprises 4.0 kb to 4.6 kb, 4.0 kb to 4.5 kb, or 4.0 kb to 4.4 kb, wherein the polynucleotide comprises 4.0 kb to 4.3 kb, 4.0 kb to 4.2 kb, or 4.0 kb to 4.1 kb, or wherein the polynucleotide comprises 3.0 kb to 3.9 kb, 3.0 kb to 3.8 kb, or 3.0 kb to 3.7 kb.

[0242] Embodiment 24. The polynucleotide of any one of embodiments 1 to 23, wherein the expression cassette is flanked by 5' and 3' inverted terminal repeats (ITRs).

[0243] Embodiment 25. The polynucleotide of embodiment 24, wherein the ITRs are AAV2 ITRs and/or the ITRs share at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with any one of SEQ ID NO: 15-21.

[0244] Embodiment 26. A gene therapy vector, comprising the polynucleotide of any one of embodiments 1 to 25.

[0245] Embodiment 27. The vector of embodiment 26, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.

[0246] Embodiment 28. The vector of embodiment 27, wherein the rAAV vector is an AAVrh74 or a functional variant thereof.

[0247] Embodiment 29. The vector of embodiment 28, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 100.

[0248] Embodiment 30. The vector of embodiment 27, wherein the rAAV vector is an AAV9 or a functional variant thereof.

[0249] Embodiment 31. The vector of embodiment 30, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NO: 97.

[0250] Embodiment 32. The vector of embodiment 27, wherein the rAAV vector is an AAV6 or a functional variant thereof.

[0251] Embodiment 33. The vector of embodiment 32, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 98.

[0252] Embodiment 34. The vector of embodiment 27, wherein the rAAV vector is an AAVrh10 or a functional variant thereof.

[0253] Embodiment 35. The vector of embodiment 34, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 99.

[0254] Embodiment 36. A method of treating and/or preventing a disease or disorder in a subject in need thereof, comprising administering the vector of any one of embodiments 26-35 to the subject.

[0255] Embodiment 37. The method of embodiment 36, wherein the disease or disorder is a cardiac disorder.

[0256] Embodiment 38. The method of embodiment 37, wherein the cardiac disorder is a cardiomyopathy, optionally BAG3-related dilated cardiomyopathy.

[0257] Embodiment 39. The method of embodiment 38, wherein the cardiomyopathy is a hypertrophic cardiomyopathy (HCM) (hypertrophic).

[0258] Embodiment 40. The method of embodiment 38, wherein the cardiomyopathy is a dilated cardiomyopathy (DCM).

[0259] Embodiment 41. The method of embodiment 37, wherein the disease or disorder is arrhythmia, optionally atrial fibrillation or sinus node disease.

[0260] Embodiment 42. The method of embodiment 37, wherein the disease or disorder is heart failure.

[0261] Embodiment 43. The method of any one of embodiments 36 to 42, wherein the subject is a mammal.

- [0262] Embodiment 44. The method of embodiment 43, wherein the subject is a primate.
- [0263] Embodiment 45. The method of embodiment 44, wherein the subject is a human.
- [0264] Embodiment 46. The method of any one of embodiments 36 to 45, wherein the subject has a mutation in a *BAG3* gene and/or reduced expression of *BAG3* as compared to a healthy subject.
- [0265] Embodiment 47. The method of any one of embodiment 36 to 46, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion, and/or cardiac catheterization.
- [0266] Embodiment 48. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by at least about 5%.
- [0267] Embodiment 49. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by at least about 30%.
- [0268] Embodiment 50. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by at least about 70%.
- [0269] Embodiment 51. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by about 5% to about 10%.
- [0270] Embodiment 52. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by about 30% to about 50%.
- [0271] Embodiment 53. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by about 50% to about 70%.
- [0272] Embodiment 54. The method of any one of embodiments 36 to 47, wherein the administration increases *BAG3* expression by about 70% to about 100%.
- [0273] Embodiment 55. The method of any one of embodiments 36 to 54, wherein the method treats and/or prevents the disease or disorder.
- [0274] Embodiment 56. The method of any one of embodiments 36 to 55, wherein the method comprises administering an effective amount of the vector.

[0275] Embodiment 57. The method of any one of embodiments 36 to 56, wherein the disease or disorder is related to or caused by truncation of BAG3 in the subject.

[0276] Embodiment 58. The method of any one of embodiments 36 to 57, wherein the method comprises administering a pharmaceutical composition comprising an effective amount of the vector.

[0277] Embodiment 59. The method of any one of embodiments 36 to 58, wherein the method comprises administering between about 1×10^{11} vector genomes and about 1×10^{13} vector genomes of the vector to the subject, administering between about 1×10^{12} vector genomes and about 1×10^{14} vector genomes of the vector to the subject, or administering between about 1×10^{13} vector genomes and about 1×10^{15} vector genomes of the vector to the subject.

[0278] Embodiment 60. A pharmaceutical composition comprising the vector of any one of embodiments 26 to 35.

[0279] Embodiment 61. A kit comprising the vector of any one of embodiments 26 to 35 or the pharmaceutical composition of embodiment 60 and optionally instructions for use.

[0280] Embodiment 62. Use of the vector of any one of embodiments 26 to 35 in treating a disease or disorder, optionally according to the method of any one of embodiments 39 to 63.

[0281] Embodiment 63. A vector according to any one of embodiments 29 to 38 for use in treating a disease or disorder, optionally according to the method of any one of embodiments 36 to 59.

[0282] Embodiment 64. A polynucleotide, comprising a polynucleotide sequences that shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of SEQ ID NOs: 107-116.

[0283] Embodiment 65. The polynucleotide of embodiment 64, wherein the promoter is a MHCK7 promoter.

[0284] Embodiment 66. The polynucleotide of embodiment 65, wherein the MHCK7 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 31.

[0285] Embodiment 67. The polynucleotide of embodiment 64, wherein the BAG3 is a human BAG3.

[0286] Embodiment 68. A gene therapy vector, comprising the polynucleotide of any one of embodiments 64 to 67.

[0287] Embodiment 69. The vector of embodiment 68, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.

[0288] Embodiment 70. The vector of embodiment 69, wherein the rAAV vector is an AArh74 vector.

[0289] Embodiment 71. The vector of embodiment 69, wherein the rAAV vector is an AAV9 vector.

[0290] Embodiment 72. A method of treating and/or preventing a cardiac disorder in a subject identified as having a mutation or truncation in BAG3, comprising administering the vector of any one of embodiments 68 to 71 to the subject.

[0291] Embodiment 73. The method of embodiment 72, wherein the disease or disorder is a cardiomyopathy, optionally a dilated cardiomyopathy (DCM).

[0292] Embodiment 74. The method of embodiment 72, wherein the cardiac disorder is arrhythmia, optionally atrial fibrillation or sinus node disease, or BAG3-related dilated cardiomyopathy.

[0293] Embodiment 75. The method of embodiment 72, wherein the cardiac disorder is heart failure.

[0294] Embodiment 76. The method of any one of embodiments 72 to 75, wherein the subject is a mammal.

[0295] Embodiment 77. The method of any one of embodiments 72 to 76, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion, and/or cardiac catheterization.

[0296] All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred

to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety.

[0297] From the foregoing it will be appreciated that, although specific embodiments of the present disclosure have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the present disclosure.

EXAMPLES

EXAMPLE 1: PRE-CLINICAL TRANSGENE EXPRESSION

[0298] Vectors illustrated in **FIGS. 1-8** are tested. AAV vectors or respective expression cassettes are tested *in vitro* using cultured cardiomyocytes (e.g., induced pluripotent stem cell cardiomyocytes, iPSC-CMs, AC16, HL-1, C2C12, H9C2) or other cells amenable to transfection or transduction with these constructs. Expression of BAG3 transgene protein is assessed by ELISA, immunofluorescence, immunohistochemistry, and Western blot. Vector DNA is detected by PCR and BAG3 transgene mRNA is detected by qRT-PCR.

[0299] Cell-based studies employing patient iPSC-derived cardiomyocytes can be very challenging given the difficulty of effectively maintaining the BAG3 KO cardiomyocytes in culture, presumably due to high levels of spontaneous apoptosis. To reveal benefit of expression of BAG3 transgene (either following AAV vector transduction and/or transfection with vector plasmids) cell models using C2C12, AC16 and H9C2 cells and an shRNA targeting BAG3 are used with the goal to mitigate/ reduce the apoptosis levels (measured by conventional methods, e.g., TUNEL) of these cells after cardiomyocyte differentiation.

[0300] Expression cassettes illustrated in **FIG. 1 to 3 and FIG. 8** were tested following packaging into an AAV.rh74 vector. The resulting AAV vectors were tested *in vitro* using cultured CHO-Lec2 (standard mutant cells that have a 70–90% deficiency of sialic acid in their glycoproteins and gangliosides that make this cell more susceptible to AAV transduction). Subsequent expression of BAG3 protein in transduced CHO-Lec2 cells was assessed by Western blot. Data illustrating AAVrh.74-BAG3 mediated expression of the transgene protein (BAG3) are presented (**FIG. 9**).

[0301] The UBC promoter produced the highest expression levels of BAG3 by WB in the CHO-Lec2 cells, followed by the hHSP70 and MHCK7. The hTnnT2 promoter (“hTnT”) was found to drive lower levels of BAG3 protein expression in these conditions. Based on these results, it can be concluded that AAVrh.74 vectors can effectively express BAG3 protein.

EXAMPLE 2: PRE-CLINICAL EFFICACY IN VIVO IN THE BAG3 KO AND BAG3 CKO MOUSE

[0302] Selected vectors are tested in vivo using mutant mouse models of cardiomyopathy. A BAG3^{-/-} knock-out mouse model exhibits severe DCM phenotype and presents one or more DCM elements of human disease. The BAG3^{-/-} knock-out mouse (described in, e.g., Homma et al., Am J Pathol, 2006) has a single retrovirus insertion that selectively disrupted the mouse bag3 gene. Histological analysis of the tissues of BAG3^{-/-} mice revealed abnormalities in skeletal and cardiac tissue but not elsewhere, suggesting the possibility of myopathy. The BAG3^{-/-} knock-out mice were indistinguishable from their wild-type (+/+) and heterozygous (+/-) littermates during the 1st week of life. The cardiac muscle from BAG3-null mice showed degenerative changes, with the atrium affected to a greater degree than the ventricle. The KO mice ceased to gain weight after day 12 and appeared dwarfed relative to littermates and all BAG3^{-/-} animals are dead by day 25. After 20 days of age, myofiber degeneration was found throughout all muscles sampled in BAG3^{-/-} mice. H&E-stained fresh-frozen sections of the muscle of BAG3^{-/-} animals showed a marked variation in myofiber size, with evidence of atrophic fibers and intracellular accumulations of basophilic material. Inflammation, myonecrosis or other dystrophic pathological abnormalities were not observed in BAG3^{-/-} muscle.

[0303] A Cre inducible heart-specific BAG3^{-/-} knock-out (also termed Bis-iCKO) is also tested as a mouse model of moderately severe DCM phenotype. This mouse model exhibits one or more DCM elements of human disease and is characterized by a cardiomyocyte-specific, tamoxifen-activated, BAG3 knockout and is referred to as “Bis-iCKO” (described in, e.g., Yun et al, Int J Mol Sci 2021). This mouse model allows control of the onset of BAG3 loss of expression, limits loss of BAG3 to adult myocytes, and initiates a progression of molecular and functional events leading to dilated cardiomyopathy. Bis-iCKO mice were viable at birth; however, they had a striking susceptibility to premature death consequent to DCM and heart failure. While sixty percent of the Bis-iCKO mice survived until 28 days of life, morphological

and histological analysis of Bis-iCKO hearts revealed marked cardiac enlargement in these mice. Echocardiography revealed an age-dependent decrease in left ventricular (LV) systolic function (percentage of fractional shortening [FS]) in mice deficient for BAG3.

[0304] Benefit of AAV-mediated BAG3 expression in either the above or similar models would be evidenced by an increase in survival, an increase in body weight gain, mitigation of the normal progression of cardiomyopathy observed on echocardiograms (e.g., LVESD, LVEDD), mitigation of enlarged size of right and/or left ventricle and/or mitigation of typical decrease in left ventricular ejection fraction and/or fractional shortening. Histological analyses would reveal benefit by diminished appearance of disease-related myofiber disarray, attenuated ventricular dilation, reduction in thinning of ventricular wall, reduction in number of apoptotic cells, reduction of DNA damage and reduction in disease-related change in absolute size of heart.

EXAMPLE 3: RESCUE OF HEART FAILURE IN VIVO AFTER TRANSVERSE AORTIC CONSTRICTION (TAC)

[0305] AAV-BAG3 gene therapy with select AAV vectors described above is performed essentially as described in Knezevic et al. (JACC, 2016). AAV expression cassettes are packaged and delivered in vivo using different capsid serotypes such as AAVrh.74 and/or AAV9.

[0306] Mouse TAC Model: Transaortic constriction (TAC) in the mouse is an experimentally induced cardiac hypertrophy due to pressure overload with subsequent heart failure. Compared to other experimental mouse models of heart failure, the TAC model results in more reproducible cardiac hypertrophy and a gradual time course of development of heart failure. Following TAC in the mouse, a progressive decrease in ejection fraction and other measures of heart function are paralleled by a progressive decrease of cardiac BAG3 levels. Male C57BI/6J mice (approximately 4 months of age) are anesthetized and the aortic arch is visualized by performing an anterior thoracotomy to the level of the third intercostal space. Constriction is performed by tying a silk suture against a 28-gauge needle between the first and second trunk of the aortic arch. For consistency, constriction levels are quantified by measuring alterations in Doppler velocities of the right and left carotid arteries 7 days post-surgery. Right-to-left carotid peak velocity ratios may range from 5.0 to 6.5 and 2-week post TAC ejection fractions may range from 40%–50%.

[0307] Functional Evidence of Efficacy by Echocardiography: Evidence of bioactivity and efficacy for cardiac benefit in the TAC model is evaluated using transthoracic echocardiography at predefined timepoints including baseline and various intervals after TAC. To screen animals with sufficient heart failure suitable for this mouse model, Doppler ratios of right carotid to left carotid peak velocity (RC/LC) are determined 1-week post-TAC and those that do not meet criteria (RC/LC of 5.0-6.5) are excluded from study. Additionally, echocardiography at 2 weeks post-TAC is performed and animals outside the range of 40 – 50% ejection fraction (EF) are also excluded. Mice with appropriate Doppler RC/EV and EF by echocardiogram are then injected (either intra-venously or intra-retro-orbitally) at week 8 post-TAC with AAV constructs overexpressing BAG3 protein or with formulation buffer (FB; vehicle control). Efficacy will be evident in AAV-BAG3 treated animals by significantly increased EF and FS compared to the FB control group across time. Echocardiography will reveal that FB injected mice will be found to have an EF and FS that declines progressively across time. In contrast, AAV-BAG3 injected animals will be found to have an EF and FS returning to the control levels during the weeks following treatment. Histological analyses will reveal attenuation of myocardial fiber disarray.

CLAIMS

1. A polynucleotide, comprising an expression cassette and optionally flanking adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the polynucleotide comprises a polynucleotide sequence encoding a B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3), or a functional variant thereof, operatively linked to a promoter, optionally wherein the promoter is a heterologous promoter.
2. The polynucleotide of claim 1, wherein the promoter is a cardiac-specific promoter.
3. The polynucleotide of claim 1 or claim 2, wherein the promoter is a muscle-specific promoter.
4. The polynucleotide of any one of claims 1 to 3, wherein the promoter is a cardiomyocyte-specific promoter.
5. The polynucleotide of any one of claims 1 to 4, wherein the promoter is a Myosin Heavy-chain Creatine Kinase 7 (MHCK7) promoter.
6. The polynucleotide of claim 5, wherein the MHCK7 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 31.
7. The polynucleotide of any one of claims 1 to 4, wherein the promoter is a cardiac troponin T (hTNNT2) promoter.
8. The polynucleotide of claim 7, wherein the hTNNT2 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 32.
9. The polynucleotide of any one of claims 1 to 4, wherein the promoter is a human heat shock factor 70 (hHSP70) promoter.
10. The polynucleotide of claim 9, wherein the hHSP70 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 115.
11. The polynucleotide of any one of claims 1 to 10, wherein the expression cassette comprises exon 1 of the cardiac troponin T (hTNNT2) gene, wherein optionally the hTNNT2 promoter and exon 1 together share at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 32.

12. The polynucleotide of any one of claims 1 to 4, wherein the promoter is a ubiquitous promoter, optionally a CMV promoter or a CAG promoter or a chicken b-globin promoter or a UBC promoter (SEQ ID NO: 116).
13. The polynucleotide of any one of claims 1 to 12, wherein the expression cassette comprises a polyA signal.
14. The polynucleotide of claim 13, wherein the polyA signal is a human growth hormone (hGH) polyA.
15. The polynucleotide of any one of claims 1 to 14, wherein the expression cassette comprises a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE), optionally a mutant or modified WPRE (WPRE(x)), optionally WPRE Mut6 (SEQ ID NO:63).
16. The polynucleotide of any one of claims 1 to 15, wherein the expression cassette comprises a polynucleotide sequence encoding a Green Fluorescence Protein (GFP).
17. The polynucleotide of any one of claims 1 to 16, wherein the B-cell Lymphoma 2-Associated Anthanogene 3 (BAG3) or functional fragment or variant thereof is a full length or wild-type BAG3.
18. The polynucleotide of any one of claims 1 to 17, wherein the BAG3 is a human BAG3.
19. The polynucleotide of any one of claims 1 to 18, wherein the polynucleotide sequence encoding BAG3 shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 2.
20. The polynucleotide of any one of claims 1 to 19, wherein the polynucleotide sequence encoding BAG3 is a human BAG3 polynucleotide.
21. The polynucleotide of any one of claims 1 to 20, wherein the polynucleotide comprises at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, at least about 3.5 kb, at least about 3.7 kb, at least about 4.0 kb, at least about 4.1 kb, at least about 4.2 kb, at least about 4.3 kb, at least about 4.4 kb, at least about 4.5 kb, at least about 4.6 kb, at least about 4.7 kb, at least about 4.8 kb, or at least about 5.0 kb.
22. The polynucleotide of any one of claims 1 to 21, wherein the polynucleotide comprises at most about 3.1 kb, at most about 3.3 kb, at most about 3.5 kb, at most about 3.7 kb, at most

about 3.9 kb, at most about 4.1 kb, at most about 4.2 kb, at most about 4.3 kb, at most about 4.4 kb, at most about 4.5 kb, at most about 4.6 kb, at most about 4.7 kb, at most about 4.8 kb, at most about 4.9 kb, or at most about 5.0 kb.

23. The polynucleotide of any one of claims 1 to 22, wherein the polynucleotide comprises 4.4 kb to 5.0 kb, 4.4 kb to 4.9 kb, or 4.4 kb to 4.8 kb, wherein the polynucleotide comprises 4.0 kb to 4.6 kb, 4.0 kb to 4.5 kb, or 4.0 kb to 4.4 kb, wherein the polynucleotide comprises 4.0 kb to 4.3 kb, 4.0 kb to 4.2 kb, or 4.0 kb to 4.1 kb, or wherein the polynucleotide comprises 3.0 kb to 3.9 kb, 3.0 kb to 3.8 kb, or 3.0 kb to 3.7 kb.

24. The polynucleotide of any one of claims 1 to 23, wherein the expression cassette is flanked by 5' and 3' inverted terminal repeats (ITRs).

25. The polynucleotide of claim 24, wherein the ITRs are AAV2 ITRs and/or the ITRs share at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with any one of SEQ ID NO: 15-21.

26. A gene therapy vector, comprising the polynucleotide of any one of claims 1 to 25.

27. The vector of claim 26, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.

28. The vector of claim 27, wherein the rAAV vector is an AAVrh74 or a functional variant thereof.

29. The vector of claim 28, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 100.

30. The vector of claim 27, wherein the rAAV vector is an AAV9 or a functional variant thereof.

31. The vector of claim 30, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NO: 97.

32. The vector of claim 27, wherein the rAAV vector is an AAV6 or a functional variant thereof.

33. The vector of claim 32, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 98.
34. The vector of claim 27, wherein the rAAV vector is an AAVrh10 or a functional variant thereof.
35. The vector of claim 34, wherein the rAAV vector comprises a capsid protein that shares 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 99.
36. A method of treating and/or preventing a disease or disorder in a subject in need thereof, comprising administering the vector of any one of claims 26-35 to the subject.
37. The method of claim 36, wherein the disease or disorder is a cardiac disorder.
38. The method of claim 37, wherein the cardiac disorder is a cardiomyopathy, optionally BAG3-related dilated cardiomyopathy.
39. The method of claim 38, wherein the cardiomyopathy is a hypertrophic cardiomyopathy (HCM) (hypertrophic).
40. The method of claim 38, wherein the cardiomyopathy is a dilated cardiomyopathy (DCM).
41. The method of claim 37, wherein the disease or disorder is arrhythmia, optionally atrial fibrillation or sinus node disease.
42. The method of claim 37, wherein the disease or disorder is heart failure.
43. The method of any one of claims 36 to 42, wherein the subject is a mammal.
44. The method of claim 43, wherein the subject is a primate.
45. The method of claim 44, wherein the subject is a human.
46. The method of any one of claims 36 to 45, wherein the subject has a mutation in a *BAG3* gene and/or reduced expression of *BAG3* as compared to a healthy subject.

47. The method of any one of claim 36 to 46, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion, and/or cardiac catheterization.
48. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 5%.
49. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 30%.
50. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 70%.
51. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 5% to about 10%.
52. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 30% to about 50%.
53. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 50% to about 70%.
54. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 70% to about 100%.
55. The method of any one of claims 36 to 54, wherein the method treats and/or prevents the disease or disorder.
56. The method of any one of claims 36 to 55, wherein the method comprises administering an effective amount of the vector.
57. The method of any one of claims 36 to 56, wherein the disease or disorder is related to or caused by truncation of BAG3 in the subject.
58. The method of any one of claims 36 to 57, wherein the method comprises administering a pharmaceutical composition comprising an effective amount of the vector.
59. The method of any one of claims 36 to 58, wherein the method comprises administering between about 1×10^{11} vector genomes and about 1×10^{13} vector genomes of the vector to the

subject, administering between about 1×10^{12} vector genomes and about 1×10^{14} vector genomes of the vector to the subject, or administering between about 1×10^{13} vector genomes and about 1×10^{15} vector genomes of the vector to the subject.

60. A pharmaceutical composition comprising the vector of any one of claims 26 to 35.

61. A kit comprising the vector of any one of claims 26 to 35 or the pharmaceutical composition of claim 60 and optionally instructions for use.

62. Use of the vector of any one of claims 26 to 35 in treating a disease or disorder, optionally according to the method of any one of claims 39 to 63.

63. A vector according to any one of claims 29 to 38 for use in treating a disease or disorder, optionally according to the method of any one of claims 36 to 59.

64. A polynucleotide, comprising a polynucleotide sequences that shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of SEQ ID NOs: 107-116.

65. The polynucleotide of claim 64, wherein the promoter is a MHCK7 promoter.

66. The polynucleotide of claim 65, wherein the MHCK7 promoter shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 31.

67. The polynucleotide of claim 64, wherein the BAG3 is a human BAG3.

68. A gene therapy vector, comprising the polynucleotide of any one of claims 64 to 67.

69. The vector of claim 68, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.

70. The vector of claim 69, wherein the rAAV vector is an AArh74 vector.

71. The vector of claim 69, wherein the rAAV vector is an AAV9 vector.

72. A method of treating and/or preventing a cardiac disorder in a subject identified as having a mutation or truncation in BAG3, comprising administering the vector of any one of claims 68 to 71 to the subject.

73. The method of claim 72, wherein the disease or disorder is a cardiomyopathy, optionally a dilated cardiomyopathy (DCM).
74. The method of claim 72, wherein the cardiac disorder is arrhythmia, optionally atrial fibrillation or sinus node disease, or BAG3-related dilated cardiomyopathy.
75. The method of claim 72, wherein the cardiac disorder is heart failure.
76. The method of any one of claims 72 to 75, wherein the subject is a mammal.
77. The method of any one of claims 72 to 76, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion, and/or cardiac catheterization.